{"directed": true, "multigraph": true, "graph": {"pybel_version": "0.13.1-dev", "document_metadata": {"name": "Acetylcholine signaling subgraph", "version": "5.1.2", "copyright": "Copyright © 2019 Fraunhofer SCAI, All rights reserved.", "licenses": "CC BY 4.0", "contact": "daniel.domingo.fernandez@scai.fraunhofer.de"}, "namespace_url": {"CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/1b20f0637c395f8aa89c2e2e342d7b704062c242/external/chebi-names.belns", "ECCODE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns", "GFAM": "https://raw.githubusercontent.com/pharmacome/terminology/3f89d31906739fce9678d868b6a599a851aa7c00/external/hgnc.genefamily-names.belns", "GO": "https://raw.githubusercontent.com/pharmacome/terminology/1b20f0637c395f8aa89c2e2e342d7b704062c242/external/go.belns", "HBP": "https://raw.githubusercontent.com/pharmacome/terminology/570376e4c233483b667eab12a1f964950368282a/export/hbp-names.belns", "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/1b20f0637c395f8aa89c2e2e342d7b704062c242/external/hgnc-symbols.belns", "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/1b20f0637c395f8aa89c2e2e342d7b704062c242/external/mesh.belns", "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns", "CTO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/clinical-trial-ontology/clinical-trial-ontology-1.0.0.belns", "DO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170725.belns", "GOBP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/go-biological-process/go-biological-process-20170725.belns", "GOCC": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/go-cellular-component/go-cellular-component-20170725.belns", "HP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns", "MESHC": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-chemicals/mesh-chemicals-20170725.belns", "MESHCS": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-cell-structures/mesh-cell-structures-20170511.belns", "MESHD": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-diseases/mesh-diseases-20170725.belns", "MESHPP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-processes/mesh-processes-20170725.belns", "MGI": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mgi-mouse-genes/mgi-mouse-genes-20170725.belns", "RGD": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/rgd-rat-genes/rgd-rat-genes-20170725.belns", "SCOMP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-named-complexes/selventa-named-complexes-20170725.belns", "SFAM": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-protein-families/selventa-protein-families-20170725.belns", "INTERPRO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/interpro/interpro-20170731.belns", "ADO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/alzheimer-disease-ontology/alzheimer-disease-ontology-1.0.2.belns", "BRCO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/brain-region-ontology/brain-region-ontology-1.0.0.belns", "NIFT": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/imaging-ontology/imaging-ontology-1.0.6.belns", "PTS": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/neurodegeneration-pathways/neurodegeneration-pathways-1.0.0.belns"}, "namespace_pattern": {"DBSNP": "^rs\\d+$", "TAXONOMY": "^\\d+$"}, "namespaces_uncached": [], "annotation_url": {"Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno", "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno", "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno", "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno", "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno", "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno", "Gender": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno", "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno", "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno", "Subgraph": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno", "TextLocation": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"}, "annotation_pattern": {"Species": "\\d+"}, "annotation_list": {"Duration_of_Chemical_Exposure": ["Chronic", "Subchronic"], "NIFT": ["Positron Emission Tomography", "Volumetric MRI"], "Published": ["CDR story", "Epilepsy comorbidity paper"], "Race": ["Caucasian", "Chinese", "Colombian", "Italian", "Swedish", "Taiwanese"], "Condition": ["Normal Healthy State"], "Encode_Feature_Types": ["Promoter"], "Experimental_Group": ["Physical exercised group", "Sedentary group"], "KnockoutMice": ["App transgenic"], "DiseaseState": ["Early-onset AD", "Familial Alzheimers Disease", "Late-onset AD", "Mild AD", "Moderate AD", "Sporadic Alzheimers Disease"], "FDASTATUS": ["Phase 2", "Phase 3"], "UserdefinedCellLine": ["293APPwt", "App transgenic", "CHOAPPsw", "INS-1 cells", "N2a695 cell", "NT2N cells", "Neuroblastoma cell", "primary cortical neuron", "primary neuron"], "Patient": ["AD T2DM +ve", "AD T2DM -ve", "APOE e4 +ve", "APOE e4 -ve"], "Developmental_Phase__of_patient": ["Developmental stage", "Old"], "Transcriptionally_active_region": ["3 prime UTR", "5 prime UTR"]}}, "nodes": [{"function": "Abundance", "namespace": "CHEBI", "name": "(R)-adrenaline", "id": "94172c9577abc720b64d61470971f34a16b72e136d004bcab21c8011b8bcdf5cc3e0b7256764001e3155f9cfa47baa00ca742d44b356fd20a398e0e645573725"}, {"function": "Abundance", "namespace": "CHEBI", "name": "EC 3.1.1.7 (acetylcholinesterase) inhibitor", "id": "f5115583612f3f2c40ebc54f2c528dbe7732517483538bd78de15d36df42904885a4fb82e5b4feac53e21bbdcf5c7e8e78c1985c4ff40c3fe99509119cf8984b"}, {"function": "Abundance", "namespace": "CHEBI", "name": "EC 3.1.1.8 (cholinesterase) inhibitor", "id": "5cdf90b9ebeb48ea6da8c329a1c3e1e6c1b8e9daad552a694c220dd3c31ff1111ffc03f910f60ea65250121cc0a71b870a07cc4cf548b39be2fa66f42982a0c9"}, {"function": "Abundance", "namespace": "CHEBI", "name": "Luteinizing hormone", "id": "b312422f004167933c6296000fd157650b3f8c14edfc8aed0dcecad7cac346ad0add3dcb422a80eeb0a49ebe450dff2b876fed459f04659427e1c46001014761"}, {"function": "Abundance", "namespace": "CHEBI", "name": "amyloid-beta", "id": "a9487b29439483c6840095610dd3e496e3ca9cccc3a8d71e0385a39b570f3c0a26965ac06d83265e1c08deaae7998272d4f4c21ec0534f8be3fd8e4e57dbb3a2"}, {"function": "Abundance", "namespace": "CHEBI", "name": "calcium(2+)", "id": "4fb8648e4c5fea95cea6a46291d28175bba677d8b6fa8d607b1febef51c8370cbc1ff98d09312dc418ff31d04177d26f231d4f0a1a963f43fbc29cfb3269d3c9"}, {"function": "Abundance", "namespace": "CHEBI", "name": "cholinergic agonist", "id": "8f17043eff709881912a237707e2a1350597ff655770d3a574b4938c273e53fd8c208131e462f9b5245ea9bb2fb898bee6b41c55bda53aceacbcc27700ee6fd3"}, {"function": "Abundance", "namespace": "CHEBI", "name": "copper(II) sulfate pentahydrate", "id": "29db84f0b573f34f0fbbbe5d3557c5a1a8c1750d192d8cfa7114fd3c52744f9c30cd2bc3aac3dd4962ddb4aa11d799a53af5de984a9b2f7cddb8d43a02459c73"}, {"function": "Abundance", "namespace": "CHEBI", "name": "cyclosporin A", "id": "cc2d9386ffb706a1d62ee95b31327612e3263da9936967c06daa1c7b62c93eaf1f898d6288db7b59eae92826e3a840b321586a964d50f783936b7987a42606f6"}, {"function": "Abundance", "namespace": "CHEBI", "name": "folic acid", "id": "0067b63b17fb418f62f6e4c6b7f89668fcab7dcfd51227d8ba969f205f188f274c24057cc76d07ee1bd6f599a5c2d5c6eae57a57b3354f97e1ec5b36fff591f8"}, {"function": "Abundance", "namespace": "CHEBI", "name": "gamma-aminobutyric acid", "id": "9583f9418a889245078b43a5744b3aee37f76bff3bff369f21f4091c2ad475d69415b09ff3b3b7e7aa6014f4e5dab6706477099218ce8a665f6751daba94e6b3"}, {"function": "Abundance", "namespace": "CHEBI", "name": "glutamate(1-)", "id": "fc1b84427efecfb8e3a837d65b6e115ffa8c7fc53ebacb54b967fd3aaafd25a6f47c147e986961e53c4ef1d5c36420fd9194019b5f81eeb5d33310f314818875"}, {"function": "Abundance", "namespace": "CHEBI", "name": "glutamate(2-)", "id": "9749d43ec7dd166b90348b70de96bca3f824fa7c4624aa5f0d82f2dbd2e1d559cccd5b7e74c86268f2e152cea542c1a7c99fc9b98d5d12853d44f9a56b615e4a"}, {"function": "Abundance", "namespace": "CHEBI", "name": "growth hormone", "id": "738564ee0b2b9fbafbb500375ab22b7b0744f0bb07c939c053d25143ef53f014c90eaad60f812cc06e1f47c932cebab11b068d0abf8b4d9a4a7984a790d28035"}, {"function": "Abundance", "namespace": "CHEBI", "name": "hydrogen peroxide", "id": "4d65b5d180890b98afe0bc10614fde44ee750b2d1af6fdd925fc31ead7ee9a7248bda3d67c52aebf220b8c048d999f2d878a97a70b0e027a7294cbd3c7bf61bf"}, {"function": "Abundance", "namespace": "CHEBI", "name": "muscarinic agonist", "id": "b3c7f23031bc26023b7dfd0042c712a8c24763f9d38029348a6a25772330f5c321b55e6ae522a25f41dc2bd8333c7b27179e185a530bafeb54a98268c331b453"}, {"function": "Abundance", "namespace": "CHEBI", "name": "nicotinic acetylcholine receptor agonist", "id": "fc6fb75f41a3ae25bcce72b6848a0a4ca5f3c45b495a894c7b278d2851f4a07a201fb7402153571cbcf47dafbab3240d324f4b208bd81d15241ae2c9a4a3d037"}, {"function": "Abundance", "namespace": "CHEBI", "name": "acetylcholine", "id": "bae5841bb74f1e9eb73cd433cda657927031217c24e17f21bb2975128d1d9be4dc899448ede71d9aa18224145a1681b90b33287454eabf938f405bc1b8894b62"}, {"function": "Abundance", "namespace": "CHEBI", "name": "arecoline", "id": "1a8c75b43e9fb5a1636dbacc870d403c6d78a4ce24235ba25ee19bf09a3d8cd8365b20a8fea0287ed96668bee60ca80b87a16be4c46a5da88cd81960689b35b1"}, {"function": "Abundance", "namespace": "CHEBI", "name": "choline", "id": "88fb57fa667be5fcf348ed86cb041de48401b10103512c286ebe600483744af962b0f34c7d2f8cfb57af6f72aaab29d8787cb64de2aa5d58ecd6fe01876d0cee"}, {"function": "Abundance", "namespace": "CHEBI", "name": "corticotropin", "id": "e34e89c28f510eff03f1ced1aa7529ba14f86723e210b1e9ede4de11cb10f6a764c49f19295a8fc69cf8dc691c1667dfa41b142dd180b1a8fbcfeb4742a9e802"}, {"function": "Abundance", "namespace": "CHEBI", "name": "cortisol", "id": "0cbffd7aee83b2b6b0988a7fe82a94c3cf4a009c0f24f68a79978fdbfea37c68d56ce7ab7e760c44779fbe5349c3e9002fedad6095cd6bd6c1b068c1f718cdd9"}, {"function": "Abundance", "namespace": "CHEBI", "name": "donepezil", "id": "e1d832febdffe3cc8c4fa21718e0b21719272a1a10c2945cdd3b36cc6ff66c3ec70289ed1ddc3a7a6b79ca44a4bc0fac6ecb12683fc043cdac26b952f7cf5223"}, {"function": "Abundance", "namespace": "CHEBI", "name": "estradiol", "id": "904ad56311bf85f6b904e16f8c23ba43255d705b6e623b83cc7002fea20feeab61d0ca62933f1ff52578a7885c1af9372264dcbd602303ede2b77e6e6f260a7f"}, {"function": "Abundance", "namespace": "CHEBI", "name": "galanthamine", "id": "829d639ffa1b9cf0dc884553079510b093dde8971a129c58afff24ea1d1103f0db214945577b66dc941db450715ecdfe7951a8498afafb02cb1653b60845fc57"}, {"function": "Abundance", "namespace": "CHEBI", "name": "glutathione", "id": "a75431c9ce7065ec867a86011c2371dd04187869fb2f21220cb8b8686a5a63863e8f98d2e96f23b6133fe39f75169f6798972c8cae9fa7bcb3af79562e948af1"}, {"function": "Abundance", "namespace": "CHEBI", "name": "memantine", "id": "a6417701f850dae3b77bc52ab06561523bf34757aa461d008c48b9b489cf2293a3fb2bd592ae99ac7d23dd6143614f12df64ef718109abeaf9651954c612bfe7"}, {"function": "Abundance", "namespace": "CHEBI", "name": "methionine", "id": "df540561b204490bccc4c739ad03586b143ca61c655e4759646ef4b9539ec7249375760c7a8665136f8af56b8b6a1f11840624f9a82fe8d718bee74f82da0c3e"}, {"function": "Abundance", "namespace": "CHEBI", "name": "nefiracetam", "id": "7f3196ad00a4b8a75e29e44a626e93fcda0f2cb134af8c104089342b21c96731807b3ff9e3513070762c21b58fd4cc2b16b6df1c9fbc061a8176113f81e4b3d4"}, {"function": "Abundance", "namespace": "CHEBI", "name": "physostigmine", "id": "4863cd75469275d1fdae01cd33cc5695cff4b2e8f14b82887b79659862c96e5d2ebd72c6b76f6c8772ca126c36e3f8bb680e9c4a80c7d9a5edc319fb822a45c8"}, {"function": "Abundance", "namespace": "CHEBI", "name": "resveratrol", "id": "545daa8c15363de2760fcbff1fa1c472c83bfc4fa06d5cfaaaf1259fab8d6ac783ae0bdf7ae00fd6f6e0c5c7541242453b6423c657fbd723321fbcfb5bf953f7"}, {"function": "Abundance", "namespace": "CHEBI", "name": "rivastigmine", "id": "317d5b18448e148088204c7a7dce78316c0ea8b56c70a7adaffe344826b17688e05873b2746050d29c18ae658658e81a2d775ba56b6f5abf8821f4eaca725064"}, {"function": "Abundance", "namespace": "CHEBI", "name": "serotonin", "id": "8d7ceea95cec905de8941facf48d632e3c509b6ce451f835af1fab5789daacc5bbf8d1bdb7cfd90863a70871a9a9a07b093896248712aa6567895ae8cf3b3502"}, {"function": "Abundance", "namespace": "CHEBI", "name": "tacrine", "id": "c1560ac01f8b46a59d909fe73d5cd84dad7f9c83d170b6000eac634fc33a12091ff9cd73964d98a326de73abd7f9dd033ae78f40624c6984e29ad84d21436720"}, {"function": "Abundance", "namespace": "CHEBI", "name": "vasopressin", "id": "6bb6f8cbdc7a4b69a87b3ca4d413295def5c49332ae9746c9eece54840fa7cc9bac72d420eafed79534553245530254707ce2b540458567e7fed00260b9cd895"}, {"function": "Abundance", "namespace": "MESH", "name": "D001253", "id": "f6eff273aed16a1c4eb263f30e6f6d351b7f048b4106cd024e4b027755388b96e38f11874b392ea8f27135bdcf74a7a52708c20fe873aaf236a1b2fa317aeb9b"}, {"function": "Abundance", "namespace": "MESH", "name": "D017628", "id": "fcc356e52444a8c553a49f05187c2da6466b949532dc9e4ddc579f797dbb091c900a0923369d5cbe5aeda097a509e3a34c4022d56f1588de028743e20f644e09"}, {"function": "Abundance", "namespace": "MESHC", "name": "Acetylcholine", "id": "1d469cffea352af69b9252313dc5ba9acc8cfead9dfe07d1044e8f93aaf6ef38b4a6143a93d7f73968560068dfc7de4ca191131bacfdc84dd0b39406aa7f2f51"}, {"function": "Abundance", "namespace": "MESHC", "name": "pozanicline", "id": "1bec5f57e891c736fbc5babb02a73bf9f34314a8b0963af8df7a010b44f70635b0f9b72558685022068262f9a3a53b7cd74ef32a70a33244fa1b41ac07ef6fc9"}, {"function": "Abundance", "namespace": "NIFT", "name": "Cerebral atrophy", "id": "e9c026cd65b9968b1fc7e5be36c8af88aef8e53145b0b5109acd8fb71630c5a2c7d3b0f5eaea666c1349056c3b531fffa6539f0ceeb0e0481a196baf96ad8023"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "acetylcholine metabolic process", "id": "ff51d58fc9fb0027a606e7c16e531f4c943a61da289be28bb4dc24f3cde8935ca6b4ce5c985890cc174c78e9fccade75767c17de84532b35b11beb53d07da784"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "acetylcholine secretion", "id": "f2d97e6beb74e6cfa2c12f9dfd55e004c91ee86782033e935ddca2cccd20caae6459ba955691eff858b0a6bf2eaf9dc1fa55cb2e2047ea03b9b28c6cef7002b9"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "amyloid fibril formation", "id": "a460575be4028d539aa5fffdd36f6eb8bf54249b172dc1505313a79941da14c571fd61617d190d85a389d0e06df78b9869dce79700ef23646c87dc7b6812ad7f"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "amyloid precursor protein metabolic process", "id": "6aadac6656916d17a409a2cf343ad8ad71fd345aa3f1e8e9d11a129da8de1bc37441e1ca73ecd42d80074f5a35cad18f2ccfd308a34dfcdd331585a13ee31639"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "blood circulation", "id": "89803063293ac5b5b6d656c96aade7a5d06c8d6d9b1922d18c68a91f9cb925af4cec24f4e46a16b7a7eef7a96f6ae265fece08e9fc26e56c0ccb56e90e94572e"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "calcium ion import", "id": "7f1eb5f4b3f5fb69e01ca8f4411886ea22b16521b8d3de8685535b2b46b3df749c6a3b75055159ab888f702df1a29a304f7d44b5f8f90ddd0e11fafec16d74c8"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "cell redox homeostasis", "id": "62163a1983099c24d8c80f074c4b4d79b11c2e83504dbc019f8ce55a270f2ec8a5af7950bfeab20cd393b188185d6fcca1370184581c0f329b6bb6c0debdfdec"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "glucose metabolic process", "id": "1fb35b1a2ff9df245ebf2fa935dba63a8b10a40a48c3fc7773c2978475085695e2ab88fc486dca3413a51ad6ccc65437b8fd9a773ad0010f68a1bbd632867ba4"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "inflammatory response", "id": "3d95fab3ea44ace52d93f8d514ed76a13b0141d47b3fdb540a4f251104b4455dce67e0dac58c1a127df709dc3721e03aba719c2877d49fac8c3e2abab2b721cf"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "learning or memory", "id": "b9dbee447adb27aa88d06f2cadbafc23cae4f0dbdb429ad18224de98446db263210d57acbab4c70950c67df221fa44cd2b1fe11d0994822840be54b6ae20a973"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "lipid metabolic process", "id": "fa036d7fcf3888290e364f25ccf268611b90c8fbdd71e25df0792dcf4b7bd192116720fd480abb54f9943d70f23514f1066cab369fab8cedab28e66b759ed1f8"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "long term synaptic depression", "id": "e229ad5e4dce9b5b6615d7de07958a09eb65cf4a5b2e3c2eb3667ec6d9f354d3e8ccb18626963c43e86930e49c5fc3d2cf937c4ea24315f76dd01d30bab5637f"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "negative regulation of insulin secretion involved in cellular response to glucose stimulus", "id": "cb4be967b8ec379b66d2731b070b6853be6296c342d3d13f9e646834c36727a05e3962c9e556541a77d444a4008514f1ed267eeef88406ff93ed088ca10d49c3"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "negative regulation of synaptic transmission, cholinergic", "id": "e63e3314bf3e300676fb14075033a88483912b56ee035e5c9422d3c01a29d6ec8c2c133ccf41bb2228f306bdf1f71ced1c340e6a77c9001d3d8d5886fab457e5"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "negative regulation of synaptic transmission, glutamatergic", "id": "446b2a7d3ac8d7ca5782e34fc009f06a600be30a959d79f37fc781f63cc67523710a8f0d271da0772ba4bc46450d028c37b27016d7a3b6003fc574d63784714d"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "neuron apoptotic process", "id": "d03e6f0803e977ca2408bd8e60f7f8872ed7a1adb3ef8bc9d8d22481bce67f9ebfc4fe9b04e693e27779c9e3aa27d37f78ff1e9751ef84f3c780e9bd4030bea7"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "neuron death", "id": "7a2f309b1d4a7c1ab86704418e6cffe1e917c5d1d842312e825776263f2ae593e2d871381b4a4bacf2efab95f6f8e1d9264f5e025c7676621a1e72a9e74d7c85"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "neuron-neuron synaptic transmission", "id": "5d8cc9a5602bfcee18405b6febb6a418c07b08a3e180ae7c7b84c0d379b3854090b6f290578c0bec57f73657801bca28dd87dedc1bc98f47adb4f02455cef69c"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "positive regulation of calcium ion import", "id": "2f5e4896626ea63cdb7fc38c318070c6c135cdaa84dd721d547a3ca014b5810feb4fb70f9ff029a1142c40c1d3982bfbe2f3ff920f7ff1cfc3ad4876f7459b3d"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "positive regulation of synaptic plasticity", "id": "c4126c3e0de570ae5a55a082a75a2dd3a559a6cee7cf0939d3849816892b3097aaf1d539ded05f15c11bf236d1f4aa9fb247cea1911366e2a1b4c1f4e63f747b"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "positive regulation of synaptic transmission, cholinergic", "id": "48145e0ea18516519e284433091ead6800e1453e78007c97047645bfd15a7843a1ecfef2987c5992b966dc7c6bd333ab75f74d26d2c483434ce7c010b01110ef"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "prolactin secretion", "id": "ec9eaeea8b31a87c54f0b354e4582eec5d61b6cb4e92988f1d00fcebf4e2925e23222765b7b195172c8ea9a05f68a2a7dd13dfdb770ba85ea2fb31ed835011e9"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "regulation of short-term neuronal synaptic plasticity", "id": "48032e33529259842a0331d3bab5c240591877245745a32d5dbbc49861a831b75b2a33addc3741a74da5d99f9c8a6f22d31c6585d04dd1b5371385b619bb2a28"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "regulation of synaptic transmission, cholinergic", "id": "47583ed76e2610de5bb6dc23fef797d126d55dc4d49134659323691d968a1be1d2217902e61c70839add554a401ed02f8d7268898705f951c7265156a4ad800d"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "synaptic transmission, cholinergic", "id": "1964e3b9b922a52efb1fb0fa6717cfc5689769dbd8e1569416cb67d0cbd294e1694519e5c08cae2b6895e007f265c1a47ff16cd84a196d2e458dab450d632a33"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "behavior", "id": "6864ae785bef15d653d04b551290d756c7c9a58f46d65d3bbb5f9c510374d52f44fdb2feefd03213f84144ec1171dd47545193f0c28b4e16c8dee0255eca7d69"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "cognition", "id": "7085c04c66ff00d9ede4223662139766ae23124164f0ef453fdb23a5605c09df1809749b89f32471228956018a87d82e70ba03f41ce127eb1e49a4d7b1519884"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "glycosylation", "id": "7dc1fce9006f359a424830ebf8c510ce7c4d478770fc239721d71b1852820a667203858e0e1fd99713b78359dc95e0bf74ad79486c11286ce766ba16a97a5ec0"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "learning", "id": "ee36290ab8226f450927c8f0073441e739a71eb8b905ce1e756df6ee75a571e76233bf7eeb01a829aa10342883ae0eef8728a3920800c85035fa43b364c2de13"}, {"function": "BiologicalProcess", "namespace": "GOBP", "name": "memory", "id": "2c0be3c3d7742f81a705f9ed3b9ae8ad529994d220b57b3c46cb1641073373cb3579b3c8ac29e9512cf6f3e2fd2207d508591b3c588d51484d8f1a21d05f1c8b"}, {"function": "BiologicalProcess", "namespace": "HBP", "name": "neurite retraction", "id": "ccc8df8224709077ff6cc688a504ef4c8799a205654f5f8540ab1311d3c1469353108dd69bb0081b40df78453f30f77683ef7416c9aa7f9de4f0a587991e1469"}, {"function": "BiologicalProcess", "namespace": "HBP", "name": "neuroinflammation", "id": "852fb6af6af67ae4c41cb9012bf15e6b8c45b8c674a761dada1f9f651645f80ec40f0020d722d97ec3f35c51666a87f94d25a7414e9294adac055c9f18d3d2b6"}, {"function": "BiologicalProcess", "namespace": "MESHPP", "name": "Insulin Resistance", "id": "96dc3f812c61acec35d3461636c1a56e3ae78534613e44ab749f54fd0d31181106740697aa3af01cbd519ac38cfc49710f6365241b4148accdaa65ffa4159282"}, {"function": "BiologicalProcess", "namespace": "MESHPP", "name": "Neuronal Plasticity", "id": "0d1df7b24d4660627e016795229e210538b77d4a6d479a3c695f19953f5b0f1afec564bab32eb4320ac6738be88163bb70b37568689d955b091bb08ee66c4fe3"}, {"function": "BiologicalProcess", "namespace": "PTS", "name": "APP processing pathway", "id": "f894f4a732535dcd9194f1900811a9096db1b38496bf0c1c40aaaac15acc4c3a44517e36258ee09f2763e4cdcd91da2f2febdcc19e467e3bbc3d20157a689e01"}, {"function": "Complex", "namespace": "SCOMP", "name": "CAMK2 Complex", "id": "f6cd184703ac7d520e77b35cace10c6c1c9c9cf6a4a147c0295b7314e57ca0978bbebc2cff93645ab3c8c3d953fcfb5bc196ee901840b8de169c44bf64b211c3"}, {"function": "Complex", "members": [{"function": "Abundance", "namespace": "CHEBI", "name": "amyloid-beta", "id": "a9487b29439483c6840095610dd3e496e3ca9cccc3a8d71e0385a39b570f3c0a26965ac06d83265e1c08deaae7998272d4f4c21ec0534f8be3fd8e4e57dbb3a2"}, {"function": "Protein", "namespace": "HGNC", "name": "ACHE", "id": "9d3104b5d47c472fac8109aed790de48a5955d80c72a1ca46580350b0d6c41e96ee75cb1cb868657d107abf241c10c81b1c892d4eee5a68f558f78cd14ca802f"}], "id": "53a2322980f95d96e84ccccced58c1b6b226ba276fed9b6d4c8dffdffb5b2f89ff5e88b90f98cc43ec54ea15c1f46d44a0aca7a465900679cb6c624fafcb52d1"}, {"function": "Complex", "members": [{"function": "Abundance", "namespace": "CHEBI", "name": "amyloid-beta", "id": "a9487b29439483c6840095610dd3e496e3ca9cccc3a8d71e0385a39b570f3c0a26965ac06d83265e1c08deaae7998272d4f4c21ec0534f8be3fd8e4e57dbb3a2"}, {"function": "Protein", "namespace": "HGNC", "name": "GRIN1", "id": "667514f13a70b6a863d5f79ef125df9a3ed6b79b29e376e85d5c58a99fd978bd1dbf9105c7c24a407b1accdbfeef49b9256a26da4d0a48dc47a7374927efb547"}, {"function": "Protein", "namespace": "SFAM", "name": "Cholinesterase Family", "id": "19066267b55cde865a5a0e83fe911a2104a8afc2e23aebd265674c94421c460cdacb515e26b13174c49de32f80e1a9faae4f18fad7152e9ae04862a7b6be9299"}], "id": "159433ef29fb1ad85908027cd36bc794563accee1dbb977a21f9408ddd534ae5049cb354121693750db8e255a9edd731ba7f24d9a87fa4e90ae47cc85bb12583"}, {"function": "Complex", "members": [{"function": "Abundance", "namespace": "CHEBI", "name": "nefiracetam", "id": "7f3196ad00a4b8a75e29e44a626e93fcda0f2cb134af8c104089342b21c96731807b3ff9e3513070762c21b58fd4cc2b16b6df1c9fbc061a8176113f81e4b3d4"}, {"function": "Protein", "namespace": "HGNC", "name": "PRKCA", "id": "5219ddfd45ab407e59a16ba37c54192d6d74de0a9d1658b16570713f21507ae5bde72c5b85c3a4d93e811fab5db2b129ab97648a370a0fd2add9239eff17ad06"}], "id": "c81cf3fd8fb80df2c7afa0442f88418db31556fc395e8e784bf032df0d1e1821e388d37bc6b5c5f98ecf2d1f24ff0d693c14456faed4beac28e183fa3462296c"}, {"function": "Complex", "members": [{"function": "Abundance", "namespace": "MESH", "name": "D007031", "id": "ff0158a11e6ee524522e34eb4c31db77386d110fbc88b1385a0ee96d4bd66d3a1b921e78cb6783a71977b8bb41e80544e6b59cf180c7eabdab011d388951cd0e"}, {"function": "Abundance", "namespace": "MESH", "name": "D010902", "id": "6d471bd7461f4bde04f0b3d79e2cf98ac19f254a9665f98ee12a25440535d92c66cc1047344141305a92585d31366920d2b057a21b5d37655e7b01432a464e04"}], "id": "edf919ff4e13c47cd945a627cb4b1c3aacda0a17db2282749e569efebb1638064d4e42bd99858429c8ec12092f5fd9728d5bbf1f2bb0cf2a33659c7651f7f28e"}, {"function": "Complex", "members": [{"function": "Protein", "namespace": "HGNC", "name": "ACHE", "id": "9d3104b5d47c472fac8109aed790de48a5955d80c72a1ca46580350b0d6c41e96ee75cb1cb868657d107abf241c10c81b1c892d4eee5a68f558f78cd14ca802f"}, {"function": "Protein", "namespace": "HGNC", "name": "APP", "variants": [{"kind": "frag", "start": 672, "stop": 713}], "id": "3e5de8e845a1a7b00bc3bcb2e2ce192ad8c91a9c1beb7f894571f750d8d4cbcfb96c2dcabb2c5f461e38a63cd31bbb7233e393cfba29dea19455033cd38fbe28"}], "id": "86d0b8ea6c9e31f91b5fabb49664de8e7f1e4d363bdd29084d5ff0d58c65c3e38ba3d143ff260ab4d6d399a8ac3eb367dbdd8d9124a613d6d0be078b29d73f44"}, {"function": "Complex", "members": [{"function": "Protein", "namespace": "HGNC", "name": "ACHE", "id": "9d3104b5d47c472fac8109aed790de48a5955d80c72a1ca46580350b0d6c41e96ee75cb1cb868657d107abf241c10c81b1c892d4eee5a68f558f78cd14ca802f"}, {"function": "Protein", "namespace": "HGNC", "name": "PSEN1", "id": "1bd45a944b5c10f3c058ae82889876ff98fedf45e982a4db6a034e656845574daa76c407b40b21386a2b59045178e42fa90d4c5b8226477d9f5c86c4b4aa727f"}], "id": "578d66ce2613af4c015b8c831962b3c0f9eced5e4544250ececcb0393893635ab885e0caaf8df5263d052f8dad3cc6e4a166d2695fb05e82673519a5a0566310"}, {"function": "Complex", "members": [{"function": "Protein", "namespace": "HGNC", "name": "CDK5", "id": "a85beb5b2b9417fabbbcc2135b9533cb0766b38688caf02242632843ae455bad332fb625d6e8296ff77b40e841485a56854fc14e300552425d596e8a8e70fd3f"}, {"function": "Protein", "namespace": "HGNC", "name": "CDK5R1", "id": "0207787ec1a245b4edc4d61e093cfdf729180ecde8b3c7ae6644ca38fc0a28cb03b727dba6caaf192b4a98594148ceee9ff9e34195a7f8915ee6f683b8a08526"}], "id": "f4c257e967616f0f74693d60486361c7668ea8db16385c3e7dd5002889a12e3cdeaf9ebf5d1117a23aecf4b6e93d1817024b36ec26478a5d4212822cef5e88b3"}, {"function": "Complex", "members": [{"function": "Protein", "namespace": "HGNC", "name": "CHRNA1", "id": "2c954be76ae672869d04b052482aff81e8668f2b0c084e05a07b56bc45478c32c71764e3875f446be6d7e0117f400a88ca72e5d5fc0029229d0c16c4ae3e8e6f"}, {"function": "Protein", "namespace": "HGNC", "name": "CHRNB1", "id": "1c047d2b05c2943c0d93829faf7eca2f2847720340809607e7aa7e77cf2565d0ce5534dc0153fcd6d94cf666bef778540900bf0f642be98eb5ca383f7f9e8770"}, {"function": "Protein", "namespace": "HGNC", "name": "CHRND", "id": "0fc12a3743f6213b0a8c9854f102f96f98b6d4ca5f6b93243215c6be9ef59d1071e4a981dfef35497424c052ed7d381aad79e113dad69e8c322a85d581ef69e9"}, {"function": "Protein", "namespace": "HGNC", "name": "CHRNG", "id": "fdc2324c7ab13b542120da2e930dae1aa2c84562e3bc9a659ddf97ae7412bf4cd7e8ad8fa72eca411b79eb3b1dc8c21dbdeb575bf3d6015c33aae8e21ca0cdf8"}], "id": "76fa9909b7cfbd23d587069186d43c5eca774e2fdcc9f16a69c25d02a2dae79f8435674d0efa370aa47f70a384143f531a4c168fdf208bf2b0bceaa1829ae335"}, {"function": "Complex", "members": [{"function": "Protein", "namespace": "HGNC", "name": "CHRNA3", "id": "6f78ff6a0f6731184d18899c2d440e5a27e7d27df60a82118f44199252b2aaac56d93dc20fb99caf759ea575a26ffe4179b16e056eea94d72bb48e24ab188c2c"}, {"function": "Protein", "namespace": "HGNC", "name": "CHRNB4", "id": "54a4217f39d22f6dab3931757d3288776dce65f089209e15d5c6b0a31c7346fc28b6bd9fd28653945fa42712c1e563e6e62e9b484a4896e5f385b0248ac2f9ea"}], "id": "c2a872c8548c02a60f1e06a8d384f798fe2e4d5c68bce0786ec4788ea98e9c3034227b18261bb492807e45a48591a802b06d3a9b5f81778205b8e4d57e2bf051"}, {"function": "Gene", "namespace": "HGNC", "name": "CHAT", "id": "a544ba10794e1b938ff3fdb881728e918f4223f385ca56974485b0ff375b1c4666307a966898341b9a575051756db470440c86f648edd7b156e15326a892d9c8"}, {"function": "miRNA", "namespace": "HGNC", "name": "MIR132", "id": "8e57370dcb4330120a4aed192ad033fe2b74734ac575ae115f7680da52fbb1607de92c1c42d19865f08f6868d2d511856b9ac03eb86cdef0943ad999e3f8e4bd"}, {"function": "Protein", "namespace": "CHEBI", "name": "amyloid-beta polypeptide 42", "id": "28b313e4c8862e5c5e4c61250bc7fb4a27198024ddb8bedf748b82ded0c7d1ed6d616e8cb18a27c8729f80d6e3b6a70afe480b0f772cccf217c9e3f15aa72b07"}, {"function": "Protein", "namespace": "HGNC", "name": "ACHE", "id": "9d3104b5d47c472fac8109aed790de48a5955d80c72a1ca46580350b0d6c41e96ee75cb1cb868657d107abf241c10c81b1c892d4eee5a68f558f78cd14ca802f"}, {"function": "Protein", "namespace": "HGNC", "name": "APP", "id": "ed1d45f3255226e4210017e6c179950e0e04a300727326d7fea6a9659868e8818ff64fd5e8a2a92a703fb1566b3f48323750ac6c28e7adb40843053d276710bc"}, {"function": "Protein", "namespace": "HGNC", "name": "APP", "variants": [{"kind": "frag", "start": 672, "stop": 713}], "id": "3e5de8e845a1a7b00bc3bcb2e2ce192ad8c91a9c1beb7f894571f750d8d4cbcfb96c2dcabb2c5f461e38a63cd31bbb7233e393cfba29dea19455033cd38fbe28"}, {"function": "Protein", "namespace": "HGNC", "name": "BCHE", "id": "82b8adb88edcf051792b8febba4d4eefb691627fdd5794e92fff61d19796df78598312e9daad8390028c4c45e1b1868d1839098cc3edc45e25a2c1b92260d458"}, {"function": "Protein", "namespace": "HGNC", "name": "CHAT", "id": "83616fc651645c99c1241b56d867a50ae4c018175bde3ba565013689e69f634139b6a62407ad56c90279b66bb2ed0f021686ef2123872c34ad71eb747efce213"}, {"function": "Protein", "namespace": "HGNC", "name": "CHRM3", "id": "321acd12eb1b51bc2a14b21c01d30c83c6a4ce5c3255ef3cf2690b65596f9594c541dc6fe9a23210d952a2fdac2f2d05aa91e4299d1942926ea0932119e338ff"}, {"function": "Protein", "namespace": "HGNC", "name": "CHRNA1", "id": "2c954be76ae672869d04b052482aff81e8668f2b0c084e05a07b56bc45478c32c71764e3875f446be6d7e0117f400a88ca72e5d5fc0029229d0c16c4ae3e8e6f"}, {"function": "Protein", "namespace": "HGNC", "name": "CHRNA10", "id": "0bbc48a8cfa60e08e8a1ba5af2709f120f3f13d715aee919c66261813355c8676197175be8c1904aef415d92c7c0d776e87a2149fc30b3d7f1665158f1c0c645"}, {"function": "Protein", "namespace": "HGNC", "name": "CHRNA2", "id": "019d1c092def2bddf48f48ad995d60d9628fb0125b814a5e643e6910d6eeac771b60993b4c3408eb54aa70f35c7ae8fe499737202541875d1f38277a8bb9b237"}, {"function": "Protein", "namespace": "HGNC", "name": "CHRNA3", "id": "6f78ff6a0f6731184d18899c2d440e5a27e7d27df60a82118f44199252b2aaac56d93dc20fb99caf759ea575a26ffe4179b16e056eea94d72bb48e24ab188c2c"}, {"function": "Protein", "namespace": "HGNC", "name": "CHRNA4", "id": "c49a9652cba613af55ca7c03c108df12ef9ea4e37760fcb7b2302e019899a0eaa11f06c1dcd9b9eb143b9baba0daa89737d73dafbfde9d8ddd8dd53b2a8269e0"}, {"function": "Protein", "namespace": "HGNC", "name": "CHRNA4", "variants": [{"kind": "hgvs", "identifier": "p.Ser413Leu"}], "id": "2d58bb8c46dc036309269694130e4d1f7580790dcefc1483d08a16162f38da4a1495d283a476247f3ed6f76af9b01a8dbe0643127c2edecf286f2cb40a98dd41"}, {"function": "Protein", "namespace": "HGNC", "name": "CHRNA5", "id": "615cec2665d995fe2c996d1183a4728e324f4b0f6225b7b3c5f0a0543ff18b97454ba99ae0984cf85ff27bb465eaa83c00cd65aefa96193d58a3332751cca192"}, {"function": "Protein", "namespace": "HGNC", "name": "CHRNA6", "id": "538307ae2a1fc2af82c7e0a0286320b0366e3e9a4e5b9597803273c5c0f3049fadef72ad508f6edec030727aaf62edd6170575aaa6046e40567d53e7322aaabe"}, {"function": "Protein", "namespace": "HGNC", "name": "CHRNA7", "id": "6f517aad2a254d42d4e0bd5118246057049b85324ab857629d0caa2da5e997bfcc08f9a0a2cd83bbb2b536c048ce402c0d521604c43b1b9c720f4e20b4dacd99"}, {"function": "Protein", "namespace": "HGNC", "name": "CHRNA9", "id": "8d5d3a89881c31692ed5f732b23bf994b16f9ac57317f45527031b0c2258040a2761bf4bb5132efa27de3f9d8dfa9d0950b3d1a094913610ff2bc9b8d01e8c04"}, {"function": "Protein", "namespace": "HGNC", "name": "CHRNB1", "id": "1c047d2b05c2943c0d93829faf7eca2f2847720340809607e7aa7e77cf2565d0ce5534dc0153fcd6d94cf666bef778540900bf0f642be98eb5ca383f7f9e8770"}, {"function": "Protein", "namespace": "HGNC", "name": "CHRNB2", "id": "fe8a0d337c8dfad7d9bbfcd38db3a76bbbfa276ae7af2e39600a1b845049505e52dd605173e1b8a8b67178c31bb8cde3f2669676e398c994800c15170b63033e"}, {"function": "Protein", "namespace": "HGNC", "name": "CHRNB2", "variants": [{"kind": "hgvs", "identifier": "p.Gln397Pro"}], "id": "02a6d6190f7dc62318b3fb36f3d3df98b5762668bff3c9b5b50bbc8a5936461fd37ce43992984538d93a818588a040c7126380917560263b7b94e864043d41b1"}, {"function": "Protein", "namespace": "HGNC", "name": "CHRNB3", "id": "cab3d2b7a9a4321d552b5fbe2ff10363ec8ef4b6600f91369ec41f7131fc6d427e0b159e6626d5c42f2eea7b9c11390fc4a6b2964471ee70776ea8960135e7ca"}, {"function": "Protein", "namespace": "HGNC", "name": "CHRNB4", "id": "54a4217f39d22f6dab3931757d3288776dce65f089209e15d5c6b0a31c7346fc28b6bd9fd28653945fa42712c1e563e6e62e9b484a4896e5f385b0248ac2f9ea"}, {"function": "Protein", "namespace": "HGNC", "name": "CYCS", "id": "18cad379a6a2e954cf3453bb000c42de777b83b2e638a8b3f3ce03ae93e2edabd6b794d6283d05bb292ed583113d090155b3e6a908fbcebcfa126041d9bb1e03"}, {"function": "Protein", "namespace": "HGNC", "name": "EGR1", "id": "9e06a6d40a8c0e52e3920705342d4ddef7be8aec5acbf83dfb9473e9fdfbc339a1beddba9ef7ffbc1a4fc255edc38098cb1d9acd7319bf7aa22c0b02bfe2ec94"}, {"function": "Protein", "namespace": "HGNC", "name": "GAL", "id": "57d9ab49d0be5819ca4d59a2db1d414b33c10534dacd371b85cde9d985aff13542e37c51455c5ef5a6ba52a51bb5cfb66982284bef1e98eb0f42d75cb624e36e"}, {"function": "Protein", "namespace": "HGNC", "name": "GFAP", "id": "770dc5af3e4196536cabe720b408d7b24bb48c25eaa89cca048be9e87bed6118fbd749fb5c0b8b7814422fb430d364ec871f487b806b480765332568170c04b5"}, {"function": "Protein", "namespace": "HGNC", "name": "GNRH1", "id": "c73d2d9adf61140613925a998925c50f91e3f022ab517ca6d8df65178012bf494f85790441dda4ee8fe561d6cfa3d7d7e61062d2d817ddde5f9cf432f6ea704b"}, {"function": "Protein", "namespace": "HGNC", "name": "GRIN2B", "id": "dd9815c83f93be031a07df6d80146f91f55b3ad8850ccdd967007048fd2354c2bc2fec0dd0a8f428c9c411568fced227500db81dfea20193b9138af7008527a0"}, {"function": "Protein", "namespace": "HGNC", "name": "GSK3B", "id": "ac819ecac7786e3ea9b6906b318167c6a94fbbf428aff46f85083b83c50b9604342d39c1c36ff49c2cb3a04e491913164c3e4e7889dedd513b6196d9b0560c7c"}, {"function": "Protein", "namespace": "HGNC", "name": "GSS", "id": "2391ecfed777b3394996c0d3fa5823736ad785e8cc9ae0772926925ebc771c0cc2615f661ae2488458ce7b34e582e2dd7a1c92eaaad477b7527e86c48924e294"}, {"function": "Protein", "namespace": "HGNC", "name": "IGF1", "id": "3369894fadb1dfa2a161a7804d9e5be75205b590f45176482fbb7013986d328fd7874e0e48874a6658bc4a2d90f06abaef588ce4071f2e3b42a29a7376a4e892"}, {"function": "Protein", "namespace": "HGNC", "name": "IL1B", "id": "bd7736973dc00dadc09dff75214ff05344d2e9b6dfbc09a364f08b7cae84142149292551bd60d5addd6130e971c2ccd4c73b963ad918ad9b0a418b94e5a30cfd"}, {"function": "Protein", "namespace": "HGNC", "name": "INS", "id": "bbf5c1f16cd0d6ad433776f0bfeca42c89fd769028501363322b16adc74541669b4a0e8ddaf039ade6e7341f046de2ad42cf1f110f16c8abd4666fd4ee201149"}, {"function": "Protein", "namespace": "HGNC", "name": "NGF", "id": "6280e1263996aa31e327521e5975bd06ec1fcc254924ed2e22ada8044eaafa6aeb9242e083f65427b4461e8f6a7d39b80be9b9a35d3509d266e3ced9c2b7afe4"}, {"function": "Protein", "namespace": "HGNC", "name": "PPARG", "id": "0e8e56c8283d2ecd1891f10c1af0df58cb3fddb59bda2602833ea4589421d99fc367c279c121c537f16286f31f75b15567c5ef8fc67dc6fe427743d342956700"}, {"function": "Protein", "namespace": "HGNC", "name": "PRNP", "id": "97023c238092f75f952ae0785caba6d1454099f27405c7e582078f2f49f5ef146e0c8eb3a1c25a63781a21e5d83689e958397e3115d98e65cf8c5a2ad9c7bffd"}, {"function": "Protein", "namespace": "HGNC", "name": "S100B", "id": "f7c74d78e50e9084bbd32771955eff3c412004927980d769d1edc2fba3b569af908e85437a88a7eed468bdc0b56c2c60a4bc2559ff565f010a15f1040abfc855"}, {"function": "Protein", "namespace": "HGNC", "name": "SLC5A7", "id": "d080db34955f32262c0fc79e8f93d77ff386a2798d1a72c8f93c5d8cf56a35dda7e4f4434524b58872a6bfbe8fce024fb83d7e2158bb2b5351e14a4ca9a7ba50"}, {"function": "Protein", "namespace": "HGNC", "name": "TNF", "id": "a262f5edbfb734dd0ec9696a3b78644fccfb4054a9cf9225beb17c33ef416a75809ff59ec1646e29a3cccc804c9294f8d2c48120af9f5ee98e764a584626426d"}, {"function": "Protein", "namespace": "MGI", "name": "Chat", "id": "ffd38656243bcb11a991e8162245e3ed9500bc880c18b7aa0e85c196632d3976be429258eff1448de46c4c00a6c2d1867bd0db2f8295897d909997af5deb3239"}, {"function": "Protein", "namespace": "MGI", "name": "Chrnb1", "id": "9fbf2b115a2ddc1bd11ad56b1e60d236deacdd0bb2f3d1e45e7bd319ff1e39671618e8b92e2617b927a47632a09ca791ab7bff17316e17cf606e6b09155c0aa1"}, {"function": "Protein", "namespace": "RGD", "name": "Chrna10", "id": "69ac8e4847b8dcd7b5e2009b8c6832f1f855dcfeab326ea8bce1dd3ef2666572ec7286b0eed3e574f593a298f12497e021e4323c9f7958e886cf6b1b75fa1400"}, {"function": "Protein", "namespace": "RGD", "name": "Chrna2", "id": "9317f9aaf8023cab527e708c7052887b50261c5e6bd9d2a81e7b47d2d61297224e751aee8b86ca845af606cc468052cb12b9a6ba9b0e4f065fbd611d7e7e7c9a"}, {"function": "Protein", "namespace": "RGD", "name": "Chrna3", "id": "9619bf33a45a645d83f27c3a58cb2fe2a54d438f8e910f7631d33d88a8a59f6b2eb41358ef1222f7f5b64de93d8a815f8684bc212d9f178af983d2de63badfd7"}, {"function": "Protein", "namespace": "RGD", "name": "Chrna4", "id": "ee1a0632c26dc74bf4ac34d654fa66537635d5c49fbdf5342f644636d211286537975e69b6a9d59ae410d01ad13b492e0a50120f8db27e9ebc752a38a6922951"}, {"function": "Protein", "namespace": "RGD", "name": "Chrna5", "id": "8e7f39076c12cdef7f6ced18c1c3b17577f39ce654512a81bd83c6208b04f1bdd1335ba1ad460a53cb4256d49ff2d47390c7e9ba616f62f521226cb2e5b4cbc4"}, {"function": "Protein", "namespace": "RGD", "name": "Chrna6", "id": "d43872109fb20eafdbdcb88b6e35f0334d35c8d45c58def0c2f13858a14785be519008145aec1dd4280f00d0ca69121fc3f95c73044989ee96d54d11b09d3a3d"}, {"function": "Protein", "namespace": "RGD", "name": "Chrna7", "id": "558537edd623f47f442a028a059090fdfc4001eba09a09a5d2f3bf72ac00dd4c36ad8e7d12cc322bc35b7b8c70cf8e9eb47c295e777230655fff6463c7ebc675"}, {"function": "Protein", "namespace": "RGD", "name": "Chrna9", "id": "ddb2425b74b2eb7b1e913961bce4adf94ae617381d6477933487b16ccd2592b67498eb7680c59b61ce06391b936eddd2afe47e10cba5b492515ebf22373a50b3"}, {"function": "Protein", "namespace": "RGD", "name": "Chrnb2", "id": "8cb5d91527b60fb1bdef5cc95e306950986de7181b6438f1b030b372ab541191b3cceb5efb3318c82818248a666e6f062735401129a4576c3c601a3cf26555a3"}, {"function": "Protein", "namespace": "RGD", "name": "Chrnb3", "id": "2ef69e741e727ddb2e99c7ad8f4a03a606c3c222c5d2c8aab964340e323ba1c72090edaf3cf46077e149c899647b072c4f864c1125abe6382c9fe1e2f720caea"}, {"function": "Protein", "namespace": "RGD", "name": "Chrnb4", "id": "a672e79ebbc7ba640d8fe8c7a6a63c94826eee6a7264c930f87cf76e3b4a2ecaa7fa3e6115c238f423fe9df23714b62c27937e84c247729ebf978c528930e58d"}, {"function": "Protein", "namespace": "RGD", "name": "Ins2", "id": "7350ae2f651c57430f53ef794b83b0b7daeccd1cb64e26c06334af69513187df795d68fbf32e627aacd4cba6fd6d382f7a455605f85f30b100b0f01e27221e63"}, {"function": "Protein", "namespace": "SFAM", "name": "AKT Family", "id": "3688c50ea6bd1508059871b6c133d4ddbcc43ba60fff7f2785c1c86c5a7c6000ac6be617b23ac5df27c8f40621a0f4c24a4f0509ddc82032f9784033e7845240"}, {"function": "Protein", "namespace": "SFAM", "name": "CASP Family", "id": "102c28193ab8de80bcf75454eba21062478826ccb2402455148e9eb09a349fdf46252374853f1968a612134d5a557fff583a680bdd848762d6fbd97b855a5079"}, {"function": "Pathology", "namespace": "MESHD", "name": "Alzheimer Disease", "id": "0893d59040331bc1b155187396067458820ab2635e0138b840323082d33d44b964ab1240f5aeb64c5360e1340de40545835bc744c181abb910d64c923d55ff2b"}, {"function": "Pathology", "namespace": "MESHD", "name": "Diabetes Mellitus, Type 2", "id": "34ae038f6bd570018591f1e938fce29e2bf6d60d25a9eba130f24222928ae68da387f4a3cf27a757d1cb95f08e79384b2923415a4f175e1aaa40ee0e5e819278"}, {"function": "Pathology", "namespace": "MESHD", "name": "Inflammation", "id": "105f4167508b4d96d8df8e04cfb3d84bd7d3af8b312f852502dede706fbd61636cfba0f29d669053a109275f0761f212596ee9f18453d168da563f716b9eaa15"}, {"function": "RNA", "namespace": "HGNC", "name": "BCHE", "id": "c085dbff08b5971c984503940dcedc7279f4c8a2b7d452feea994d034569cd44f18d26b27748757698ff2b931d48d8877f500189d06682297c3d37edcdad38e6"}, {"function": "RNA", "namespace": "HGNC", "name": "CHAT", "id": "db3f45ee6c46466c45ceeef6d4e14ac12979e1787a8be54fee5e34eadf546401b8474f34d6c38930d09dcef7658a989f3e41291cb0ba0c227d035a687fa9a596"}, {"function": "RNA", "namespace": "HGNC", "name": "CHRNB1", "id": "64789846cac51236bb8915ac3c714472cdd313a0e03a2f00701c6f51b4e03309599c50070b08697f765d281ecf4f84d0079038fe9a7947e1394f6a0f48fdaeb0"}], "links": [{"line": 34416, "relation": "increases", "evidence": "Loss of APP leads to aberrant localization of CHT at the neuromuscular synapses and reduced CHT activity at cholinergic projections.", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A2007", "reference": "17709753"}, "annotations": {"Subgraph": {"Amyloidogenic subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 89, "target": 124, "key": "c26b245a28d66a9d09b7ace2ad8e0cf69d02ca09613e68395ca786c8ddc8629886a3ba4bdbe3d7f9f081b08c7abf3a816e9e173f4ac2a604c765d50d650687d3"}, {"line": 34422, "relation": "regulates", "evidence": "At the cellular level, we show that APP and CHT can be found in Rab5-positive endosomal compartments and that APP affects CHT endocytosis.", "citation": {"type": "PubMed", "name": "Proc Natl Acad Sci U S A2007", "reference": "17709753"}, "annotations": {"Subgraph": {"Amyloidogenic subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "object": {"modifier": "Activity", "effect": {"name": "tport", "namespace": "bel"}}, "source": 89, "target": 124, "key": "75dcf84c1524a06e6a97dd22ecd076733409facb92c6f3f38fc00b59b5d0587cf11ebbf8d518a1d4604a8d4a45acd232b18f1fa878201dc069c5b4ca7dc6b03d"}, {"line": 30288, "relation": "association", "evidence": "At this point, inhibitors able to interact at the peripheral binding site are of particular relevance, as they might disrupt the interactions between the enzyme acetylcholinesterase and the beta-amyloid peptide. ", "citation": {"type": "PubMed", "name": "Curr Pharm Des. 2004;10(25):3131-40.", "reference": "15544503"}, "annotations": {"Subgraph": {"Non-amyloidogenic subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 90, "target": 88, "key": "219429a0b697c0cfd4a39df2e90e35c37242f77664615a3ec74dab73946d227d03bae177c1f600103bcfe1488612a19de599be03d900920d795d3147b84cb010"}, {"line": 51648, "relation": "increases", "evidence": "Ultrastructural detection of choline acetyl transferase (ChAT)-immunostaining in cerebral cortical sections/ of transgenic mice clearly demonstrated degeneration of ChAT-immunoreactive fibres in the environment of beta-amyloid/ plaques and activated glial cells suggesting a role of beta-amyloid and/or inflammation in specific degeneration of / cholinergic synaptic structures.", "citation": {"type": "PubMed", "name": "Brain Res. 2003 Jul 4;977(1):16-22.", "reference": "12788508"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 90, "target": 36, "key": "e5ccf1ab3a36c49d5ddae3f4ef856f2b6177672eb87e05112465c5f2398af121e76094389ee05f15f57c6454467c4205b8e1353306790cfe2587ccbd918d050c"}, {"line": 43966, "relation": "increases", "evidence": "Dysregulation of intracellular calcium signaling has been implicated in the pathogenesis of AlzheimerÃ¢â‚¬â„¢s disease [150]. ABeta¸ is known to act through multiple targets [151] including Ca2+ channels and various receptors in membranes. Synthetic ABeta¸ binds to the calcium permeable nAChRs with high affinity [152]. ABeta¸42 administered in the low picomolar range activates nAChRs at presynaptic nerve endings of synaptosomes [83, 153]. Under normal conditions, activation of nAChRs is necessary for the ABeta¸-induced increase in synaptic plasticity and memory [23]. However, it remains to be determined whether these effects are mediated by a direct physical interaction of the peptide with the nAChR. In addition, ABeta¸ enhances transmitter release by transient increase of glutamate release from the presynaptic terminal that results from brief periods of high frequency stimulation with Ca2+ buildup within the terminal that triggers mechanisms of short-term synaptic plasticity [154].", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"Amyloidogenic subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 90, "target": 69, "key": "9f5382f3fd196564e3bf43a6c95d99545e26fc49e04781912e5b10d93e4a918b1399b9dc87e783ae2fef49bbb76813cadcaaae2c0879c004197731ff5e628ca7"}, {"line": 43926, "relation": "increases", "evidence": "Dysregulation of intracellular calcium signaling has been implicated in the pathogenesis of AlzheimerÃ¢â‚¬â„¢s disease [150]. ABeta¸ is known to act through multiple targets [151] including Ca2+ channels and various receptors in membranes. Synthetic ABeta¸ binds to the calcium permeable nAChRs with high affinity [152]. ABeta¸42 administered in the low picomolar range activates nAChRs at presynaptic nerve endings of synaptosomes [83, 153]. Under normal conditions, activation of nAChRs is necessary for the ABeta¸-induced increase in synaptic plasticity and memory [23]. However, it remains to be determined whether these effects are mediated by a direct physical interaction of the peptide with the nAChR. In addition, ABeta¸ enhances transmitter release by transient increase of glutamate release from the presynaptic terminal that results from brief periods of high frequency stimulation with Ca2+ buildup within the terminal that triggers mechanisms of short-term synaptic plasticity [154].", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"Amyloidogenic subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "object": {"modifier": "Activity"}, "source": 90, "target": 94, "key": "227a72eea81ce74ddabbbcaa695cb5665d3dd6259f9ff9fba9d380d2c828668d75fda16ed55f7f1cf58fd62ec25068b64df6bd6f80d4c17d1e76bb4f1caaec6e"}, {"line": 43962, "relation": "increases", "evidence": "Dysregulation of intracellular calcium signaling has been implicated in the pathogenesis of AlzheimerÃ¢â‚¬â„¢s disease [150]. ABeta¸ is known to act through multiple targets [151] including Ca2+ channels and various receptors in membranes. Synthetic ABeta¸ binds to the calcium permeable nAChRs with high affinity [152]. ABeta¸42 administered in the low picomolar range activates nAChRs at presynaptic nerve endings of synaptosomes [83, 153]. Under normal conditions, activation of nAChRs is necessary for the ABeta¸-induced increase in synaptic plasticity and memory [23]. However, it remains to be determined whether these effects are mediated by a direct physical interaction of the peptide with the nAChR. In addition, ABeta¸ enhances transmitter release by transient increase of glutamate release from the presynaptic terminal that results from brief periods of high frequency stimulation with Ca2+ buildup within the terminal that triggers mechanisms of short-term synaptic plasticity [154].", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"Amyloidogenic subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 90, "target": 59, "key": "36c1c22b32eb9de72f01a7214654ab74c19661620cd3667ae5b6a1d9841947d09ca35f3b2dae8c3bb17fb35a87eeacdd881d949f56d6bfd87bff148a52ac6b63"}, {"line": 43970, "relation": "increases", "evidence": "Dysregulation of intracellular calcium signaling has been implicated in the pathogenesis of AlzheimerÃ¢â‚¬â„¢s disease [150]. ABeta¸ is known to act through multiple targets [151] including Ca2+ channels and various receptors in membranes. Synthetic ABeta¸ binds to the calcium permeable nAChRs with high affinity [152]. ABeta¸42 administered in the low picomolar range activates nAChRs at presynaptic nerve endings of synaptosomes [83, 153]. Under normal conditions, activation of nAChRs is necessary for the ABeta¸-induced increase in synaptic plasticity and memory [23]. However, it remains to be determined whether these effects are mediated by a direct physical interaction of the peptide with the nAChR. In addition, ABeta¸ enhances transmitter release by transient increase of glutamate release from the presynaptic terminal that results from brief periods of high frequency stimulation with Ca2+ buildup within the terminal that triggers mechanisms of short-term synaptic plasticity [154].", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"Amyloidogenic subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 90, "target": 12, "key": "305a9cc4c386fcbe1d8f4fa26cedcde450b62a4647be59c55d068bc485981d5cabec9a27dedcb2df559160266e68e360770e0539a126904a5e63a11ffa168e3d"}, {"line": 51644, "relation": "decreases", "evidence": "Ultrastructural detection of choline acetyl transferase (ChAT)-immunostaining in cerebral cortical sections/ of transgenic mice clearly demonstrated degeneration of ChAT-immunoreactive fibres in the environment of beta-amyloid/ plaques and activated glial cells suggesting a role of beta-amyloid and/or inflammation in specific degeneration of / cholinergic synaptic structures.", "citation": {"type": "PubMed", "name": "Brain Res. 2003 Jul 4;977(1):16-22.", "reference": "12788508"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 90, "target": 126, "key": "765ae4ed797d5e0ff7fe3d34f0d93a24be2626686e4ecf0a9f7bd0c3d08ef25a2b463c5a24238e9a207838bca388ed0bbfd29a0ee94ea23d381cc9aa204aeec4"}, {"line": 51653, "relation": "decreases", "evidence": "Ultrastructural detection of choline acetyl transferase (ChAT)-immunostaining in cerebral cortical sections/ of transgenic mice clearly demonstrated degeneration of ChAT-immunoreactive fibres in the environment of beta-amyloid/ plaques and activated glial cells suggesting a role of beta-amyloid and/or inflammation in specific degeneration of / cholinergic synaptic structures.", "citation": {"type": "PubMed", "name": "Brain Res. 2003 Jul 4;977(1):16-22.", "reference": "12788508"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 90, "target": 60, "key": "86262b9442be6d5c4979480f220c1b52e56b2a2ba8692415f0df9710729364fd384867dca979afdfc506df49fa43896e61747966decd18c81fa5fae908b10283"}, {"line": 1413, "relation": "increases", "evidence": "Acetylcholinesterase (AChE) enzyme inhibition is an important target for the management of Alzheimer disease (AD) and AChE inhibitors are the main stay drugs for its management. Coumarins are the phytochemicals with wide range of biological activities including AChE inhibition", "citation": {"type": "PubMed", "name": "Bioorg Med Chem. 2012 Feb 1;20(3):1175-80. Epub 2011 Dec 30", "reference": "22257528"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Very High": true}}, "subject": {"modifier": "Activity"}, "source": 88, "target": 142, "key": "0af13d4bb4a64fc98a494f7fc5dc3d00799dde6d28c16906b24eab7a8fcb144a2f144849192003358df183f2fdc0a7e6d47f6b69c22ef988b1b0238b48bd66e2"}, {"line": 1920, "relation": "negativeCorrelation", "evidence": "Alzheimer's disease is rapidly becoming one of the most prevalent human diseases. Inhibition of human acetylcholinestrase (hAChE) and butyrylcholinestrase (BChE) has been linked to amelioration of Alzheimer's symptoms and research into inhibitors is of critical importance", "citation": {"type": "PubMed", "name": "Bioorg Med Chem. 2012 Apr 15;20(8):2595-602. Epub 2012 Mar 8.", "reference": "22445674"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Very High": true}}, "source": 88, "target": 142, "key": "16ce10b5d4af233ccefee3059c51b569212026dd8b0ea83e51576549b1ac541598dba9072e6885ea5de31efaf710af0f3fdd58ef9fbd80743fa1a2856e6eeac1"}, {"line": 14142, "relation": "association", "evidence": "Butyrylcholinesterase and acetylcholinesterase related proteins were found common to both Alzheimer's disease and diabetes; they may play an etiological role via influencing insulin resistance and lipid metabolism.", "citation": {"type": "PubMed", "name": "Lipids Health Dis. 2006 Nov 11;5:28.", "reference": "17096857"}, "annotations": {"Subgraph": {"Insulin signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 88, "target": 142, "key": "517b6244ec74ad25b597c07826004415b11cb55fe3dfeb9ba2ae7853f3561cc0d1cdf2db54465adf1643a93a9e6583cbd0d002d79cac60b3986ddc240238cb5c"}, {"line": 3829, "relation": "regulates", "evidence": "Acetylcholinesterase (AChE) is thought to play an important role during apoptotic process. Our results showed that H2O2 induced AChE activity, a functional marker in apoptotic process, increases in neuronal-like PC12 cells. Glutathione, which is involved in cellular redox homeostasis, inhibited the increase of AChE activity, suggesting that reactive oxygen species (ROS) play a key role in this process. Further investigation showed that the elevation of AChE was observed after the degradation of Akt, release of cytochrome c from mitochondria into the cytosol, and activation of caspase family members. When nerve growth factor (NGF) was present, with the maintenance of Akt level, the elevation of AChE, the cytochrome c diffusion, as well as apoptotic process were markedly attenuated in H2O2-treated PC12 cells", "citation": {"type": "PubMed", "reference": "17213958"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"Apoptosis signaling subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "source": 88, "target": 55, "key": "edad48c20e39f1fc0a8556ee2291a3bbd0019a2982bfa62db05737f04ee4e7e3481c32952159cc1eee85fe507972308019d2ef31becd66444c3284455e12189f"}, {"line": 3976, "relation": "negativeCorrelation", "evidence": "AChE activity was reported to be enhanced by low concentrations of H2O2. explanation is that mitochondrial efflux H2O2 modifies membrane structure through lipid peroxidation, and therefore contributes to modify the activity of the membrane-bound protein AChE [31]. AChE is synthesized as an inactive precursor and then matures into an active subunit in the endoplasmic reticulum [32]. Thus, the other explanation was that AChE could be exposed to cytoplasm when endoplasmic reticulum was destroyed by H2O2. At least one protein kinase (protein kinase A , PKA), was reported to increase the AChE activity by phosphorylation at non-consensus sites of this enzyme [33]. The apoptotic stimuli also enhanced the mRNA and protein levels of AChE in cells without background AChE expression, which were mediated by calcium signalling or the c-Jun kinase pathway", "citation": {"type": "PubMed", "reference": "17213958"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"Acetylcholine signaling subgraph": true, "Hydrogen peroxide subgraph": true}, "Confidence": {"Low": true}}, "subject": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "source": 88, "target": 14, "key": "898374fe6e89e5ce90d46925eaae09f4a05981fe7b5f8b2790c452522df28ba056b77794aa30e393e2bcee89658b5d99a535bdd56427645ed534e179a294c2ac"}, {"line": 14146, "relation": "association", "evidence": "Butyrylcholinesterase and acetylcholinesterase related proteins were found common to both Alzheimer's disease and diabetes; they may play an etiological role via influencing insulin resistance and lipid metabolism.", "citation": {"type": "PubMed", "name": "Lipids Health Dis. 2006 Nov 11;5:28.", "reference": "17096857"}, "annotations": {"Subgraph": {"Insulin signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 88, "target": 143, "key": "37645cabe5e753546b56fed49ccc2ab4ca3d3f280723e5899a0b2efe7afea7ec4decbe578016d9bc74e983de77b6225bcace874d2b9123bd63725e52a76446ce"}, {"line": 14150, "relation": "association", "evidence": "Butyrylcholinesterase and acetylcholinesterase related proteins were found common to both Alzheimer's disease and diabetes; they may play an etiological role via influencing insulin resistance and lipid metabolism.", "citation": {"type": "PubMed", "name": "Lipids Health Dis. 2006 Nov 11;5:28.", "reference": "17096857"}, "annotations": {"Subgraph": {"Insulin signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 88, "target": 72, "key": "e8f6ee29e6ba5c4f995715114d969d1b55288b6f3c3617b280c8969940fbc1e1d2e0f7d6acc362a9191a002c9538671a3de3b9697331bcec9286dc9c8c00fb49"}, {"line": 14154, "relation": "regulates", "evidence": "Butyrylcholinesterase and acetylcholinesterase related proteins were found common to both Alzheimer's disease and diabetes; they may play an etiological role via influencing insulin resistance and lipid metabolism.", "citation": {"type": "PubMed", "name": "Lipids Health Dis. 2006 Nov 11;5:28.", "reference": "17096857"}, "annotations": {"Subgraph": {"Insulin signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 88, "target": 50, "key": "70cd3b59f1298cbe791899f331836c264711517c0d308a08222e5e09197b783dd2bcec3fc52a97a969fdee0da7bdff0205c9938cd1502c272f3f03203dbf3b9a"}, {"line": 15225, "relation": "decreases", "evidence": "Hence, elevated butyrylcholinesterase and acetylcholinesterase concentrations will lead to a decrease in the levels of acetylcholine that could trigger the onset of low-grade systemic inflammation seen in type 2 diabetes and Alzheimer's disease.", "citation": {"type": "PubMed", "reference": "17553629"}, "annotations": {"MeSHDisease": {"Diabetes Mellitus, Type 2": true, "Alzheimer Disease": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 88, "target": 17, "key": "7bf6540945ed31d1bb9754430ed4428259c579dd18ced2d05b6b34e155cc606a16434458f1b4fe28eab6dabc0eedbf905bbc35df938a94d95d6035b0a85392c5"}, {"line": 30302, "relation": "association", "evidence": "Acetylcholinesterase (AChE), an enzyme involved in the hydrolysis of the neurotransmitter acetylcholine, consistently colocalizes with the amyloid deposits characteristic of Alzheimer's disease and may contribute to the generation of amyloid proteins and/or physically affect fibril assembly.", "citation": {"type": "PubMed", "reference": "9325095"}, "annotations": {"Subgraph": {"Amyloidogenic subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 88, "target": 17, "key": "c310dd1844cd2a6438746fb06c102731c9d6058751793acb43b4c39098d25ebea7cc8695c763ac5b30f68420f103c84dc033fed40ca21ce900ddbd345d8c5bc5"}, {"line": 30288, "relation": "association", "evidence": "At this point, inhibitors able to interact at the peripheral binding site are of particular relevance, as they might disrupt the interactions between the enzyme acetylcholinesterase and the beta-amyloid peptide. ", "citation": {"type": "PubMed", "name": "Curr Pharm Des. 2004;10(25):3131-40.", "reference": "15544503"}, "annotations": {"Subgraph": {"Non-amyloidogenic subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 88, "target": 90, "key": "bc2c2b99b5bda9929a60967b088adfc29ba2180ec2523c1acd9d592a9d8c8b1b57d37cae96e7d465621b566aa8bbf6905dded4a6ccebe28743d9b1fddaed30f0"}, {"line": 30774, "relation": "increases", "evidence": " The fact that acetylcholinesterase accelerates amyloid formation and the effect is sensitive to peripherical anionic site blockers of the enzyme, suggests that specific and new EC 3.1.1.7 (acetylcholinesterase) inhibitors may well provide an attractive possibility for treating Alzheimer's disease. ", "citation": {"type": "PubMed", "name": "FEBS J2008", "reference": "18205831"}, "annotations": {"Subgraph": {"Amyloidogenic subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 88, "target": 90, "key": "2cfb99b049dbf1d656f2492ab6ed13dd43ba74dd260d2e5dd0f5b73dffa109774dacf9c98d49b2439fd1c0703e46440c0b68507b1cae8c1071c9028289d2be3c"}, {"line": 29059, "relation": "increases", "evidence": "The finding that acetylcholinesterase (AChE) colocalizes with beta-amyloid (Abeta) and promotes and accelerates Abeta aggregation has renewed an intense interest in developing new multifunctional AChE inhibitors as potential disease-modifying drugs for Alzheimer's therapy.", "citation": {"type": "PubMed", "name": "ACS Chem Neurosci. 2010 Nov 17;1(11):737-46", "reference": "22778810"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"Amyloidogenic subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 88, "target": 4, "key": "ed73b691755eb179d5ade7845fb2ac5ca869be26f87a5b9f0e0dc25424bfe59997fbde8e372be805550019ec6fa07620e0d95522c10f7bffbe8039970970cdae"}, {"line": 30146, "relation": "increases", "evidence": "These results, together with binding assays, have suggested that AChE may contribute to the generation of amyloid deposits and/or physically affects fibril assembly. Moreover, it has also been shown that the neurotoxicity of Abeta peptide aggregates depends on the amount of AChE bound to the complexes, suggesting that AChE may play a key role in the neurodegeneration observed in an AD patients brain.", "citation": {"type": "PubMed", "name": "Bioorg Med Chem2007", "reference": "17681794"}, "annotations": {"Subgraph": {"Amyloidogenic subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 88, "target": 4, "key": "405195735fe5fc91924f9469cc263d5e896d08b1caaacd6cc975fdb02b07117f5c6dda0d6b09b3946a3b322ae1ec8378e5aa634061d24b6b35c3ad4d0a65a2d0"}, {"line": 30304, "relation": "increases", "evidence": "Acetylcholinesterase (AChE), an enzyme involved in the hydrolysis of the neurotransmitter acetylcholine, consistently colocalizes with the amyloid deposits characteristic of Alzheimer's disease and may contribute to the generation of amyloid proteins and/or physically affect fibril assembly.", "citation": {"type": "PubMed", "reference": "9325095"}, "annotations": {"Subgraph": {"Amyloidogenic subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 88, "target": 4, "key": "6b9b53dd9cef634f947fc9173c48459b1b0e6bad45290b52daea271f8a74987581ba63191df4b354a653abf729aae1f7e5bd9b761880ae8f604532c3559fd2a5"}, {"line": 30781, "relation": "increases", "evidence": "Recent studies also indicate that acetylcholinesterase induces the aggregation of prion protein with a similar dependence on the peripherical anionic site", "citation": {"type": "PubMed", "name": "FEBS J2008", "reference": "18205831"}, "annotations": {"Subgraph": {"Amyloidogenic subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 88, "target": 122, "key": "3de4b92a2bd028d62b94faa231cfb4c44682fa4a15539a9e2ff3876cc4c782006002d7f20324924ef9b2847f70ec9e49cbf683061003c989ba342fc0cc0f7ba6"}, {"line": 30815, "relation": "increases", "evidence": "Our results suggest that such amyloid-AChE complexes are formed when AChE interacts with the growing amyloid fibrils and accelerates the assembly of Abeta peptides", "citation": {"type": "PubMed", "name": "J Mol Biol1997", "reference": "9325095"}, "annotations": {"Subgraph": {"Amyloidogenic subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 88, "target": 80, "key": "8c4b3d3db47572b4c5fc874c307e67ec11a11df46117f733522bdb3fdff3a8d6f802cdd14c5f60d67251bf20bbe849c9f004f9f023d495716ce3e45f778365e5"}, {"line": 55385, "relation": "positiveCorrelation", "evidence": "There were significant correlations between cerebral atrophy as assessed by VBR and CSF AChE activity. Cognitive impairment on MMSE also correlated significantly with VBR.", "citation": {"type": "PubMed", "name": "Psychiatry Res. 1986 Jan;17(1):23-9.", "reference": "3484831"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 88, "target": 39, "key": "5c19fab0829673a945f76a25440e79076d3c0e69406f2f06e853936334a0d19775f991e90c9746f250e81bb0a0dee6d6d91675246637ce3ce4a54bb53ce13512"}, {"line": 51649, "relation": "increases", "evidence": "Ultrastructural detection of choline acetyl transferase (ChAT)-immunostaining in cerebral cortical sections/ of transgenic mice clearly demonstrated degeneration of ChAT-immunoreactive fibres in the environment of beta-amyloid/ plaques and activated glial cells suggesting a role of beta-amyloid and/or inflammation in specific degeneration of / cholinergic synaptic structures.", "citation": {"type": "PubMed", "name": "Brain Res. 2003 Jul 4;977(1):16-22.", "reference": "12788508"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 36, "target": 48, "key": "4f55d9b887dac382f29ef93263f23e1f12fd510cb2a56758bb918cfd1bfacb74cab29d6df0dc02875267620146af2b1f49eefd52067c361ea9eb60b9a2032e2d"}, {"line": 1316, "relation": "negativeCorrelation", "evidence": "In vitro and in vivo studies have consistently demonstrated a link between cholinergic activation and APP metabolism.Reduction in cholinergic neurotransmission--experimental or pathological, such as in AD--leads to amyloidogenic metabolism and contributes to the neuropathology and cognitive dysfunction", "citation": {"type": "PubMed", "name": "Neurochem Res. 2003 Apr;28(3-4):515-22", "reference": "12675140"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "Subgraph": {"Amyloidogenic subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Very High": true}}, "source": 142, "target": 63, "key": "580c9bc8c1697f738b07ffd45d5345403c6f4768487b44a1a3143dfed43bb6cd34e45d70879db355c31f69bc5be76dfa41bd653373194cbde65c31f217d55339"}, {"line": 18258, "relation": "decreases", "evidence": "In the brain of Alzheimer's disease patients, down-regulation of both cholinergic and glutamatergic systems have been found and is thought to play an important role in impairment of cognition, learning, and memory. Nefiracetam is a pyrrolidine-related nootropic drug exhibiting various pharmacological actions such as a cognitive-enhancing effect.", "citation": {"type": "PubMed", "reference": "21821968"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 142, "target": 63, "key": "1ef775fa968ff36651895c38dfcc919fb0441eb55bbd07f128e244bf9bee5a6fe9499568f990ccc64e83c61d1030ca26f2be53bb9f459d9505e059b4eca23125"}, {"line": 1919, "relation": "negativeCorrelation", "evidence": "Alzheimer's disease is rapidly becoming one of the most prevalent human diseases. Inhibition of human acetylcholinestrase (hAChE) and butyrylcholinestrase (BChE) has been linked to amelioration of Alzheimer's symptoms and research into inhibitors is of critical importance", "citation": {"type": "PubMed", "name": "Bioorg Med Chem. 2012 Apr 15;20(8):2595-602. Epub 2012 Mar 8.", "reference": "22445674"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Very High": true}}, "object": {"modifier": "Activity"}, "source": 142, "target": 91, "key": "f519d8d3bb25c271a4abc9e68f5b519259aa71ca9d32d5ffbe22327f8040efb7086520d9ea550543c379449e6e0f0d6d02ce84df343591a9ac94f92841b1d8cc"}, {"line": 14126, "relation": "association", "evidence": "Butyrylcholinesterase and acetylcholinesterase related proteins were found common to both Alzheimer's disease and diabetes; they may play an etiological role via influencing insulin resistance and lipid metabolism.", "citation": {"type": "PubMed", "name": "Lipids Health Dis. 2006 Nov 11;5:28.", "reference": "17096857"}, "annotations": {"Subgraph": {"Insulin signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 142, "target": 91, "key": "341e6c63311ba7f9abbcf4b685f01d31bc9b8c1818419dbeebc68fe115a5d2a7bda546f75ffd994ce7dbd302b5efd62c10d4dd1ff5638fde28f56b440a237ed3"}, {"line": 1920, "relation": "negativeCorrelation", "evidence": "Alzheimer's disease is rapidly becoming one of the most prevalent human diseases. Inhibition of human acetylcholinestrase (hAChE) and butyrylcholinestrase (BChE) has been linked to amelioration of Alzheimer's symptoms and research into inhibitors is of critical importance", "citation": {"type": "PubMed", "name": "Bioorg Med Chem. 2012 Apr 15;20(8):2595-602. Epub 2012 Mar 8.", "reference": "22445674"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Very High": true}}, "source": 142, "target": 88, "key": "3b63033408a9e6d2783c20feda5bf87b074b170860fb8eaa570e110b077062d2eda15d840006229d8ae1a99af9a490dd5fd3ad47acaff24da04a335527ac78d8"}, {"line": 14142, "relation": "association", "evidence": "Butyrylcholinesterase and acetylcholinesterase related proteins were found common to both Alzheimer's disease and diabetes; they may play an etiological role via influencing insulin resistance and lipid metabolism.", "citation": {"type": "PubMed", "name": "Lipids Health Dis. 2006 Nov 11;5:28.", "reference": "17096857"}, "annotations": {"Subgraph": {"Insulin signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 142, "target": 88, "key": "b7af33dd766b6ce14adf2114bf999583934c070c0ca0737dd9641e656c3fbef3775c5ccf6c8b5520f7786cbebd172bcb0c3a130bd2e9ca601663c80bb15a030b"}, {"line": 4556, "relation": "association", "evidence": "Two novel missense point mutations, Ser413Leu in the CHRNA4 gene and Gln397Pro in the CHRNB2 gene, were identified in two different AD cases but were not found in other AD cases and controls. These findings suggested that genetic polymorphisms of the neuronal nAChR genes might be related to the pathogenesis of sporadic AD.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2002 Apr;4(2):71-6", "reference": "12214130"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 142, "target": 99, "key": "65fc289325f1d22b855abb96d98d78eafa695bfe8f9c2a5d600a05c333049504ac5cd7d2ca64e1d4229a1a4d36ce3695b76bfb4a0f1c1938cf9d3c68d20b910f"}, {"line": 4560, "relation": "association", "evidence": "Two novel missense point mutations, Ser413Leu in the CHRNA4 gene and Gln397Pro in the CHRNB2 gene, were identified in two different AD cases but were not found in other AD cases and controls. These findings suggested that genetic polymorphisms of the neuronal nAChR genes might be related to the pathogenesis of sporadic AD.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2002 Apr;4(2):71-6", "reference": "12214130"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 142, "target": 106, "key": "1a9354b47944cb7e2863e982de59839101da014a217cd6ee1a39db052b79c90781906d6fca69e3e869207728329b3387dd983630fac51b6099c2cdbff5004e8a"}, {"line": 9179, "relation": "negativeCorrelation", "evidence": "In addition, the studies demonstrated AD Braak stage-associated declines in choline acetyltransferase (ChAT) expression with reduced colocalization of ChAT with insulin or IGF-1 receptor immunoreactivity in cortical neurons. These results correspond with experimental data demonstrating that neuronal tau and ChAT gene expression are regulated by IGF-1 and insulin stimulation.88 Therefore, brain insulin and IGF deficiency and resistance could account for the cytoskeletal collapse, neurite retraction, synaptic disconnection, loss of neuronal plasticity, and deficiencies in acetylcholine production, all of which correlate with cognitive decline and dementia in AD", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 142, "target": 85, "key": "771214e1b223ebb9628272f62df3dd73856b6e92202ed24ac1724c5bb21814cb343de47960bd3a090af8a759be2ffe36e3ed9593b20a04cc6288a3678f3d0c6c"}, {"line": 16393, "relation": "decreases", "evidence": "Deficit in central cholinergic neurotransmission is a consistent change associated with Alzheimer's disease (AD). Donepezil hydrochloride exhibits selective inhibition of acetylcholinesterase (AChE) and is widely used for the treatment of AD.", "citation": {"type": "PubMed", "name": "Br J Clin Pharmacol. 2008 Apr;65(4):472-9", "reference": "18070217"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 142, "target": 64, "key": "dbfd7f1394a51e633d5a817250419cefaf8b3679e5fda6bda79be641bc3f70729fb489694934dd428f641886771bc651affa50d9013a7a4463ad922abd5074c1"}, {"line": 18236, "relation": "decreases", "evidence": "The nefiracetam-induced increase in the frequency of mEPSCs and mIPSCs over and above the level achieved by ACh alone would contribute to the therapeutic effect of nefiracetam as the cholinergic system is known to be downregulated in the brain of Alzheimer's disease patients.The therapeutic effects of galantamine are ascribed to the modest potentiation of nACh receptor and NMDA receptor activities in addition to the modest inhibition of acetylcholinesterase.", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 142, "target": 64, "key": "cd35ccc953d0f8a85775261a53543ad320ae36c6d5e33fa39b0fc0cd688524e7f498299ba3390310c02ab817bfb1dc6f3c3dee1d92110304df27e1e61e7f4838"}, {"line": 17390, "relation": "decreases", "evidence": "The mechanisms by which arecoline improves cognitive function are not known. We have demonstrated that arecoline can differentially influence cerebral blood flow and metabolism with both acute and chronic administration. Studies of cerebral glucose metabolism in patients with early or late onset of AD demonstrate glucose metabolic deficits in the temporal and parietal cortex. In advanced cases of AD, cerebral blood flow also can be reduced throughout the cortex.", "citation": {"type": "PubMed", "name": "Brain Res. 1994 Mar 28;641(1):65-75", "reference": "8019853"}, "annotations": {"MeSHAnatomy": {"Cerebrum": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 142, "target": 47, "key": "a9b498e17708b0389eb32a4070cf6f190dbaf61ad62f01f8952a29398c46e0ab65a82a4cf8fb4e1124f8765b1a1a16b2798b48f1c69957f56c3df601c2569334"}, {"line": 17391, "relation": "decreases", "evidence": "The mechanisms by which arecoline improves cognitive function are not known. We have demonstrated that arecoline can differentially influence cerebral blood flow and metabolism with both acute and chronic administration. Studies of cerebral glucose metabolism in patients with early or late onset of AD demonstrate glucose metabolic deficits in the temporal and parietal cortex. In advanced cases of AD, cerebral blood flow also can be reduced throughout the cortex.", "citation": {"type": "PubMed", "name": "Brain Res. 1994 Mar 28;641(1):65-75", "reference": "8019853"}, "annotations": {"MeSHAnatomy": {"Cerebrum": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 142, "target": 44, "key": "c7431621a2609608229d17c3c87eb5993678ae71f85a706cc6ed360f2f6a0daaa69cc7fac7b2e8b070cac0f24d685b164525e60309e8023427ab93f8b97cd51b"}, {"line": 18274, "relation": "increases", "evidence": "In the brain of Alzheimer's disease patients, down-regulation of both cholinergic and glutamatergic systems have been found and is thought to play an important role in impairment of cognition, learning, and memory. Nefiracetam is a pyrrolidine-related nootropic drug exhibiting various pharmacological actions such as a cognitive-enhancing effect.", "citation": {"type": "PubMed", "reference": "21821968"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 142, "target": 54, "key": "a775389aceba458aabc3a00826acad86f0a3f3a4e716891d7c7602c046591f89abe677dac022dd344271801771577e0ebc2aff67299e42916c439808bb331c7b"}, {"line": 1316, "relation": "negativeCorrelation", "evidence": "In vitro and in vivo studies have consistently demonstrated a link between cholinergic activation and APP metabolism.Reduction in cholinergic neurotransmission--experimental or pathological, such as in AD--leads to amyloidogenic metabolism and contributes to the neuropathology and cognitive dysfunction", "citation": {"type": "PubMed", "name": "Neurochem Res. 2003 Apr;28(3-4):515-22", "reference": "12675140"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "Subgraph": {"Amyloidogenic subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Very High": true}}, "source": 63, "target": 142, "key": "450a09f708e04dd35f74d578b3c6c3cd0b4e61a5a949d383f10e67a97fb28829a54df3ca51c7cd6b6b0507fb396ee5f170b3d7fe6a2e9d8dcf4c34f2467cedc8"}, {"line": 1320, "relation": "increases", "evidence": "In vitro and in vivo studies have consistently demonstrated a link between cholinergic activation and APP metabolism.Reduction in cholinergic neurotransmission--experimental or pathological, such as in AD--leads to amyloidogenic metabolism and contributes to the neuropathology and cognitive dysfunction", "citation": {"type": "PubMed", "name": "Neurochem Res. 2003 Apr;28(3-4):515-22", "reference": "12675140"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "Subgraph": {"Amyloidogenic subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Very High": true}}, "source": 63, "target": 4, "key": "3f4fd8e51578d346d89a44bae2120f182820035b17414b2d76e0ced8e019c9bfbe576d34c0ba6fe249f160bec29feb6a3c0f6d4b93265f2cbc52f9a1cf8d80b9"}, {"line": 1324, "relation": "increases", "evidence": "In vitro and in vivo studies have consistently demonstrated a link between cholinergic activation and APP metabolism.Reduction in cholinergic neurotransmission--experimental or pathological, such as in AD--leads to amyloidogenic metabolism and contributes to the neuropathology and cognitive dysfunction", "citation": {"type": "PubMed", "name": "Neurochem Res. 2003 Apr;28(3-4):515-22", "reference": "12675140"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "Subgraph": {"Amyloidogenic subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Very High": true}}, "source": 63, "target": 66, "key": "937149f0d1433eb75c4c079ba8b5d74ad58de79f0648da800a451315a3b2dfd9ae73b649de9d6b31fabde4756d5ee795c1c4c4247ec7b79faa033653eb38bea5"}, {"line": 18262, "relation": "increases", "evidence": "In the brain of Alzheimer's disease patients, down-regulation of both cholinergic and glutamatergic systems have been found and is thought to play an important role in impairment of cognition, learning, and memory. Nefiracetam is a pyrrolidine-related nootropic drug exhibiting various pharmacological actions such as a cognitive-enhancing effect.", "citation": {"type": "PubMed", "reference": "21821968"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 63, "target": 66, "key": "f44ec9cb2ac6c607b1a0b718c245d5e2da84ab70e8814ef7ef10a4384e50d00659b7e10501dd3774efc9302216cc9e1e5be6e74bd390434f7233297f9fe84439"}, {"line": 18266, "relation": "increases", "evidence": "In the brain of Alzheimer's disease patients, down-regulation of both cholinergic and glutamatergic systems have been found and is thought to play an important role in impairment of cognition, learning, and memory. Nefiracetam is a pyrrolidine-related nootropic drug exhibiting various pharmacological actions such as a cognitive-enhancing effect.", "citation": {"type": "PubMed", "reference": "21821968"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 63, "target": 68, "key": "b3f16a96cb1a5951b9bb60fcd17e1479836719da2ff4e3f7da8ac9152a16a6ccd647c76a58d80dcf55d0584105ce26dac20d6d68eddc495ce0c3cc2448bff222"}, {"line": 18270, "relation": "increases", "evidence": "In the brain of Alzheimer's disease patients, down-regulation of both cholinergic and glutamatergic systems have been found and is thought to play an important role in impairment of cognition, learning, and memory. Nefiracetam is a pyrrolidine-related nootropic drug exhibiting various pharmacological actions such as a cognitive-enhancing effect.", "citation": {"type": "PubMed", "reference": "21821968"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 63, "target": 69, "key": "9f249c0a4ece792c774dde60b9998b7bea4d53c0de48495f494589a891eb576daa76857908d1dca5606505b96e9dd580f9ac26d1ca9cf5344f98519400405859"}, {"line": 1919, "relation": "negativeCorrelation", "evidence": "Alzheimer's disease is rapidly becoming one of the most prevalent human diseases. Inhibition of human acetylcholinestrase (hAChE) and butyrylcholinestrase (BChE) has been linked to amelioration of Alzheimer's symptoms and research into inhibitors is of critical importance", "citation": {"type": "PubMed", "name": "Bioorg Med Chem. 2012 Apr 15;20(8):2595-602. Epub 2012 Mar 8.", "reference": "22445674"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Very High": true}}, "subject": {"modifier": "Activity"}, "source": 91, "target": 142, "key": "bac73d74b5cf8302a8303a78bf66fca740bf7425cd34a8ce459d062948e5cf2b089f17ebb610fe7ce4fc6b5be1669e93b5a6423b2dbcccaaf69a50d6fcc8ede2"}, {"line": 14126, "relation": "association", "evidence": "Butyrylcholinesterase and acetylcholinesterase related proteins were found common to both Alzheimer's disease and diabetes; they may play an etiological role via influencing insulin resistance and lipid metabolism.", "citation": {"type": "PubMed", "name": "Lipids Health Dis. 2006 Nov 11;5:28.", "reference": "17096857"}, "annotations": {"Subgraph": {"Insulin signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 91, "target": 142, "key": "686ed2bc801c9dd538266d99baa40414cdd5c710278d5341fce938ef6d9d66f0fe3acff2025c4003fda6f81c260c8c4d5ff0f70e63a0413e13cac5cd9618a5a4"}, {"line": 14130, "relation": "association", "evidence": "Butyrylcholinesterase and acetylcholinesterase related proteins were found common to both Alzheimer's disease and diabetes; they may play an etiological role via influencing insulin resistance and lipid metabolism.", "citation": {"type": "PubMed", "name": "Lipids Health Dis. 2006 Nov 11;5:28.", "reference": "17096857"}, "annotations": {"Subgraph": {"Insulin signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 91, "target": 143, "key": "051dc6b93a3aa099a71040f4248e6cf1249d23b358f027dc4467b07a03a72e7e5e7aeb7a7f928bdec072010d167fd7f5f02d79a59a546f59459601349db8f0b3"}, {"line": 14134, "relation": "regulates", "evidence": "Butyrylcholinesterase and acetylcholinesterase related proteins were found common to both Alzheimer's disease and diabetes; they may play an etiological role via influencing insulin resistance and lipid metabolism.", "citation": {"type": "PubMed", "name": "Lipids Health Dis. 2006 Nov 11;5:28.", "reference": "17096857"}, "annotations": {"Subgraph": {"Insulin signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 91, "target": 72, "key": "025d2ecb9d82febb6ea9e420756f34f63a5e26aa8f8b2d8e7e13ef7576ee3159b6ffb706ac018b53bb29c9b932509cf9b4eca91ad647e2d767929f27399fea75"}, {"line": 14138, "relation": "regulates", "evidence": "Butyrylcholinesterase and acetylcholinesterase related proteins were found common to both Alzheimer's disease and diabetes; they may play an etiological role via influencing insulin resistance and lipid metabolism.", "citation": {"type": "PubMed", "name": "Lipids Health Dis. 2006 Nov 11;5:28.", "reference": "17096857"}, "annotations": {"Subgraph": {"Insulin signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 91, "target": 50, "key": "72bb318a085040887ab7a3529ac371bf15711ccabd397b49def123ad0b47b318b7c14aae3fbd239c3a423b05efe60e67d2575913901aea3c85a51ed4f7cddf7f"}, {"line": 15221, "relation": "decreases", "evidence": "Hence, elevated butyrylcholinesterase and acetylcholinesterase concentrations will lead to a decrease in the levels of acetylcholine that could trigger the onset of low-grade systemic inflammation seen in type 2 diabetes and Alzheimer's disease.", "citation": {"type": "PubMed", "reference": "17553629"}, "annotations": {"MeSHDisease": {"Diabetes Mellitus, Type 2": true, "Alzheimer Disease": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 91, "target": 17, "key": "052edf47de1a98a391ab10452fca925a095b37e6149b7bfcd5f00c74b4fb1eac533ec8b5b228e2d0d06203e0e48bddf95e4dfc942b94149f12130c5b9a9c4c61"}, {"line": 47068, "relation": "positiveCorrelation", "evidence": "Butyrylcholinesterase (BuChE) activity is associated with activated astrocytes in Alzheimer's disease brain. BuChE genotype was linked with differential CSF levels of glial fibrillary acidic protein, S100B, interleukin-1beta, and tumor necrosis factor (TNF)-alpha. BCHE-K noncarriers displayed 100%-150% higher glial fibrillary acidic protein and 64%-110% higher S100B than BCHE-K carriers, who, in contrast, had 40%-80% higher interleukin-1beta and 21%-27% higher TNF-alpha compared with noncarriers. A high level of CSF BuChE enzymatic phenotype also significantly correlated with higher CSF levels of astroglial markers and several factors of the innate complement system, but lower levels of proinflammatory cytokines. These individuals also displayed beneficial paraclinical and clinical findings, such as high cerebral glucose utilization, low beta-amyloid load, and less severe progression of clinical symptoms.", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2013 Nov;34(11):2465-81. doi: 10.1016/j.neurobiolaging.2013.04.027. Epub 2013 Jun 4.", "reference": "23759148"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Very High": true}}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Activity"}, "source": 91, "target": 35, "key": "2aa916f7c075ff19e2be712a419cae069e2b842543048ec6cef27c1513faa43e8eb9cd82de0c9b755086271bf60382283bf0269a903b14e1544884295e835710"}, {"line": 47072, "relation": "association", "evidence": "Butyrylcholinesterase (BuChE) activity is associated with activated astrocytes in Alzheimer's disease brain. BuChE genotype was linked with differential CSF levels of glial fibrillary acidic protein, S100B, interleukin-1beta, and tumor necrosis factor (TNF)-alpha. BCHE-K noncarriers displayed 100%-150% higher glial fibrillary acidic protein and 64%-110% higher S100B than BCHE-K carriers, who, in contrast, had 40%-80% higher interleukin-1beta and 21%-27% higher TNF-alpha compared with noncarriers. A high level of CSF BuChE enzymatic phenotype also significantly correlated with higher CSF levels of astroglial markers and several factors of the innate complement system, but lower levels of proinflammatory cytokines. These individuals also displayed beneficial paraclinical and clinical findings, such as high cerebral glucose utilization, low beta-amyloid load, and less severe progression of clinical symptoms.", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2013 Nov;34(11):2465-81. doi: 10.1016/j.neurobiolaging.2013.04.027. Epub 2013 Jun 4.", "reference": "23759148"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Very High": true}}, "source": 91, "target": 112, "key": "0d6aba80d8d384b21aee67e3297b8b38fd7e5c1a6276fccd00b8008ade8bdc0099d4877772c9e061098191940d952409f6aa2b33dd4fc01dbc3aca1863c99242"}, {"line": 47078, "relation": "association", "evidence": "Butyrylcholinesterase (BuChE) activity is associated with activated astrocytes in Alzheimer's disease brain. BuChE genotype was linked with differential CSF levels of glial fibrillary acidic protein, S100B, interleukin-1beta, and tumor necrosis factor (TNF)-alpha. BCHE-K noncarriers displayed 100%-150% higher glial fibrillary acidic protein and 64%-110% higher S100B than BCHE-K carriers, who, in contrast, had 40%-80% higher interleukin-1beta and 21%-27% higher TNF-alpha compared with noncarriers. A high level of CSF BuChE enzymatic phenotype also significantly correlated with higher CSF levels of astroglial markers and several factors of the innate complement system, but lower levels of proinflammatory cytokines. These individuals also displayed beneficial paraclinical and clinical findings, such as high cerebral glucose utilization, low beta-amyloid load, and less severe progression of clinical symptoms.", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2013 Nov;34(11):2465-81. doi: 10.1016/j.neurobiolaging.2013.04.027. Epub 2013 Jun 4.", "reference": "23759148"}, "annotations": {"Subgraph": {"Calcium-dependent signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Very High": true}}, "source": 91, "target": 123, "key": "8bac0e97d9c727203b37556a58742d2a69649460d7f86bc2f3461d988bd1bf4d31ed14a0cc11bf73f0216840d4c9cfe5c88f6d31b288d2685cccdaf77d75802f"}, {"line": 47084, "relation": "association", "evidence": "Butyrylcholinesterase (BuChE) activity is associated with activated astrocytes in Alzheimer's disease brain. BuChE genotype was linked with differential CSF levels of glial fibrillary acidic protein, S100B, interleukin-1beta, and tumor necrosis factor (TNF)-alpha. BCHE-K noncarriers displayed 100%-150% higher glial fibrillary acidic protein and 64%-110% higher S100B than BCHE-K carriers, who, in contrast, had 40%-80% higher interleukin-1beta and 21%-27% higher TNF-alpha compared with noncarriers. A high level of CSF BuChE enzymatic phenotype also significantly correlated with higher CSF levels of astroglial markers and several factors of the innate complement system, but lower levels of proinflammatory cytokines. These individuals also displayed beneficial paraclinical and clinical findings, such as high cerebral glucose utilization, low beta-amyloid load, and less severe progression of clinical symptoms.", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2013 Nov;34(11):2465-81. doi: 10.1016/j.neurobiolaging.2013.04.027. Epub 2013 Jun 4.", "reference": "23759148"}, "annotations": {"Subgraph": {"Interleukin signaling subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Very High": true}}, "source": 91, "target": 118, "key": "6542fa02a0b66929c231e4e86fc3c17253b5cb36a8ad0f5b190ff025df03da2ce5d22fdce35d31bfcf9955f19994982a6572ff23cfb488268d64296f84cce9b9"}, {"line": 47090, "relation": "association", "evidence": "Butyrylcholinesterase (BuChE) activity is associated with activated astrocytes in Alzheimer's disease brain. BuChE genotype was linked with differential CSF levels of glial fibrillary acidic protein, S100B, interleukin-1beta, and tumor necrosis factor (TNF)-alpha. BCHE-K noncarriers displayed 100%-150% higher glial fibrillary acidic protein and 64%-110% higher S100B than BCHE-K carriers, who, in contrast, had 40%-80% higher interleukin-1beta and 21%-27% higher TNF-alpha compared with noncarriers. A high level of CSF BuChE enzymatic phenotype also significantly correlated with higher CSF levels of astroglial markers and several factors of the innate complement system, but lower levels of proinflammatory cytokines. These individuals also displayed beneficial paraclinical and clinical findings, such as high cerebral glucose utilization, low beta-amyloid load, and less severe progression of clinical symptoms.", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2013 Nov;34(11):2465-81. doi: 10.1016/j.neurobiolaging.2013.04.027. Epub 2013 Jun 4.", "reference": "23759148"}, "annotations": {"Subgraph": {"Tumor necrosis factor subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Very High": true}}, "source": 91, "target": 125, "key": "d6de9dd0b7a5dbc536e205dc345cd97cd05d9382c7441689953c748fb244b71e4c51bd3a69d46e6f2d3ac8ab0fd7be54a872dac465f07e822f3093e180d16013"}, {"line": 4556, "relation": "association", "evidence": "Two novel missense point mutations, Ser413Leu in the CHRNA4 gene and Gln397Pro in the CHRNB2 gene, were identified in two different AD cases but were not found in other AD cases and controls. These findings suggested that genetic polymorphisms of the neuronal nAChR genes might be related to the pathogenesis of sporadic AD.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2002 Apr;4(2):71-6", "reference": "12214130"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 99, "target": 142, "key": "2c3b7517db140f75baf51508b1fb5449ffb982fb33bfbf1b6c34ec27f9885ff07d800f8a69657a8f00c7b70ba6ddf96d8b9e5ba2b1089d5c998934365c3e9b89"}, {"line": 4560, "relation": "association", "evidence": "Two novel missense point mutations, Ser413Leu in the CHRNA4 gene and Gln397Pro in the CHRNB2 gene, were identified in two different AD cases but were not found in other AD cases and controls. These findings suggested that genetic polymorphisms of the neuronal nAChR genes might be related to the pathogenesis of sporadic AD.", "citation": {"type": "PubMed", "name": "J Alzheimers Dis. 2002 Apr;4(2):71-6", "reference": "12214130"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 106, "target": 142, "key": "141bf6ce90e62ebc73c2ff2811805876a341a6a3a42e07c1da5db00577b1ea39c27d73f8a76eb273aa81d6ba26e5414e6eb008d7904515cd8661c808414533ac"}, {"line": 9179, "relation": "negativeCorrelation", "evidence": "In addition, the studies demonstrated AD Braak stage-associated declines in choline acetyltransferase (ChAT) expression with reduced colocalization of ChAT with insulin or IGF-1 receptor immunoreactivity in cortical neurons. These results correspond with experimental data demonstrating that neuronal tau and ChAT gene expression are regulated by IGF-1 and insulin stimulation.88 Therefore, brain insulin and IGF deficiency and resistance could account for the cytoskeletal collapse, neurite retraction, synaptic disconnection, loss of neuronal plasticity, and deficiencies in acetylcholine production, all of which correlate with cognitive decline and dementia in AD", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 85, "target": 142, "key": "c01e0a1be82bfb2266672211c3d56ffe7f417e7a79f2b0cb00b77540496ea6b4574a627b105eb915f433e55165bc8405b2cf44e2bad1cf88774a7bd9e226c272"}, {"line": 43976, "relation": "increases", "evidence": "Dysregulation of intracellular calcium signaling has been implicated in the pathogenesis of AlzheimerÃ¢â‚¬â„¢s disease [150]. ABeta¸ is known to act through multiple targets [151] including Ca2+ channels and various receptors in membranes. Synthetic ABeta¸ binds to the calcium permeable nAChRs with high affinity [152]. ABeta¸42 administered in the low picomolar range activates nAChRs at presynaptic nerve endings of synaptosomes [83, 153]. Under normal conditions, activation of nAChRs is necessary for the ABeta¸-induced increase in synaptic plasticity and memory [23]. However, it remains to be determined whether these effects are mediated by a direct physical interaction of the peptide with the nAChR. In addition, ABeta¸ enhances transmitter release by transient increase of glutamate release from the presynaptic terminal that results from brief periods of high frequency stimulation with Ca2+ buildup within the terminal that triggers mechanisms of short-term synaptic plasticity [154].", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"Amyloidogenic subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 5, "target": 62, "key": "c7a0670492516f92eda47df6bc860f4f890ca115a80422be9147554b2a3d24f6b69b1237ed18dd930cab202b9d8319d204f0a6f5ec989843458850f32bee68b5"}, {"line": 3835, "relation": "directlyIncreases", "evidence": "Acetylcholinesterase (AChE) is thought to play an important role during apoptotic process. Our results showed that H2O2 induced AChE activity, a functional marker in apoptotic process, increases in neuronal-like PC12 cells. Glutathione, which is involved in cellular redox homeostasis, inhibited the increase of AChE activity, suggesting that reactive oxygen species (ROS) play a key role in this process. Further investigation showed that the elevation of AChE was observed after the degradation of Akt, release of cytochrome c from mitochondria into the cytosol, and activation of caspase family members. When nerve growth factor (NGF) was present, with the maintenance of Akt level, the elevation of AChE, the cytochrome c diffusion, as well as apoptotic process were markedly attenuated in H2O2-treated PC12 cells", "citation": {"type": "PubMed", "reference": "17213958"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"Acetylcholine signaling subgraph": true, "Hydrogen peroxide subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "source": 14, "target": 88, "key": "4ea6a82f699eb493785ee9a9f56c70d912ad17277ab4c7190e823e44bae98d423a13c147cb18f9bdba6bb2b75546cf0d5e1c0b50ff2aa2cfe2d5ce1d15c25211"}, {"line": 3976, "relation": "negativeCorrelation", "evidence": "AChE activity was reported to be enhanced by low concentrations of H2O2. explanation is that mitochondrial efflux H2O2 modifies membrane structure through lipid peroxidation, and therefore contributes to modify the activity of the membrane-bound protein AChE [31]. AChE is synthesized as an inactive precursor and then matures into an active subunit in the endoplasmic reticulum [32]. Thus, the other explanation was that AChE could be exposed to cytoplasm when endoplasmic reticulum was destroyed by H2O2. At least one protein kinase (protein kinase A , PKA), was reported to increase the AChE activity by phosphorylation at non-consensus sites of this enzyme [33]. The apoptotic stimuli also enhanced the mRNA and protein levels of AChE in cells without background AChE expression, which were mediated by calcium signalling or the c-Jun kinase pathway", "citation": {"type": "PubMed", "reference": "17213958"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"Acetylcholine signaling subgraph": true, "Hydrogen peroxide subgraph": true}, "Confidence": {"Low": true}}, "object": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "source": 14, "target": 88, "key": "f4950050ed1f03755a7cfe6040e5190df60d7dea499ef88b5c910f3d7d124fc86d393b4508a2383e5ecac4ca3bb455496b61200e46cedb967a123c558b6952ff"}, {"line": 47090, "relation": "association", "evidence": "Butyrylcholinesterase (BuChE) activity is associated with activated astrocytes in Alzheimer's disease brain. BuChE genotype was linked with differential CSF levels of glial fibrillary acidic protein, S100B, interleukin-1beta, and tumor necrosis factor (TNF)-alpha. BCHE-K noncarriers displayed 100%-150% higher glial fibrillary acidic protein and 64%-110% higher S100B than BCHE-K carriers, who, in contrast, had 40%-80% higher interleukin-1beta and 21%-27% higher TNF-alpha compared with noncarriers. A high level of CSF BuChE enzymatic phenotype also significantly correlated with higher CSF levels of astroglial markers and several factors of the innate complement system, but lower levels of proinflammatory cytokines. These individuals also displayed beneficial paraclinical and clinical findings, such as high cerebral glucose utilization, low beta-amyloid load, and less severe progression of clinical symptoms.", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2013 Nov;34(11):2465-81. doi: 10.1016/j.neurobiolaging.2013.04.027. Epub 2013 Jun 4.", "reference": "23759148"}, "annotations": {"Subgraph": {"Tumor necrosis factor subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Very High": true}}, "source": 125, "target": 91, "key": "94d84f4229f2882c140fa8e963906e1eab8cdb52d0aa329ee3bb6508b464f4aa938e819d02a2380f864e6bcaeb8279a597e315c50947320d6fe961a3aa8706d4"}, {"line": 47084, "relation": "association", "evidence": "Butyrylcholinesterase (BuChE) activity is associated with activated astrocytes in Alzheimer's disease brain. BuChE genotype was linked with differential CSF levels of glial fibrillary acidic protein, S100B, interleukin-1beta, and tumor necrosis factor (TNF)-alpha. BCHE-K noncarriers displayed 100%-150% higher glial fibrillary acidic protein and 64%-110% higher S100B than BCHE-K carriers, who, in contrast, had 40%-80% higher interleukin-1beta and 21%-27% higher TNF-alpha compared with noncarriers. A high level of CSF BuChE enzymatic phenotype also significantly correlated with higher CSF levels of astroglial markers and several factors of the innate complement system, but lower levels of proinflammatory cytokines. These individuals also displayed beneficial paraclinical and clinical findings, such as high cerebral glucose utilization, low beta-amyloid load, and less severe progression of clinical symptoms.", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2013 Nov;34(11):2465-81. doi: 10.1016/j.neurobiolaging.2013.04.027. Epub 2013 Jun 4.", "reference": "23759148"}, "annotations": {"Subgraph": {"Interleukin signaling subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Very High": true}}, "source": 118, "target": 91, "key": "d87391ea94c8e02a6c42d72d2a269fb1a6aa3bd47bf524d446d078dc2d835624f3712e61b39cc7ff76f92d403e117eebcd823e1ccd7fa81010babf3af53150a9"}, {"line": 9276, "relation": "negativeCorrelation", "evidence": "In addition, the studies demonstrated AD Braak stage-associated declines in choline acetyltransferase (ChAT) expression with reduced colocalization of ChAT with insulin or IGF-1 receptor immunoreactivity in cortical neurons. These results correspond with experimental data demonstrating that neuronal tau and ChAT gene expression are regulated by IGF-1 and insulin stimulation.88 Therefore, brain insulin and IGF deficiency and resistance could account for the cytoskeletal collapse, neurite retraction, synaptic disconnection, loss of neuronal plasticity, and deficiencies in acetylcholine production, all of which correlate with cognitive decline and dementia in AD", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 66, "target": 51, "key": "41d1c134f8ba1d2d8c3d2940a00fc7569135eda94ee9561244195988f7b8ddb4920552a89f532920a22d74d1b7ea5aab79c62f65752e87d7bd0a1b3ec02a0e6f"}, {"line": 9280, "relation": "positiveCorrelation", "evidence": "In addition, the studies demonstrated AD Braak stage-associated declines in choline acetyltransferase (ChAT) expression with reduced colocalization of ChAT with insulin or IGF-1 receptor immunoreactivity in cortical neurons. These results correspond with experimental data demonstrating that neuronal tau and ChAT gene expression are regulated by IGF-1 and insulin stimulation.88 Therefore, brain insulin and IGF deficiency and resistance could account for the cytoskeletal collapse, neurite retraction, synaptic disconnection, loss of neuronal plasticity, and deficiencies in acetylcholine production, all of which correlate with cognitive decline and dementia in AD", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 66, "target": 73, "key": "5b7dd3fe4ca2a614addccbca2e60d921169591e0a3cb87af92a8f721b47b0284da2d608e940600cc564db243de03e52a2f533597362065834bfdc64bca0f292f"}, {"line": 9284, "relation": "positiveCorrelation", "evidence": "In addition, the studies demonstrated AD Braak stage-associated declines in choline acetyltransferase (ChAT) expression with reduced colocalization of ChAT with insulin or IGF-1 receptor immunoreactivity in cortical neurons. These results correspond with experimental data demonstrating that neuronal tau and ChAT gene expression are regulated by IGF-1 and insulin stimulation.88 Therefore, brain insulin and IGF deficiency and resistance could account for the cytoskeletal collapse, neurite retraction, synaptic disconnection, loss of neuronal plasticity, and deficiencies in acetylcholine production, all of which correlate with cognitive decline and dementia in AD", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 66, "target": 41, "key": "627d3ba654268763c87049a4997ec62ca7b7b97dc13c7cc43f04e5143da8a39ba84c9556c7cd4690b5f43180b47243176f472c55b04d84ce977362b54e3dcc60"}, {"line": 3937, "relation": "directlyDecreases", "evidence": "As indicated in Fig. 2, the presence of GSH protected the cells against H2O2-induced apoptosis and the increase in AChE activity. Therefore, the redox imbalance resulted in mitochondrial dysfunction and enhanced mitochondrial reactive oxygen species (ROS) generation.", "citation": {"type": "PubMed", "reference": "17213958"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"Glutathione reductase subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 116, "target": 55, "key": "45817417300c3522ff801e6e5f89f0e6aa82827240916d4430df837830c54d383e7d510ae15ede8e353604e971a73d85c9317e71ac55b5665d6adad1f949fc79"}, {"line": 3941, "relation": "directlyDecreases", "evidence": "As indicated in Fig. 2, the presence of GSH protected the cells against H2O2-induced apoptosis and the increase in AChE activity. Therefore, the redox imbalance resulted in mitochondrial dysfunction and enhanced mitochondrial reactive oxygen species (ROS) generation.", "citation": {"type": "PubMed", "reference": "17213958"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"Glutathione reductase subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "source": 116, "target": 88, "key": "5ef5fdb9f8aa561aa03f6b74ab4f803af2de10922560ed3de382a17ccdddd562d954d23ff517837b81c2570b9458635a80b7ed4f6530a6e532b59fd2aab94ce3"}, {"line": 3839, "relation": "directlyIncreases", "evidence": "Acetylcholinesterase (AChE) is thought to play an important role during apoptotic process. Our results showed that H2O2 induced AChE activity, a functional marker in apoptotic process, increases in neuronal-like PC12 cells. Glutathione, which is involved in cellular redox homeostasis, inhibited the increase of AChE activity, suggesting that reactive oxygen species (ROS) play a key role in this process. Further investigation showed that the elevation of AChE was observed after the degradation of Akt, release of cytochrome c from mitochondria into the cytosol, and activation of caspase family members. When nerve growth factor (NGF) was present, with the maintenance of Akt level, the elevation of AChE, the cytochrome c diffusion, as well as apoptotic process were markedly attenuated in H2O2-treated PC12 cells", "citation": {"type": "PubMed", "reference": "17213958"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"Acetylcholine signaling subgraph": true, "Hydrogen peroxide subgraph": true}, "Confidence": {"High": true}}, "source": 25, "target": 46, "key": "745f3c1d4dcf04989a17f0bcbe884938452d9a4eb701696331b654052ece3a1195bb28f37e6c7b68b95a53f64fc670c5c1b5b72ecc34af5d93eb555bafdeb009"}, {"line": 3846, "relation": "directlyDecreases", "evidence": "Acetylcholinesterase (AChE) is thought to play an important role during apoptotic process. Our results showed that H2O2 induced AChE activity, a functional marker in apoptotic process, increases in neuronal-like PC12 cells. Glutathione, which is involved in cellular redox homeostasis, inhibited the increase of AChE activity, suggesting that reactive oxygen species (ROS) play a key role in this process. Further investigation showed that the elevation of AChE was observed after the degradation of Akt, release of cytochrome c from mitochondria into the cytosol, and activation of caspase family members. When nerve growth factor (NGF) was present, with the maintenance of Akt level, the elevation of AChE, the cytochrome c diffusion, as well as apoptotic process were markedly attenuated in H2O2-treated PC12 cells", "citation": {"type": "PubMed", "reference": "17213958"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"Acetylcholine signaling subgraph": true, "Hydrogen peroxide subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "source": 25, "target": 88, "key": "84801ca4733c1a48cf7ae4d4874d909ac0c7e45e0396274d67422055f719a053a7a427badf787963c9575fd295307e3e556323a62dfacc22e96fef51b129d73f"}, {"line": 9276, "relation": "negativeCorrelation", "evidence": "In addition, the studies demonstrated AD Braak stage-associated declines in choline acetyltransferase (ChAT) expression with reduced colocalization of ChAT with insulin or IGF-1 receptor immunoreactivity in cortical neurons. These results correspond with experimental data demonstrating that neuronal tau and ChAT gene expression are regulated by IGF-1 and insulin stimulation.88 Therefore, brain insulin and IGF deficiency and resistance could account for the cytoskeletal collapse, neurite retraction, synaptic disconnection, loss of neuronal plasticity, and deficiencies in acetylcholine production, all of which correlate with cognitive decline and dementia in AD", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 51, "target": 66, "key": "a254a4bb7d6ae675538e06eb86189629fefb4d1430d3ebe015790b1c7ec909508c0239b5372fbfcde9c155f84a8624ef02cabba04f45fb4bed7d9fbf69eaf2cc"}, {"line": 9280, "relation": "positiveCorrelation", "evidence": "In addition, the studies demonstrated AD Braak stage-associated declines in choline acetyltransferase (ChAT) expression with reduced colocalization of ChAT with insulin or IGF-1 receptor immunoreactivity in cortical neurons. These results correspond with experimental data demonstrating that neuronal tau and ChAT gene expression are regulated by IGF-1 and insulin stimulation.88 Therefore, brain insulin and IGF deficiency and resistance could account for the cytoskeletal collapse, neurite retraction, synaptic disconnection, loss of neuronal plasticity, and deficiencies in acetylcholine production, all of which correlate with cognitive decline and dementia in AD", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 73, "target": 66, "key": "820f13d8788c61c98c69a0e9abfa311591beb8583749d9b403a8f6131082dc02e602baaf2192e4968d1b46af455d44eba7937ba296e610aac001604746e5dab0"}, {"line": 9256, "relation": "positiveCorrelation", "evidence": "In addition, the studies demonstrated AD Braak stage-associated declines in choline acetyltransferase (ChAT) expression with reduced colocalization of ChAT with insulin or IGF-1 receptor immunoreactivity in cortical neurons. These results correspond with experimental data demonstrating that neuronal tau and ChAT gene expression are regulated by IGF-1 and insulin stimulation.88 Therefore, brain insulin and IGF deficiency and resistance could account for the cytoskeletal collapse, neurite retraction, synaptic disconnection, loss of neuronal plasticity, and deficiencies in acetylcholine production, all of which correlate with cognitive decline and dementia in AD", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"MeSHAnatomy": {"Brain": true}, "Subgraph": {"Insulin signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 41, "target": 119, "key": "8e47dea11ee172ac9e2d8425eb76f5da82fe079b3c8619d06949e57c2ab4ba72c5b05f74ec04410a5a4bbf621abab19952bae63c13bd5907354f4b1b5df3e6fa"}, {"line": 9260, "relation": "positiveCorrelation", "evidence": "In addition, the studies demonstrated AD Braak stage-associated declines in choline acetyltransferase (ChAT) expression with reduced colocalization of ChAT with insulin or IGF-1 receptor immunoreactivity in cortical neurons. These results correspond with experimental data demonstrating that neuronal tau and ChAT gene expression are regulated by IGF-1 and insulin stimulation.88 Therefore, brain insulin and IGF deficiency and resistance could account for the cytoskeletal collapse, neurite retraction, synaptic disconnection, loss of neuronal plasticity, and deficiencies in acetylcholine production, all of which correlate with cognitive decline and dementia in AD", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"MeSHAnatomy": {"Brain": true}, "Subgraph": {"Insulin signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 41, "target": 117, "key": "c7803cad2a3592faec57bea615a21cd0641faaba4af0535f74879666edab87348521735344e21869dc6b09f95bb0bbcaabd0617c96a32d0e15bb825b97e78e05"}, {"line": 9284, "relation": "positiveCorrelation", "evidence": "In addition, the studies demonstrated AD Braak stage-associated declines in choline acetyltransferase (ChAT) expression with reduced colocalization of ChAT with insulin or IGF-1 receptor immunoreactivity in cortical neurons. These results correspond with experimental data demonstrating that neuronal tau and ChAT gene expression are regulated by IGF-1 and insulin stimulation.88 Therefore, brain insulin and IGF deficiency and resistance could account for the cytoskeletal collapse, neurite retraction, synaptic disconnection, loss of neuronal plasticity, and deficiencies in acetylcholine production, all of which correlate with cognitive decline and dementia in AD", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 41, "target": 66, "key": "549842ac2fd11b23f9688207f9840f7874659a8ef2faf1110d1999157f6f27e9f9ed44d8c165691085c8221aee2a6870770067ce8d7ebfbe8012f6c96ffcd544"}, {"line": 14130, "relation": "association", "evidence": "Butyrylcholinesterase and acetylcholinesterase related proteins were found common to both Alzheimer's disease and diabetes; they may play an etiological role via influencing insulin resistance and lipid metabolism.", "citation": {"type": "PubMed", "name": "Lipids Health Dis. 2006 Nov 11;5:28.", "reference": "17096857"}, "annotations": {"Subgraph": {"Insulin signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 143, "target": 91, "key": "1b8537de56be32627f51b83e125c9e918b7ea1e16a70655e0b62ec45e71979a596dce6013136b2da467256577c98821a37678880bb08a0a844f3554a0f146393"}, {"line": 14146, "relation": "association", "evidence": "Butyrylcholinesterase and acetylcholinesterase related proteins were found common to both Alzheimer's disease and diabetes; they may play an etiological role via influencing insulin resistance and lipid metabolism.", "citation": {"type": "PubMed", "name": "Lipids Health Dis. 2006 Nov 11;5:28.", "reference": "17096857"}, "annotations": {"Subgraph": {"Insulin signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 143, "target": 88, "key": "8f9d54a389afedda21a1a2f87a6b4a7ade9002a4e575b7092bc669571fd10bd2a562852c31425d713798f86f26f015078c1689306bfc6ff499b72876fe68ff52"}, {"line": 9264, "relation": "decreases", "evidence": "In addition, the studies demonstrated AD Braak stage-associated declines in choline acetyltransferase (ChAT) expression with reduced colocalization of ChAT with insulin or IGF-1 receptor immunoreactivity in cortical neurons. These results correspond with experimental data demonstrating that neuronal tau and ChAT gene expression are regulated by IGF-1 and insulin stimulation.88 Therefore, brain insulin and IGF deficiency and resistance could account for the cytoskeletal collapse, neurite retraction, synaptic disconnection, loss of neuronal plasticity, and deficiencies in acetylcholine production, all of which correlate with cognitive decline and dementia in AD", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"MeSHAnatomy": {"Brain": true}, "Subgraph": {"Insulin signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 72, "target": 41, "key": "9ff172515f44b5878c4ad4516dc778620788cc96bf12f68eeaa05288ff13de08e1fb8d80f9b483ae83e05f44d6c9dd1d90fda92255b68618768e9a1515bb65eb"}, {"line": 14150, "relation": "association", "evidence": "Butyrylcholinesterase and acetylcholinesterase related proteins were found common to both Alzheimer's disease and diabetes; they may play an etiological role via influencing insulin resistance and lipid metabolism.", "citation": {"type": "PubMed", "name": "Lipids Health Dis. 2006 Nov 11;5:28.", "reference": "17096857"}, "annotations": {"Subgraph": {"Insulin signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 72, "target": 88, "key": "13cbd41029fd236b9b9084e8a14e6708914dc87798f81a50237a7f3f21c37a6b707bcf4bc37e41cef273215dc2cdb3248f140ce1c73ce3325c46ba0bd7914bd0"}, {"line": 15229, "relation": "negativeCorrelation", "evidence": "Hence, elevated butyrylcholinesterase and acetylcholinesterase concentrations will lead to a decrease in the levels of acetylcholine that could trigger the onset of low-grade systemic inflammation seen in type 2 diabetes and Alzheimer's disease.", "citation": {"type": "PubMed", "reference": "17553629"}, "annotations": {"MeSHDisease": {"Diabetes Mellitus, Type 2": true, "Alzheimer Disease": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 17, "target": 144, "key": "57d86e163543a57441ee54eb23ebbec50c6ea89022957baa1bf87e6970de51383fc0543dac22f68f17c9034248f731ee1bd597870a8635970e16d5e2445b20b7"}, {"line": 17424, "relation": "increases", "evidence": "The hypothalamic-pituitary-adrenal (HPA) axis is regulated by cholinergic mechanisms. Acetylcholine (ACh), the cholinergic neurotransmitter, has been reported to alter the levels of cortisol as well as those of prolactin, growth hormone, leutinizing hormone and vasopressin. Prolactin secretion, however, is suppressed by increased pure cholinergic activity. Central actions of cholinomimetic drugs that either increase the concentration of ACh in brain (e.g. physostigmine) or activate the postsynaptic muscarinic receptors (e.g. arecoline), can also activate the HPA axis in both animals and human subjects.", "citation": {"type": "PubMed", "reference": "8584603"}, "annotations": {"MeSHAnatomy": {"Brain": true}, "Subgraph": {"Cortisol subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 17, "target": 21, "key": "115159389ca25747f71b0d9372b27b16e809fd1c633b074efdd6c34b8a30b399e75ed9ebda10c53a30de83ab449d5b92fbae0fe2254edfc5d5f459c05a5d9a36"}, {"line": 17432, "relation": "regulates", "evidence": "The hypothalamic-pituitary-adrenal (HPA) axis is regulated by cholinergic mechanisms. Acetylcholine (ACh), the cholinergic neurotransmitter, has been reported to alter the levels of cortisol as well as those of prolactin, growth hormone, leutinizing hormone and vasopressin. Prolactin secretion, however, is suppressed by increased pure cholinergic activity. Central actions of cholinomimetic drugs that either increase the concentration of ACh in brain (e.g. physostigmine) or activate the postsynaptic muscarinic receptors (e.g. arecoline), can also activate the HPA axis in both animals and human subjects.", "citation": {"type": "PubMed", "reference": "8584603"}, "annotations": {"MeSHAnatomy": {"Brain": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 17, "target": 13, "key": "63f1f111c2e2b7ed18615c2a4183df896220771517945d14a2c1a3b9a232c66319504fa333b9b243226afb66bac7e8b6426bf5c4cfd1917d04a35bfe78bed553"}, {"line": 17436, "relation": "regulates", "evidence": "The hypothalamic-pituitary-adrenal (HPA) axis is regulated by cholinergic mechanisms. Acetylcholine (ACh), the cholinergic neurotransmitter, has been reported to alter the levels of cortisol as well as those of prolactin, growth hormone, leutinizing hormone and vasopressin. Prolactin secretion, however, is suppressed by increased pure cholinergic activity. Central actions of cholinomimetic drugs that either increase the concentration of ACh in brain (e.g. physostigmine) or activate the postsynaptic muscarinic receptors (e.g. arecoline), can also activate the HPA axis in both animals and human subjects.", "citation": {"type": "PubMed", "reference": "8584603"}, "annotations": {"MeSHAnatomy": {"Brain": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 17, "target": 3, "key": "9d29b0f99f41e431bff69959b2d9555b2976f127b45641a55e2f53068a9be1713fe5f0d2d00df983bc1759f245fe76d54e55388f1b61cfb9df4e27655983a89e"}, {"line": 17440, "relation": "regulates", "evidence": "The hypothalamic-pituitary-adrenal (HPA) axis is regulated by cholinergic mechanisms. Acetylcholine (ACh), the cholinergic neurotransmitter, has been reported to alter the levels of cortisol as well as those of prolactin, growth hormone, leutinizing hormone and vasopressin. Prolactin secretion, however, is suppressed by increased pure cholinergic activity. Central actions of cholinomimetic drugs that either increase the concentration of ACh in brain (e.g. physostigmine) or activate the postsynaptic muscarinic receptors (e.g. arecoline), can also activate the HPA axis in both animals and human subjects.", "citation": {"type": "PubMed", "reference": "8584603"}, "annotations": {"MeSHAnatomy": {"Brain": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 17, "target": 34, "key": "ea8cb942620941fd2800bd013695d0c79a59bc97bdb44e5b62d08b5727c8e1597f659b7b19f8c59c6e9519719fcedc3b65eb9ab74dbb043895e916c9f6f56c36"}, {"line": 17444, "relation": "negativeCorrelation", "evidence": "The hypothalamic-pituitary-adrenal (HPA) axis is regulated by cholinergic mechanisms. Acetylcholine (ACh), the cholinergic neurotransmitter, has been reported to alter the levels of cortisol as well as those of prolactin, growth hormone, leutinizing hormone and vasopressin. Prolactin secretion, however, is suppressed by increased pure cholinergic activity. Central actions of cholinomimetic drugs that either increase the concentration of ACh in brain (e.g. physostigmine) or activate the postsynaptic muscarinic receptors (e.g. arecoline), can also activate the HPA axis in both animals and human subjects.", "citation": {"type": "PubMed", "reference": "8584603"}, "annotations": {"MeSHAnatomy": {"Brain": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 17, "target": 61, "key": "6f667d2de0f746f9a5ce57e9663bc56e1e154daf975fa20d1ac2efac34e07f22827cec6413bca834599c48873a4cc1c54dc7880121ad518564ca27e958d52967"}, {"line": 18899, "relation": "association", "evidence": "On a molecular level, studies suggest that acetylcholine (ACh) increases serotonin (5-HT) release through nicotinic receptors located at nerve terminals.", "citation": {"type": "PubMed", "reference": "16426583"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 17, "target": 96, "key": "3d697d8a9e54625eecb3428ce8947666e4ce772728f816e0313d3080e3a249282afda894a72293d2d17421a7155f3bf7cf8e8965c6331855867509fcfa9fe646"}, {"line": 18903, "relation": "association", "evidence": "On a molecular level, studies suggest that acetylcholine (ACh) increases serotonin (5-HT) release through nicotinic receptors located at nerve terminals.", "citation": {"type": "PubMed", "reference": "16426583"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 17, "target": 97, "key": "758981177464942ce95a6230ee059c8515a5dcf7b89facd77a29ba0b75e05cf7156310f382f6b3b8030ae36489c8c0536935c4b9f7a15cb211ff323b10aeaf31"}, {"line": 18907, "relation": "association", "evidence": "On a molecular level, studies suggest that acetylcholine (ACh) increases serotonin (5-HT) release through nicotinic receptors located at nerve terminals.", "citation": {"type": "PubMed", "reference": "16426583"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 17, "target": 98, "key": "062cd7dc5268964001fb3298ca98faff50c3ac2652179ae9ea2b9517ce03734051de6f666e9ab93a0161e1790584f86efdb45062a0b5371320b2b414d4cf4bbc"}, {"line": 18911, "relation": "association", "evidence": "On a molecular level, studies suggest that acetylcholine (ACh) increases serotonin (5-HT) release through nicotinic receptors located at nerve terminals.", "citation": {"type": "PubMed", "reference": "16426583"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 17, "target": 100, "key": "e9e2dacd0d806ee89bae848610168e1b2ed8e2cd671eba4c2fb3da3cfd9baf380eb297f662f591cb873a71d61b707c47a28f9b6ff570df099a9e513c97c56141"}, {"line": 18915, "relation": "association", "evidence": "On a molecular level, studies suggest that acetylcholine (ACh) increases serotonin (5-HT) release through nicotinic receptors located at nerve terminals.", "citation": {"type": "PubMed", "reference": "16426583"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 17, "target": 101, "key": "55a7112132207a937af9568eaa8686afe8ad7f9986e9bcdc6159787b43e5f48eafeb38d5e4ef03f3543861a6023164626f9e6dfcea117ecb84f7b06c691b1c96"}, {"line": 18919, "relation": "association", "evidence": "On a molecular level, studies suggest that acetylcholine (ACh) increases serotonin (5-HT) release through nicotinic receptors located at nerve terminals.", "citation": {"type": "PubMed", "reference": "16426583"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 17, "target": 102, "key": "2e91c36fc80e4bcc1e6b2b0936e7ad320841955edc86d4831a721947bcb2e104b6041774dcfef7d8c02d8636dc49832209388bdad44599dcc21f49d455c32524"}, {"line": 18923, "relation": "association", "evidence": "On a molecular level, studies suggest that acetylcholine (ACh) increases serotonin (5-HT) release through nicotinic receptors located at nerve terminals.", "citation": {"type": "PubMed", "reference": "16426583"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 17, "target": 103, "key": "5dcaee056ce7c22aea7f28471b9e29093920a313b9cd9f29763e9584386f5ab4d53ec96ab1e17253fcaf32350d43f27526ba99756a65ffdf444ba8ec0ddaa4a7"}, {"line": 18927, "relation": "association", "evidence": "On a molecular level, studies suggest that acetylcholine (ACh) increases serotonin (5-HT) release through nicotinic receptors located at nerve terminals.", "citation": {"type": "PubMed", "reference": "16426583"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 17, "target": 95, "key": "9b234558760d85c4480526bb9a61ad7602d9978972e3e9e718b72feabddddcc12548f987da97c6e53620b31dfad08ca9f6f13ab9ad1732cd148d5cb07ffffe89"}, {"line": 18931, "relation": "association", "evidence": "On a molecular level, studies suggest that acetylcholine (ACh) increases serotonin (5-HT) release through nicotinic receptors located at nerve terminals.", "citation": {"type": "PubMed", "reference": "16426583"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 17, "target": 105, "key": "b118f4a1ec533843692eaac19cef591c98a69fa87b14a31dd425358b1253df9d28597b0bc846253bba05ca567e12b516d2ec1ee0f105646bef0fd252eebbf5fb"}, {"line": 18935, "relation": "association", "evidence": "On a molecular level, studies suggest that acetylcholine (ACh) increases serotonin (5-HT) release through nicotinic receptors located at nerve terminals.", "citation": {"type": "PubMed", "reference": "16426583"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 17, "target": 107, "key": "824eeea830ac989e620dc0c278831ebab3d5846a2bd7b238eb0e683f10e7007dd685f0f9d058aaa49e1c2a4f0e6187ecbd1dd1543cb061af33293c55225e7260"}, {"line": 18939, "relation": "association", "evidence": "On a molecular level, studies suggest that acetylcholine (ACh) increases serotonin (5-HT) release through nicotinic receptors located at nerve terminals.", "citation": {"type": "PubMed", "reference": "16426583"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 17, "target": 108, "key": "06a67ffcf0e9aa51f2c5e049dd103ecfd80bd12c57804e236946e6f9f94a3b91d5578cdcc6e421efb5f31b7c31205a7321049b23ac2d01634cac528e76380496"}, {"line": 18945, "relation": "increases", "evidence": "On a molecular level, studies suggest that acetylcholine (ACh) increases serotonin (5-HT) release through nicotinic receptors located at nerve terminals.", "citation": {"type": "PubMed", "reference": "16426583"}, "annotations": {"Subgraph": {"Serotonergic subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 17, "target": 32, "key": "4a34b691638a38b23c1420838def6b8445647b913f9771ceae93f3a39586c3c31f4009e3b48a078cb5352ebc3f8d35acd6721e234df42facf7e8ead37ada6877"}, {"line": 29415, "relation": "increases", "evidence": "Rivastigmine treatment prevented the inhibitory effects of LPS and resulted in an increase (P â‰¤ 0.01) in GnRH concentrations compared to control-treated ewes or concentrations prior to treatment. The stimulation of GnRH secretion by treatment with LPS and rivastigmine may result from ACh accumulation in the brain.", "citation": {"type": "PubMed", "name": "Anim Reprod Sci. 2013 May;138(3-4):203-12", "reference": "23557940"}, "annotations": {"MeSHAnatomy": {"Brain": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 17, "target": 113, "key": "374c1c0aee54f22165998cdfdb2b96294df0c85a6cf6bd5b2b9d17e657ec70d92631d06495c23d3bb0b0a09b6f77dad00ab55ee0376a08a0661dd2a8e6628bc1"}, {"line": 30302, "relation": "association", "evidence": "Acetylcholinesterase (AChE), an enzyme involved in the hydrolysis of the neurotransmitter acetylcholine, consistently colocalizes with the amyloid deposits characteristic of Alzheimer's disease and may contribute to the generation of amyloid proteins and/or physically affect fibril assembly.", "citation": {"type": "PubMed", "reference": "9325095"}, "annotations": {"Subgraph": {"Amyloidogenic subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "object": {"modifier": "Activity"}, "source": 17, "target": 88, "key": "73b629ac494c93cb1e88f5a06d5db57d7c08aa3f3d18b0b13fc41596eeebb7eff6721d744a87dfabee5dd78fba484be3e5ab9cf5f75f0d2fe91e481e9a5db10b"}, {"line": 30312, "relation": "increases", "evidence": "Our results suggest that such amyloid-AChE complexes are formed when AChE interacts with the growing amyloid fibrils and accelerates the assembly of Abeta peptides", "citation": {"type": "PubMed", "reference": "9325095"}, "annotations": {"Subgraph": {"Amyloidogenic subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 80, "target": 90, "key": "95628d619ef0d42201c0b48ea53337a46e6d51768558b634b55ea68cf111849f63c3c3cefa45e1bc70eb5ca2873f8a3af38461678a0025b33d9b7eb7b8a2f97b"}, {"line": 1501, "relation": "increases", "evidence": "The neurotoxicity induced by AChE-Abeta complexes indicated that they trigger more neurodegeneration than those of the Abeta peptide alone.The fact that AChE is able to accelerate amyloid formation", "citation": {"type": "PubMed", "reference": "15709485"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"Apoptosis signaling subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Very High": true}}, "source": 80, "target": 56, "key": "95ea534cd4b050e83b2f24864b4cddf498db97237c3870ed8f143a5e59b0efd51ab3c37373112fdedfd9ffac5af593f626a7be62fd192059003663c7092a5326"}, {"line": 55385, "relation": "positiveCorrelation", "evidence": "There were significant correlations between cerebral atrophy as assessed by VBR and CSF AChE activity. Cognitive impairment on MMSE also correlated significantly with VBR.", "citation": {"type": "PubMed", "name": "Psychiatry Res. 1986 Jan;17(1):23-9.", "reference": "3484831"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 39, "target": 88, "key": "7c1c5f5a11cd6e479faf6d2e3a932be989d6a3216aaa0833796e84fd4913edeb25c18cc1a04cf291ad852b9874c1ac0f0186a6c24b81fe1a3b0d1feba631710d"}, {"line": 47068, "relation": "positiveCorrelation", "evidence": "Butyrylcholinesterase (BuChE) activity is associated with activated astrocytes in Alzheimer's disease brain. BuChE genotype was linked with differential CSF levels of glial fibrillary acidic protein, S100B, interleukin-1beta, and tumor necrosis factor (TNF)-alpha. BCHE-K noncarriers displayed 100%-150% higher glial fibrillary acidic protein and 64%-110% higher S100B than BCHE-K carriers, who, in contrast, had 40%-80% higher interleukin-1beta and 21%-27% higher TNF-alpha compared with noncarriers. A high level of CSF BuChE enzymatic phenotype also significantly correlated with higher CSF levels of astroglial markers and several factors of the innate complement system, but lower levels of proinflammatory cytokines. These individuals also displayed beneficial paraclinical and clinical findings, such as high cerebral glucose utilization, low beta-amyloid load, and less severe progression of clinical symptoms.", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2013 Nov;34(11):2465-81. doi: 10.1016/j.neurobiolaging.2013.04.027. Epub 2013 Jun 4.", "reference": "23759148"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Very High": true}}, "subject": {"modifier": "Activity"}, "object": {"modifier": "Activity"}, "source": 35, "target": 91, "key": "20da3b3eab2b49948fe070ebcadddc77f88b1d460ac52932e622c0cb55c4499a8776245c639cb929d3a863ce4bddb0c6f04b1f91584805d65d8c95f02e90a8fb"}, {"line": 47072, "relation": "association", "evidence": "Butyrylcholinesterase (BuChE) activity is associated with activated astrocytes in Alzheimer's disease brain. BuChE genotype was linked with differential CSF levels of glial fibrillary acidic protein, S100B, interleukin-1beta, and tumor necrosis factor (TNF)-alpha. BCHE-K noncarriers displayed 100%-150% higher glial fibrillary acidic protein and 64%-110% higher S100B than BCHE-K carriers, who, in contrast, had 40%-80% higher interleukin-1beta and 21%-27% higher TNF-alpha compared with noncarriers. A high level of CSF BuChE enzymatic phenotype also significantly correlated with higher CSF levels of astroglial markers and several factors of the innate complement system, but lower levels of proinflammatory cytokines. These individuals also displayed beneficial paraclinical and clinical findings, such as high cerebral glucose utilization, low beta-amyloid load, and less severe progression of clinical symptoms.", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2013 Nov;34(11):2465-81. doi: 10.1016/j.neurobiolaging.2013.04.027. Epub 2013 Jun 4.", "reference": "23759148"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Very High": true}}, "source": 112, "target": 91, "key": "6d365c08f2ad3650c30726556f3570aaf81224ebf7c6cb3475165a54a0f1c7462dfbec451c9b3aa16878dbc075577f58c7d82d9a48cd86057b83d1f1d44dfc38"}, {"line": 47078, "relation": "association", "evidence": "Butyrylcholinesterase (BuChE) activity is associated with activated astrocytes in Alzheimer's disease brain. BuChE genotype was linked with differential CSF levels of glial fibrillary acidic protein, S100B, interleukin-1beta, and tumor necrosis factor (TNF)-alpha. BCHE-K noncarriers displayed 100%-150% higher glial fibrillary acidic protein and 64%-110% higher S100B than BCHE-K carriers, who, in contrast, had 40%-80% higher interleukin-1beta and 21%-27% higher TNF-alpha compared with noncarriers. A high level of CSF BuChE enzymatic phenotype also significantly correlated with higher CSF levels of astroglial markers and several factors of the innate complement system, but lower levels of proinflammatory cytokines. These individuals also displayed beneficial paraclinical and clinical findings, such as high cerebral glucose utilization, low beta-amyloid load, and less severe progression of clinical symptoms.", "citation": {"type": "PubMed", "name": "Neurobiol Aging. 2013 Nov;34(11):2465-81. doi: 10.1016/j.neurobiolaging.2013.04.027. Epub 2013 Jun 4.", "reference": "23759148"}, "annotations": {"Subgraph": {"Calcium-dependent signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Very High": true}}, "source": 123, "target": 91, "key": "7181160a0b22254c60fe521cb32ebef744c9adc81f03c3f628f25643b30cc2c15defa705a4e21aaf15ea06679b8882acc0f4d3e8f05006bae95c01117f70baa1"}, {"line": 3862, "relation": "directlyIncreases", "evidence": "Acetylcholinesterase (AChE) is thought to play an important role during apoptotic process. Our results showed that H2O2 induced AChE activity, a functional marker in apoptotic process, increases in neuronal-like PC12 cells. Glutathione, which is involved in cellular redox homeostasis, inhibited the increase of AChE activity, suggesting that reactive oxygen species (ROS) play a key role in this process. Further investigation showed that the elevation of AChE was observed after the degradation of Akt, release of cytochrome c from mitochondria into the cytosol, and activation of caspase family members. When nerve growth factor (NGF) was present, with the maintenance of Akt level, the elevation of AChE, the cytochrome c diffusion, as well as apoptotic process were markedly attenuated in H2O2-treated PC12 cells", "citation": {"type": "PubMed", "reference": "17213958"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"Caspase subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity", "effect": {"name": "kin", "namespace": "bel"}}, "object": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "source": 141, "target": 88, "key": "7eaaa7899fe70c05f4926c923ee3983ec0873de59646bd9ad2e704a5c9b7cec4b224a19f9197d97930ebecac2ba4cb02bcee692cb9dbc88ccf3421a6312828bc"}, {"line": 18321, "relation": "increases", "evidence": "In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.", "citation": {"type": "PubMed", "reference": "21821968"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 114, "target": 66, "key": "e20a6149450cf9e3ec8c6d821e340f58596920c070233fab4a6daf82a718a2db75ce92527d78e7a9d66bc2952a6a4840909cafdb1884e2945561863343948fe5"}, {"line": 18325, "relation": "increases", "evidence": "In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.", "citation": {"type": "PubMed", "reference": "21821968"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 114, "target": 68, "key": "78f9d5cc50d866a076312f276830619bb39fbfdb551c8327d618c5f013816c722ee3a729e1fab2e9ffc52c44fcaf9e9dcfe5a78fc823447cb1abe77fac958002"}, {"line": 18329, "relation": "increases", "evidence": "In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.", "citation": {"type": "PubMed", "reference": "21821968"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 114, "target": 69, "key": "6e77d31c49b5cad43e01f8e5c451c58f992c3b7b0c9edb95ded3e6199a17c82ea198840a8c452ae73ad74786874ddc26667e95a8d9f13d29e8e28f953d5f08e8"}, {"line": 3852, "relation": "directlyIncreases", "evidence": "Acetylcholinesterase (AChE) is thought to play an important role during apoptotic process. Our results showed that H2O2 induced AChE activity, a functional marker in apoptotic process, increases in neuronal-like PC12 cells. Glutathione, which is involved in cellular redox homeostasis, inhibited the increase of AChE activity, suggesting that reactive oxygen species (ROS) play a key role in this process. Further investigation showed that the elevation of AChE was observed after the degradation of Akt, release of cytochrome c from mitochondria into the cytosol, and activation of caspase family members. When nerve growth factor (NGF) was present, with the maintenance of Akt level, the elevation of AChE, the cytochrome c diffusion, as well as apoptotic process were markedly attenuated in H2O2-treated PC12 cells", "citation": {"type": "PubMed", "reference": "17213958"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"Akt subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Degradation"}, "object": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "source": 140, "target": 88, "key": "e51aa1d62c100a085397308a2cfc51264efd0352c68b30925568f25ce695ff506903fb787752ba60b5736a18d9803bc6737b320831a02f86635381f91a57ae80"}, {"line": 3856, "relation": "directlyIncreases", "evidence": "Acetylcholinesterase (AChE) is thought to play an important role during apoptotic process. Our results showed that H2O2 induced AChE activity, a functional marker in apoptotic process, increases in neuronal-like PC12 cells. Glutathione, which is involved in cellular redox homeostasis, inhibited the increase of AChE activity, suggesting that reactive oxygen species (ROS) play a key role in this process. Further investigation showed that the elevation of AChE was observed after the degradation of Akt, release of cytochrome c from mitochondria into the cytosol, and activation of caspase family members. When nerve growth factor (NGF) was present, with the maintenance of Akt level, the elevation of AChE, the cytochrome c diffusion, as well as apoptotic process were markedly attenuated in H2O2-treated PC12 cells", "citation": {"type": "PubMed", "reference": "17213958"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"Akt subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "MESH", "name": "D008928"}, "toLoc": {"namespace": "MESHCS", "name": "Cytosol"}}}, "object": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "source": 109, "target": 88, "key": "105a5a652129f7bf194798c2ee040034201837d192000400ee3607fefea7cdd8c91a4b1f534526bef062cd0bfb92d9a11956f75e13bb04c2248212f5015a310f"}, {"line": 3866, "relation": "directlyDecreases", "evidence": "Acetylcholinesterase (AChE) is thought to play an important role during apoptotic process. Our results showed that H2O2 induced AChE activity, a functional marker in apoptotic process, increases in neuronal-like PC12 cells. Glutathione, which is involved in cellular redox homeostasis, inhibited the increase of AChE activity, suggesting that reactive oxygen species (ROS) play a key role in this process. Further investigation showed that the elevation of AChE was observed after the degradation of Akt, release of cytochrome c from mitochondria into the cytosol, and activation of caspase family members. When nerve growth factor (NGF) was present, with the maintenance of Akt level, the elevation of AChE, the cytochrome c diffusion, as well as apoptotic process were markedly attenuated in H2O2-treated PC12 cells", "citation": {"type": "PubMed", "reference": "17213958"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"Caspase subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity", "effect": {"name": "pep", "namespace": "bel"}}, "source": 120, "target": 88, "key": "9e9332e2e8ebb4ddd3b7744b316ea23864f1b23ccb6214bfd4ce8271e5cb09e0cd0865157176c57c1d10fea4862b5fe98f20322ec6d05a66bb69817e777f3836"}, {"line": 3870, "relation": "directlyDecreases", "evidence": "Acetylcholinesterase (AChE) is thought to play an important role during apoptotic process. Our results showed that H2O2 induced AChE activity, a functional marker in apoptotic process, increases in neuronal-like PC12 cells. Glutathione, which is involved in cellular redox homeostasis, inhibited the increase of AChE activity, suggesting that reactive oxygen species (ROS) play a key role in this process. Further investigation showed that the elevation of AChE was observed after the degradation of Akt, release of cytochrome c from mitochondria into the cytosol, and activation of caspase family members. When nerve growth factor (NGF) was present, with the maintenance of Akt level, the elevation of AChE, the cytochrome c diffusion, as well as apoptotic process were markedly attenuated in H2O2-treated PC12 cells", "citation": {"type": "PubMed", "reference": "17213958"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"Caspase subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 120, "target": 55, "key": "a8cf0a428c93f46145aabecba0624e01800d8b2dd9cf11f6e5706a38483b04a008f4fefc88d784488ef583cc2d19722deea3c85e4b4a2e5fdc42ef9d9b309f73"}, {"line": 3874, "relation": "directlyDecreases", "evidence": "Acetylcholinesterase (AChE) is thought to play an important role during apoptotic process. Our results showed that H2O2 induced AChE activity, a functional marker in apoptotic process, increases in neuronal-like PC12 cells. Glutathione, which is involved in cellular redox homeostasis, inhibited the increase of AChE activity, suggesting that reactive oxygen species (ROS) play a key role in this process. Further investigation showed that the elevation of AChE was observed after the degradation of Akt, release of cytochrome c from mitochondria into the cytosol, and activation of caspase family members. When nerve growth factor (NGF) was present, with the maintenance of Akt level, the elevation of AChE, the cytochrome c diffusion, as well as apoptotic process were markedly attenuated in H2O2-treated PC12 cells", "citation": {"type": "PubMed", "reference": "17213958"}, "annotations": {"Condition": {"Normal Healthy State": true}, "Subgraph": {"Caspase subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Translocation", "effect": {"fromLoc": {"namespace": "MESH", "name": "D008928"}, "toLoc": {"namespace": "MESHCS", "name": "Cytosol"}}}, "source": 120, "target": 109, "key": "bcb51d66661f4b0efb429285d84a855fe5fd83a21fbe3195608de55363d5a030298ece82b7d3d7efffc4791ccfd634b3fcb27b91f5bc8f6f196af55950de5ade"}, {"line": 18150, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 98, "target": 10, "key": "ad2f7d327c12543613d2e79039e4b999e6da9ee3609be0281e46fde2f40d877f9b4bfcc7f4286bea8a24ab17de278226371983c2906d31f12df60766c1cee8e2"}, {"line": 18194, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 98, "target": 11, "key": "d461ac095ccfcc406073a0e76283c6dbab093e233117ee60b7ba3882f68eba5dc413fd6a52a2cab6fde19bbc9991218cf0a96c7fe2da424c0a7ce7baab89d739"}, {"line": 18907, "relation": "association", "evidence": "On a molecular level, studies suggest that acetylcholine (ACh) increases serotonin (5-HT) release through nicotinic receptors located at nerve terminals.", "citation": {"type": "PubMed", "reference": "16426583"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 98, "target": 17, "key": "1e112b451075257ac54b9114acde4d5fb85a2fc9b74d96043f60d47903c7a13e281f9158dcbe4c8b90dff0f46bff8803bbea03c7b136bee17e5d23e3eeb929e8"}, {"line": 44215, "relation": "increases", "evidence": "Nicotinic acetylcholine receptors (nAChRs). Activation of the neuronal pentameric nAChRs is involved in diverse brain functions including synaptic plasticity and memory [237, 238] and enhances transmitter release in several brain regions including the hippocampus [239], the spinal cord dorsal horn [240], the olfactory bulb, and the amygdala [241]. The increase of synaptic plasticity by ABeta¸ requires activation of nAChRs [242]. Because activation of nAChRs is necessary for the ABeta¸-induced increase of synaptic plasticity and memory under normal conditions, ABeta¸ may modify glutamate release with a mechanism dependent upon activation of nAChRs [83]. However, several reports of the effect of ABeta¸42 on nAChRs are conflicting. Some studies have reported that ABeta¸42 activates nAChRs [243, 244], while others indicate that ABeta¸42 inhibits nAChRs [245, 246]. Interestingly, picomolar concentrations of ABeta¸42 were effective in activating nAChRs while higher levels of ABeta¸ produced inhibitory action. The disparity may depend on the nanomolar ABeta¸1Ã¢â‚¬â€œ42 inhibition of nicotine-induced Ca2+ responses while picomolar ABeta¸42 directly evokes sustained increases in presynaptic Ca2+ via nAChRs [244]. ABeta¸42 binds to the nAChR with picomolar affinity [247]. This binding can modulate presynaptic, glutamate-mediated synaptic transmission or glutamate release, suggesting that ABeta¸42-dependent cholinergic modulation activates signal transduction mechanisms that ultimately result in synaptic transmission and memory consolidation [248]. However, it remains to be determined whether these effects are mediated by a direct physical interaction of the ABeta¸ peptide with the nAChRs. Immunohistochemical studies on human sporadic AD brains show that ABeta¸42 and nAChR, are both present in neuritic plaques and co-localize in individual cortical neurons suggesting that ABeta¸ could be tightly associated with nAChR [247]. Alternatively, ABeta¸ might be responsible for regulation of nAChR function through strong binding with membrane lipids [249]. Picomolar or higher ABeta¸42 acting through nAChRs, can elicit ERK MAPK activation in hippocampal cultures [245, 250] possibly triggered by Ca2+ influx [243, 251]. ERK is known to regulate transcription factors such as CREB and Elk-1 by phosphorylation [140], which help initiate transcription of memory-associated genes that contain their respective regulatory elements [252]. Therefore, over-activation of nAChRs and excessive Ca2+ influx or dysregulation of Ca2+ homeostasis provide a molecular mechanism for the cholinergic dysfunction that is a hallmark of AD [253, 254].", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 98, "target": 45, "key": "56e6644c087ab21e92914d63e1ffe501545bfb8c605d3b67c79250f3da32d84604fb6e1f764a0465299fc86580215dd2fe14f53a08569f744ec673f02b2ded3c"}, {"line": 47039, "relation": "positiveCorrelation", "evidence": "Inflammatory components related to AD neuroinflammation include brain cells such as microglia and astrocytes, the classic and alternate pathways of the complement system, the pentraxin acute-phase proteins, neuronal-type nicotinic acetylcholine receptors (AChRs), peroxisomal proliferators-activated receptors (PPARs), as well as cytokines and chemokines. Both the microglia and astrocytes have been shown to generate beta-amyloid protein (Abeta), one of the main pathologic features of AD. Abeta itself has been shown to act as a pro-inflammatory agent causing the activation of many of the inflammatory components", "citation": {"type": "PubMed", "name": "Int J Biochem Cell Biol. 2005 Feb;37(2):289-305.", "reference": "15474976"}, "annotations": {"Subgraph": {"Inflammatory response subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 98, "target": 71, "key": "3742d67a6891c8e5d871e5baf6cfd884f106297fca8407276bdcb9e1eee2984b637b18baacc899ad3ffb5fa43b4ecb922b305544b9b6d80c36e40f7f8fbe792e"}, {"line": 47027, "relation": "positiveCorrelation", "evidence": "Inflammatory components related to AD neuroinflammation include brain cells such as microglia and astrocytes, the classic and alternate pathways of the complement system, the pentraxin acute-phase proteins, neuronal-type nicotinic acetylcholine receptors (AChRs), peroxisomal proliferators-activated receptors (PPARs), as well as cytokines and chemokines. Both the microglia and astrocytes have been shown to generate beta-amyloid protein (Abeta), one of the main pathologic features of AD. Abeta itself has been shown to act as a pro-inflammatory agent causing the activation of many of the inflammatory components", "citation": {"type": "PubMed", "name": "Int J Biochem Cell Biol. 2005 Feb;37(2):289-305.", "reference": "15474976"}, "annotations": {"Subgraph": {"Inflammatory response subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 71, "target": 100, "key": "befdc20585b935e05525f69d0bf7c4cdc35f37c6d5aa85b6d3a0e64dea8c06f48cbe348ade975916cce947fa1766c16c26628098bca14f4feebf273dd4f431ed"}, {"line": 47031, "relation": "positiveCorrelation", "evidence": "Inflammatory components related to AD neuroinflammation include brain cells such as microglia and astrocytes, the classic and alternate pathways of the complement system, the pentraxin acute-phase proteins, neuronal-type nicotinic acetylcholine receptors (AChRs), peroxisomal proliferators-activated receptors (PPARs), as well as cytokines and chemokines. Both the microglia and astrocytes have been shown to generate beta-amyloid protein (Abeta), one of the main pathologic features of AD. Abeta itself has been shown to act as a pro-inflammatory agent causing the activation of many of the inflammatory components", "citation": {"type": "PubMed", "name": "Int J Biochem Cell Biol. 2005 Feb;37(2):289-305.", "reference": "15474976"}, "annotations": {"Subgraph": {"Inflammatory response subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 71, "target": 97, "key": "9e76638602bdde2e9e6e39cb60100300681211aa72802a9e313789809c002117614ddff7b9c10dbd05254ad8fdbfaabc0674d678e703ca441704ca163b23c826"}, {"line": 47035, "relation": "positiveCorrelation", "evidence": "Inflammatory components related to AD neuroinflammation include brain cells such as microglia and astrocytes, the classic and alternate pathways of the complement system, the pentraxin acute-phase proteins, neuronal-type nicotinic acetylcholine receptors (AChRs), peroxisomal proliferators-activated receptors (PPARs), as well as cytokines and chemokines. Both the microglia and astrocytes have been shown to generate beta-amyloid protein (Abeta), one of the main pathologic features of AD. Abeta itself has been shown to act as a pro-inflammatory agent causing the activation of many of the inflammatory components", "citation": {"type": "PubMed", "name": "Int J Biochem Cell Biol. 2005 Feb;37(2):289-305.", "reference": "15474976"}, "annotations": {"Subgraph": {"Inflammatory response subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 71, "target": 102, "key": "0bf79edb82f94038869a69dae49fc3f658de7d76e889ba766da8a3cfd6c82e448f756d78cc4348e670ca87fac8d4d0422a27577a10b1fd59d2a732e3f30172a6"}, {"line": 47039, "relation": "positiveCorrelation", "evidence": "Inflammatory components related to AD neuroinflammation include brain cells such as microglia and astrocytes, the classic and alternate pathways of the complement system, the pentraxin acute-phase proteins, neuronal-type nicotinic acetylcholine receptors (AChRs), peroxisomal proliferators-activated receptors (PPARs), as well as cytokines and chemokines. Both the microglia and astrocytes have been shown to generate beta-amyloid protein (Abeta), one of the main pathologic features of AD. Abeta itself has been shown to act as a pro-inflammatory agent causing the activation of many of the inflammatory components", "citation": {"type": "PubMed", "name": "Int J Biochem Cell Biol. 2005 Feb;37(2):289-305.", "reference": "15474976"}, "annotations": {"Subgraph": {"Inflammatory response subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 71, "target": 98, "key": "7e829b260ab590a811165e768db2c87b93766cd534eb762bfd50f7bc69ec3bf07d188164094fd4a98dd483eaf0054206466b01f5876c8cf008c1622a42b79d58"}, {"line": 47043, "relation": "positiveCorrelation", "evidence": "Inflammatory components related to AD neuroinflammation include brain cells such as microglia and astrocytes, the classic and alternate pathways of the complement system, the pentraxin acute-phase proteins, neuronal-type nicotinic acetylcholine receptors (AChRs), peroxisomal proliferators-activated receptors (PPARs), as well as cytokines and chemokines. Both the microglia and astrocytes have been shown to generate beta-amyloid protein (Abeta), one of the main pathologic features of AD. Abeta itself has been shown to act as a pro-inflammatory agent causing the activation of many of the inflammatory components", "citation": {"type": "PubMed", "name": "Int J Biochem Cell Biol. 2005 Feb;37(2):289-305.", "reference": "15474976"}, "annotations": {"Subgraph": {"Inflammatory response subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 71, "target": 105, "key": "2a269af91fd4445eb7817cdc9e1e83b99a4837858041b4d219c118168080decc8ce0530cd0606b1a1bf28e2839973b2df1fb2e27fa7cd3e371f12615d3858eaa"}, {"line": 47047, "relation": "positiveCorrelation", "evidence": "Inflammatory components related to AD neuroinflammation include brain cells such as microglia and astrocytes, the classic and alternate pathways of the complement system, the pentraxin acute-phase proteins, neuronal-type nicotinic acetylcholine receptors (AChRs), peroxisomal proliferators-activated receptors (PPARs), as well as cytokines and chemokines. Both the microglia and astrocytes have been shown to generate beta-amyloid protein (Abeta), one of the main pathologic features of AD. Abeta itself has been shown to act as a pro-inflammatory agent causing the activation of many of the inflammatory components", "citation": {"type": "PubMed", "name": "Int J Biochem Cell Biol. 2005 Feb;37(2):289-305.", "reference": "15474976"}, "annotations": {"Subgraph": {"Inflammatory response subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 71, "target": 121, "key": "280271b45e981fe9fba7f22d3b5231cd9d93c9c2fa2053e9c81c1cd7f11c03f4839b58ddf285546dac1f738d32d133a70d46be99a0f05524a3424b40763dc81c"}, {"line": 18174, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 105, "target": 11, "key": "cf7be62d797efaba525afa6b7fca4e15478786059c12fdb4665146f8a9fbd9503793748b92a5317a4ca0415280f83ad74c70ed80363e6d0c7fc5f678e8e980a5"}, {"line": 18931, "relation": "association", "evidence": "On a molecular level, studies suggest that acetylcholine (ACh) increases serotonin (5-HT) release through nicotinic receptors located at nerve terminals.", "citation": {"type": "PubMed", "reference": "16426583"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 105, "target": 17, "key": "a2e8d2468b26f20b9d35b74b2b218b97a7030fb8e1c7e5aa4247d2c567c4a8f5035325f594d35ef6ffd2f57630b780ac4429b1f0c1f35eb135ce97f9ebf452f8"}, {"line": 44194, "relation": "regulates", "evidence": "Nicotinic acetylcholine receptors (nAChRs). Activation of the neuronal pentameric nAChRs is involved in diverse brain functions including synaptic plasticity and memory [237, 238] and enhances transmitter release in several brain regions including the hippocampus [239], the spinal cord dorsal horn [240], the olfactory bulb, and the amygdala [241]. The increase of synaptic plasticity by ABeta¸ requires activation of nAChRs [242]. Because activation of nAChRs is necessary for the ABeta¸-induced increase of synaptic plasticity and memory under normal conditions, ABeta¸ may modify glutamate release with a mechanism dependent upon activation of nAChRs [83]. However, several reports of the effect of ABeta¸42 on nAChRs are conflicting. Some studies have reported that ABeta¸42 activates nAChRs [243, 244], while others indicate that ABeta¸42 inhibits nAChRs [245, 246]. Interestingly, picomolar concentrations of ABeta¸42 were effective in activating nAChRs while higher levels of ABeta¸ produced inhibitory action. The disparity may depend on the nanomolar ABeta¸1Ã¢â‚¬â€œ42 inhibition of nicotine-induced Ca2+ responses while picomolar ABeta¸42 directly evokes sustained increases in presynaptic Ca2+ via nAChRs [244]. ABeta¸42 binds to the nAChR with picomolar affinity [247]. This binding can modulate presynaptic, glutamate-mediated synaptic transmission or glutamate release, suggesting that ABeta¸42-dependent cholinergic modulation activates signal transduction mechanisms that ultimately result in synaptic transmission and memory consolidation [248]. However, it remains to be determined whether these effects are mediated by a direct physical interaction of the ABeta¸ peptide with the nAChRs. Immunohistochemical studies on human sporadic AD brains show that ABeta¸42 and nAChR, are both present in neuritic plaques and co-localize in individual cortical neurons suggesting that ABeta¸ could be tightly associated with nAChR [247]. Alternatively, ABeta¸ might be responsible for regulation of nAChR function through strong binding with membrane lipids [249]. Picomolar or higher ABeta¸42 acting through nAChRs, can elicit ERK MAPK activation in hippocampal cultures [245, 250] possibly triggered by Ca2+ influx [243, 251]. ERK is known to regulate transcription factors such as CREB and Elk-1 by phosphorylation [140], which help initiate transcription of memory-associated genes that contain their respective regulatory elements [252]. Therefore, over-activation of nAChRs and excessive Ca2+ influx or dysregulation of Ca2+ homeostasis provide a molecular mechanism for the cholinergic dysfunction that is a hallmark of AD [253, 254].", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 105, "target": 90, "key": "a7b8e7e87cc9fb92cac47cee493a75d4cc4523744ccad944eefd519e3ca15abd40c4943c6b7e89846310e88abb815e94791cc50782b5b6031a69c6e09017a24e"}, {"line": 44239, "relation": "increases", "evidence": "Nicotinic acetylcholine receptors (nAChRs). Activation of the neuronal pentameric nAChRs is involved in diverse brain functions including synaptic plasticity and memory [237, 238] and enhances transmitter release in several brain regions including the hippocampus [239], the spinal cord dorsal horn [240], the olfactory bulb, and the amygdala [241]. The increase of synaptic plasticity by ABeta¸ requires activation of nAChRs [242]. Because activation of nAChRs is necessary for the ABeta¸-induced increase of synaptic plasticity and memory under normal conditions, ABeta¸ may modify glutamate release with a mechanism dependent upon activation of nAChRs [83]. However, several reports of the effect of ABeta¸42 on nAChRs are conflicting. Some studies have reported that ABeta¸42 activates nAChRs [243, 244], while others indicate that ABeta¸42 inhibits nAChRs [245, 246]. Interestingly, picomolar concentrations of ABeta¸42 were effective in activating nAChRs while higher levels of ABeta¸ produced inhibitory action. The disparity may depend on the nanomolar ABeta¸1Ã¢â‚¬â€œ42 inhibition of nicotine-induced Ca2+ responses while picomolar ABeta¸42 directly evokes sustained increases in presynaptic Ca2+ via nAChRs [244]. ABeta¸42 binds to the nAChR with picomolar affinity [247]. This binding can modulate presynaptic, glutamate-mediated synaptic transmission or glutamate release, suggesting that ABeta¸42-dependent cholinergic modulation activates signal transduction mechanisms that ultimately result in synaptic transmission and memory consolidation [248]. However, it remains to be determined whether these effects are mediated by a direct physical interaction of the ABeta¸ peptide with the nAChRs. Immunohistochemical studies on human sporadic AD brains show that ABeta¸42 and nAChR, are both present in neuritic plaques and co-localize in individual cortical neurons suggesting that ABeta¸ could be tightly associated with nAChR [247]. Alternatively, ABeta¸ might be responsible for regulation of nAChR function through strong binding with membrane lipids [249]. Picomolar or higher ABeta¸42 acting through nAChRs, can elicit ERK MAPK activation in hippocampal cultures [245, 250] possibly triggered by Ca2+ influx [243, 251]. ERK is known to regulate transcription factors such as CREB and Elk-1 by phosphorylation [140], which help initiate transcription of memory-associated genes that contain their respective regulatory elements [252]. Therefore, over-activation of nAChRs and excessive Ca2+ influx or dysregulation of Ca2+ homeostasis provide a molecular mechanism for the cholinergic dysfunction that is a hallmark of AD [253, 254].", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 105, "target": 45, "key": "c81dddaf32c91edf65ea5ec78ee544366703ef60f943928e98682c092ab1879b67f03fb458758b8ef6ddabfb5247d0da8d5dfbac9716d435c83c05ed91997489"}, {"line": 47043, "relation": "positiveCorrelation", "evidence": "Inflammatory components related to AD neuroinflammation include brain cells such as microglia and astrocytes, the classic and alternate pathways of the complement system, the pentraxin acute-phase proteins, neuronal-type nicotinic acetylcholine receptors (AChRs), peroxisomal proliferators-activated receptors (PPARs), as well as cytokines and chemokines. Both the microglia and astrocytes have been shown to generate beta-amyloid protein (Abeta), one of the main pathologic features of AD. Abeta itself has been shown to act as a pro-inflammatory agent causing the activation of many of the inflammatory components", "citation": {"type": "PubMed", "name": "Int J Biochem Cell Biol. 2005 Feb;37(2):289-305.", "reference": "15474976"}, "annotations": {"Subgraph": {"Inflammatory response subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 105, "target": 71, "key": "c1637e85ae37360a501206abc91e3016098bc6542c0d2a0fb266721e4bc849cb1e8958a222624e4a6bc1b5bc0251ed9c2710a014d4d76c6da425573f20d78f33"}, {"line": 47047, "relation": "positiveCorrelation", "evidence": "Inflammatory components related to AD neuroinflammation include brain cells such as microglia and astrocytes, the classic and alternate pathways of the complement system, the pentraxin acute-phase proteins, neuronal-type nicotinic acetylcholine receptors (AChRs), peroxisomal proliferators-activated receptors (PPARs), as well as cytokines and chemokines. Both the microglia and astrocytes have been shown to generate beta-amyloid protein (Abeta), one of the main pathologic features of AD. Abeta itself has been shown to act as a pro-inflammatory agent causing the activation of many of the inflammatory components", "citation": {"type": "PubMed", "name": "Int J Biochem Cell Biol. 2005 Feb;37(2):289-305.", "reference": "15474976"}, "annotations": {"Subgraph": {"Inflammatory response subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 121, "target": 71, "key": "39446921471aa40ba448cfee0844221a71f2cd796dc5c35860680dddfaa595c47288db7ec1b2ec3ff49afb9b5a131a61f4a24bdd26f010df291351b912b1adee"}, {"line": 15557, "relation": "association", "evidence": "In the central nervous system, galanin alters the release of several neurotransmitters. In particular the ability of galanin to inhibit acetylcholine release, along with the observation of hyperinervation of galanin fibres in the human basal forebrain of Alzheimer's disease patients, suggest a possible role for galanin in the cholinergic dysfunction, characteristic of the disease. Moreover, galanin has been suggested to be involved in other neuronal functions, such as learning and memory, epileptic activity, nociception, spinal reflexes and feeding. Galanin has also been shown to increase the levels of growth hormone, prolactin and luteinizing hormone, to inhibit glucose induced insulin release and to affect gastrointestinal motility.", "citation": {"type": "PubMed", "name": "Curr Drug Targets CNS Neurol Disord. 2002 Dec;1(6):531-41.", "reference": "12769595"}, "annotations": {"Subgraph": {"Galanin subgraph": true, "Neuroprotection subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 49, "target": 111, "key": "7fd89c26fbf98591cb56c4b24fa97b7e4f4ecd805ad32137b5a80973ee4d0c2138e07c833b0baa134132618f014a863e1129eb83fcc1b39e7db9f5d7fbf5aa75"}, {"line": 15549, "relation": "decreases", "evidence": "In the central nervous system, galanin alters the release of several neurotransmitters. In particular the ability of galanin to inhibit acetylcholine release, along with the observation of hyperinervation of galanin fibres in the human basal forebrain of Alzheimer's disease patients, suggest a possible role for galanin in the cholinergic dysfunction, characteristic of the disease. Moreover, galanin has been suggested to be involved in other neuronal functions, such as learning and memory, epileptic activity, nociception, spinal reflexes and feeding. Galanin has also been shown to increase the levels of growth hormone, prolactin and luteinizing hormone, to inhibit glucose induced insulin release and to affect gastrointestinal motility.", "citation": {"type": "PubMed", "name": "Curr Drug Targets CNS Neurol Disord. 2002 Dec;1(6):531-41.", "reference": "12769595"}, "annotations": {"Subgraph": {"Galanin subgraph": true, "Neuroprotection subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 111, "target": 41, "key": "39156bab29146fbec34d52ced58518d5bbd0fe5d2cdfc235fac8fcbf580329beb1b0ce1b0f48bbeac117c6b115952766651d73c37a517582a86a5e9169f04892"}, {"line": 15553, "relation": "association", "evidence": "In the central nervous system, galanin alters the release of several neurotransmitters. In particular the ability of galanin to inhibit acetylcholine release, along with the observation of hyperinervation of galanin fibres in the human basal forebrain of Alzheimer's disease patients, suggest a possible role for galanin in the cholinergic dysfunction, characteristic of the disease. Moreover, galanin has been suggested to be involved in other neuronal functions, such as learning and memory, epileptic activity, nociception, spinal reflexes and feeding. Galanin has also been shown to increase the levels of growth hormone, prolactin and luteinizing hormone, to inhibit glucose induced insulin release and to affect gastrointestinal motility.", "citation": {"type": "PubMed", "name": "Curr Drug Targets CNS Neurol Disord. 2002 Dec;1(6):531-41.", "reference": "12769595"}, "annotations": {"Subgraph": {"Galanin subgraph": true, "Neuroprotection subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 111, "target": 53, "key": "4daeba92961c8fe56817bd63eccf6026e9d05386f149f3ec6ee9481b171a413dce87478138622a62af73115e17fb7620f1a4cfb959710dc9ecb99fc963bf4584"}, {"line": 15557, "relation": "association", "evidence": "In the central nervous system, galanin alters the release of several neurotransmitters. In particular the ability of galanin to inhibit acetylcholine release, along with the observation of hyperinervation of galanin fibres in the human basal forebrain of Alzheimer's disease patients, suggest a possible role for galanin in the cholinergic dysfunction, characteristic of the disease. Moreover, galanin has been suggested to be involved in other neuronal functions, such as learning and memory, epileptic activity, nociception, spinal reflexes and feeding. Galanin has also been shown to increase the levels of growth hormone, prolactin and luteinizing hormone, to inhibit glucose induced insulin release and to affect gastrointestinal motility.", "citation": {"type": "PubMed", "name": "Curr Drug Targets CNS Neurol Disord. 2002 Dec;1(6):531-41.", "reference": "12769595"}, "annotations": {"Subgraph": {"Galanin subgraph": true, "Neuroprotection subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 111, "target": 49, "key": "a12b405dba3be31c7142d79754da0a74da63d504acf8de4f5bbf5b446ec4836244c98469414a2ca9cbc4c141a42c996004482aff381c2df4bb2e74bbd968cdd2"}, {"line": 15561, "relation": "decreases", "evidence": "In the central nervous system, galanin alters the release of several neurotransmitters. In particular the ability of galanin to inhibit acetylcholine release, along with the observation of hyperinervation of galanin fibres in the human basal forebrain of Alzheimer's disease patients, suggest a possible role for galanin in the cholinergic dysfunction, characteristic of the disease. Moreover, galanin has been suggested to be involved in other neuronal functions, such as learning and memory, epileptic activity, nociception, spinal reflexes and feeding. Galanin has also been shown to increase the levels of growth hormone, prolactin and luteinizing hormone, to inhibit glucose induced insulin release and to affect gastrointestinal motility.", "citation": {"type": "PubMed", "name": "Curr Drug Targets CNS Neurol Disord. 2002 Dec;1(6):531-41.", "reference": "12769595"}, "annotations": {"Subgraph": {"Galanin subgraph": true, "Neuroprotection subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 111, "target": 52, "key": "b7147e06444bdb71380f4921eade8c1b0bc1e472aa98a5dc154e79f0c362e119b40df66606bdb8548a8ce657b494db4d5b11bbcd7e946bf4a4694efae46d344d"}, {"line": 9205, "relation": "increases", "evidence": "In addition, the studies demonstrated AD Braak stage-associated declines in choline acetyltransferase (ChAT) expression with reduced colocalization of ChAT with insulin or IGF-1 receptor immunoreactivity in cortical neurons. These results correspond with experimental data demonstrating that neuronal tau and ChAT gene expression are regulated by IGF-1 and insulin stimulation.88 Therefore, brain insulin and IGF deficiency and resistance could account for the cytoskeletal collapse, neurite retraction, synaptic disconnection, loss of neuronal plasticity, and deficiencies in acetylcholine production, all of which correlate with cognitive decline and dementia in AD", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Subgraph": {"Insulin signal transduction": true, "Acetylcholine signaling subgraph": true}, "MeSHAnatomy": {"Neurons": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 119, "target": 146, "key": "c3b5be69876112710d24763399ddc655132dc326ec28c596f1dd272b3924055b41771add8dceb42e5095df49e7773f5c1135fe475013637d21615abd22b87877"}, {"line": 9256, "relation": "positiveCorrelation", "evidence": "In addition, the studies demonstrated AD Braak stage-associated declines in choline acetyltransferase (ChAT) expression with reduced colocalization of ChAT with insulin or IGF-1 receptor immunoreactivity in cortical neurons. These results correspond with experimental data demonstrating that neuronal tau and ChAT gene expression are regulated by IGF-1 and insulin stimulation.88 Therefore, brain insulin and IGF deficiency and resistance could account for the cytoskeletal collapse, neurite retraction, synaptic disconnection, loss of neuronal plasticity, and deficiencies in acetylcholine production, all of which correlate with cognitive decline and dementia in AD", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"MeSHAnatomy": {"Brain": true}, "Subgraph": {"Insulin signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 119, "target": 41, "key": "cfc317f2a29f9c7af725c7e00560c9cdecc79009abecc3a408a184e8362bef40aa7556b93dcc8a56a83c0b12a7e42cdf1cf76d9067b1db4df3d631d654204d27"}, {"line": 14364, "relation": "regulates", "evidence": "This abnormality along with a reduction in brain insulin concentration is assumed to induce a cascade-like process of disturbances including cellular glucose, acetylcholine, cholesterol, and ATP associated with abnormalities in membrane pathology and the formation of both amyloidogenic derivatives and hyperphosphorylated tau protein.", "citation": {"type": "PubMed", "reference": "11956956"}, "annotations": {"MeSHAnatomy": {"Brain": true}, "Disease": {"Alzheimer's disease": true}, "Subgraph": {"Insulin signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 119, "target": 40, "key": "4aaf986d491c11e0c5b77745ca61be69ff7c81d04dc8c702cfb83545a860cd0046337ad2e6339b700e7e51ba7756ff72e996ca88f289fc440a920e7a0e7f4ab7"}, {"line": 9193, "relation": "regulates", "evidence": "In addition, the studies demonstrated AD Braak stage-associated declines in choline acetyltransferase (ChAT) expression with reduced colocalization of ChAT with insulin or IGF-1 receptor immunoreactivity in cortical neurons. These results correspond with experimental data demonstrating that neuronal tau and ChAT gene expression are regulated by IGF-1 and insulin stimulation.88 Therefore, brain insulin and IGF deficiency and resistance could account for the cytoskeletal collapse, neurite retraction, synaptic disconnection, loss of neuronal plasticity, and deficiencies in acetylcholine production, all of which correlate with cognitive decline and dementia in AD", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Subgraph": {"Tau protein subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}, "MeSHAnatomy": {"Neurons": true}}, "subject": {"modifier": "Activity"}, "source": 117, "target": 85, "key": "7b214256f23d5aab9fe54aee61f4f5a36277a5c890c2796f0f3ff13b5f94a2834321707d5a893747a5a465f0941b93b0a2a478038387afc77b5b7cdd83191225"}, {"line": 9260, "relation": "positiveCorrelation", "evidence": "In addition, the studies demonstrated AD Braak stage-associated declines in choline acetyltransferase (ChAT) expression with reduced colocalization of ChAT with insulin or IGF-1 receptor immunoreactivity in cortical neurons. These results correspond with experimental data demonstrating that neuronal tau and ChAT gene expression are regulated by IGF-1 and insulin stimulation.88 Therefore, brain insulin and IGF deficiency and resistance could account for the cytoskeletal collapse, neurite retraction, synaptic disconnection, loss of neuronal plasticity, and deficiencies in acetylcholine production, all of which correlate with cognitive decline and dementia in AD", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"MeSHAnatomy": {"Brain": true}, "Subgraph": {"Insulin signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 117, "target": 41, "key": "b5e8b9b62f2cb616f6c8d72c0eb1ee5a0a5122dd6865344f3135edd7a5d153a51db37004ee5a0c49abb43c8e33edc77233f44eba2d9a25e5a0234054f18b00f3"}, {"line": 15229, "relation": "negativeCorrelation", "evidence": "Hence, elevated butyrylcholinesterase and acetylcholinesterase concentrations will lead to a decrease in the levels of acetylcholine that could trigger the onset of low-grade systemic inflammation seen in type 2 diabetes and Alzheimer's disease.", "citation": {"type": "PubMed", "reference": "17553629"}, "annotations": {"MeSHDisease": {"Diabetes Mellitus, Type 2": true, "Alzheimer Disease": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 144, "target": 17, "key": "e6f2b176605e6a37c65f633316b5c200e1417bdc1ef4db2288af1190aae07f128845365c15314ea463d573596f27b5a6f7b4f42d2e12c8cb82f6e7b2c4f7e886"}, {"line": 9272, "relation": "decreases", "evidence": "In addition, the studies demonstrated AD Braak stage-associated declines in choline acetyltransferase (ChAT) expression with reduced colocalization of ChAT with insulin or IGF-1 receptor immunoreactivity in cortical neurons. These results correspond with experimental data demonstrating that neuronal tau and ChAT gene expression are regulated by IGF-1 and insulin stimulation.88 Therefore, brain insulin and IGF deficiency and resistance could account for the cytoskeletal collapse, neurite retraction, synaptic disconnection, loss of neuronal plasticity, and deficiencies in acetylcholine production, all of which correlate with cognitive decline and dementia in AD", "citation": {"type": "PubMed", "reference": "19885299"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 70, "target": 66, "key": "4d95077c2dd0271577bfb2ee21a5a50394837d6042a2201b491e0d672ca73d658bf88b512c9e6584789f8fe5cd35389634c986186db37d5c528961faff010532"}, {"line": 10170, "relation": "regulates", "evidence": "Initially, the expression of p35 was believed to be restricted to the central nervous system, the lens (22), and recently in developing muscle, where it forms a p35/CDK5 active complex that regulates the expression of the acetylcholine receptor gene (23). Despite its name CDK5 does not affect the cell division cycle; it is expressed postmitotically, and its function is related to cytoskeletal dynamics, cell migration, cell differentiation, and exocytosis (14) instead of cellular proliferation. Recently, Pho-85, a yeast ortholog of CDK5, was shown to be involved in metabolic control by regulating different steps of glycogen and phosphate metabolism (13). Expression of CDK5 in insulin-producing cells is not surprising because widespread expression of this kinase has been described. CDK5 expression in beta-cells has also been reported (24).", "citation": {"type": "PubMed", "reference": "14976144"}, "annotations": {"Subgraph": {"Cyclin-CDK subgraph": true, "Acetylcholine signaling subgraph": true}, "MeSHAnatomy": {"Muscles": true}, "Confidence": {"Medium": true}}, "object": {"modifier": "Activity"}, "source": 82, "target": 88, "key": "568818d422d2e4a548a0790c96a485663631f86762eee2af69680cf415ea30dccfb6a84695a4892a5bd9d0cbdfde05493816eb9e45b576f0c1614270e95b1461"}, {"line": 17543, "relation": "increases", "evidence": "Cumulative evidence from human and animal studies suggests that central activation of the HPA axis by cholinergic drugs can result in the elevation of plasma levels of several neuropeptides including adrenocorticotrophic hormone (ACTH), cortisol, b-endorphin, vasopressin, and epinephrine. Neuropeptides can modulate neurotransmission and can effect cognition. It has, therefore, been speculated that cognitive enhancement by cholinergic drugs could be mediated by the central activation of the HPA axis.", "citation": {"type": "PubMed", "reference": "8584603"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 21, "target": 57, "key": "b2dbae90a5e81ccac886bf5d41470bf6d4ccf149e218da29d9e7e7c40b92fac65a6750a971c9e72beff930f8b3bdcc7446d24faa317908c7cd2ff358882b9a4b"}, {"line": 17563, "relation": "increases", "evidence": "Cumulative evidence from human and animal studies suggests that central activation of the HPA axis by cholinergic drugs can result in the elevation of plasma levels of several neuropeptides including adrenocorticotrophic hormone (ACTH), cortisol, b-endorphin, vasopressin, and epinephrine. Neuropeptides can modulate neurotransmission and can effect cognition. It has, therefore, been speculated that cognitive enhancement by cholinergic drugs could be mediated by the central activation of the HPA axis.", "citation": {"type": "PubMed", "reference": "8584603"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 21, "target": 66, "key": "00466e797f94ba81a98e058d759d299e555146eb43150f02281d43dc1f7f13db474f24c6e9269e130b9878872ef660681690de7d1ac680b85c4e035d7acaab30"}, {"line": 17555, "relation": "increases", "evidence": "Cumulative evidence from human and animal studies suggests that central activation of the HPA axis by cholinergic drugs can result in the elevation of plasma levels of several neuropeptides including adrenocorticotrophic hormone (ACTH), cortisol, b-endorphin, vasopressin, and epinephrine. Neuropeptides can modulate neurotransmission and can effect cognition. It has, therefore, been speculated that cognitive enhancement by cholinergic drugs could be mediated by the central activation of the HPA axis.", "citation": {"type": "PubMed", "reference": "8584603"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 57, "target": 66, "key": "d768013a8930f7cc5ee466ef8fd05aaa16899458b3708fa9a7bfb054df685849bc2452906c495bfe6d88326dc17ad775f2346037f69368bbbfb25515f8478561"}, {"line": 68523, "relation": "increases", "evidence": "Not only do these two molecules stimulate (miR-132 & EGR1) synaptic activity and plasticity, they are also involved in Alzheimer's disease pathology and might, in addition, affect cholinergic function. In addition, miR-132 and EGR1 showed a significant positive correlation with choline acetyltransferase expression.", "citation": {"type": "PubMed", "name": "Brain. 2016 Mar;139(Pt 3):908-21. doi: 10.1093/brain/awv383. Epub 2016 Jan 20.", "reference": "26792551"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 86, "target": 64, "key": "6145a1506040f4729285d290d37bf1c64cbe0897cf0f6f6f24a197c90e016e4caf291afccb8117d1e3217e51540ee50a783259b59509ceeed8906f75c23801fb"}, {"line": 68527, "relation": "positiveCorrelation", "evidence": "Not only do these two molecules stimulate (miR-132 & EGR1) synaptic activity and plasticity, they are also involved in Alzheimer's disease pathology and might, in addition, affect cholinergic function. In addition, miR-132 and EGR1 showed a significant positive correlation with choline acetyltransferase expression.", "citation": {"type": "PubMed", "name": "Brain. 2016 Mar;139(Pt 3):908-21. doi: 10.1093/brain/awv383. Epub 2016 Jan 20.", "reference": "26792551"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 86, "target": 92, "key": "8e4f7b5b7a897c87a33db0d11a7497a6ad4a6fbce3457d3a987441e83d8b7f97f1a789da9698b02468947dfbd023dca1c3eaabcbce9939903879108d445d36fe"}, {"line": 68527, "relation": "positiveCorrelation", "evidence": "Not only do these two molecules stimulate (miR-132 & EGR1) synaptic activity and plasticity, they are also involved in Alzheimer's disease pathology and might, in addition, affect cholinergic function. In addition, miR-132 and EGR1 showed a significant positive correlation with choline acetyltransferase expression.", "citation": {"type": "PubMed", "name": "Brain. 2016 Mar;139(Pt 3):908-21. doi: 10.1093/brain/awv383. Epub 2016 Jan 20.", "reference": "26792551"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 92, "target": 86, "key": "f94649922992cb63e9f85a3e734aca6a60d135821178b6efebf8513653a1b283aa750b8c90e94eeb23f4a7a92def2d43547a1cbb6963a45a93998b49add48715"}, {"line": 68547, "relation": "positiveCorrelation", "evidence": "Not only do these two molecules stimulate (miR-132 & EGR1) synaptic activity and plasticity, they are also involved in Alzheimer's disease pathology and might, in addition, affect cholinergic function. In addition, miR-132 and EGR1 showed a significant positive correlation with choline acetyltransferase expression.", "citation": {"type": "PubMed", "name": "Brain. 2016 Mar;139(Pt 3):908-21. doi: 10.1093/brain/awv383. Epub 2016 Jan 20.", "reference": "26792551"}, "annotations": {"Subgraph": {"Gamma secretase subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 92, "target": 110, "key": "2a7b798350a2bf8fc9f01068ab0818f4c0eaee87ce32577334519948d255ad7b781fef106fa0f6e8afad53ea4b217ea1127bbb6f94d5cf5eb56e9e803b43c169"}, {"line": 17547, "relation": "increases", "evidence": "Cumulative evidence from human and animal studies suggests that central activation of the HPA axis by cholinergic drugs can result in the elevation of plasma levels of several neuropeptides including adrenocorticotrophic hormone (ACTH), cortisol, b-endorphin, vasopressin, and epinephrine. Neuropeptides can modulate neurotransmission and can effect cognition. It has, therefore, been speculated that cognitive enhancement by cholinergic drugs could be mediated by the central activation of the HPA axis.", "citation": {"type": "PubMed", "reference": "8584603"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 34, "target": 57, "key": "52653c70daf5a316fc4833a66d8459be167abcf81fbf2d6ae53c5fa60caa800a1b06bd1a42215b88ef909e39b4f46bb1cf98df95b190f3df37bf274dd664ed22"}, {"line": 17567, "relation": "increases", "evidence": "Cumulative evidence from human and animal studies suggests that central activation of the HPA axis by cholinergic drugs can result in the elevation of plasma levels of several neuropeptides including adrenocorticotrophic hormone (ACTH), cortisol, b-endorphin, vasopressin, and epinephrine. Neuropeptides can modulate neurotransmission and can effect cognition. It has, therefore, been speculated that cognitive enhancement by cholinergic drugs could be mediated by the central activation of the HPA axis.", "citation": {"type": "PubMed", "reference": "8584603"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 34, "target": 66, "key": "69d16a85caba6077b375cd998b71f7c5e12b84bf449c97d2d70ba24c81784459b49e82e7989a2b1d5818dfd909c87da31b42fad96f64454eda1820e5b43aebe7"}, {"line": 17444, "relation": "negativeCorrelation", "evidence": "The hypothalamic-pituitary-adrenal (HPA) axis is regulated by cholinergic mechanisms. Acetylcholine (ACh), the cholinergic neurotransmitter, has been reported to alter the levels of cortisol as well as those of prolactin, growth hormone, leutinizing hormone and vasopressin. Prolactin secretion, however, is suppressed by increased pure cholinergic activity. Central actions of cholinomimetic drugs that either increase the concentration of ACh in brain (e.g. physostigmine) or activate the postsynaptic muscarinic receptors (e.g. arecoline), can also activate the HPA axis in both animals and human subjects.", "citation": {"type": "PubMed", "reference": "8584603"}, "annotations": {"MeSHAnatomy": {"Brain": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 61, "target": 17, "key": "882c724c9d53bc1c3e7f61e7aeb53e3a0a17b97a26cc9632e8b96751dbddb181a9647c63383814db06f69b0e8d437cae1202c42423525221595caf1ee73a2bf2"}, {"line": 18142, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 96, "target": 10, "key": "ec77b565e66bd5e6c44ea30d38cdec6c58cafbd5b96e2cd220e23aa9e644171bcbfac717014e7d32d1875fc98cb468d5fffa8bf5338d82fa8d9f12c9b07c62b8"}, {"line": 18186, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 96, "target": 11, "key": "1e558e1ee13734987bf68a9f65761da56a5d67a5d36541a62b193559a3857276029a809cfff8d32ad05b13afd4c5a271f00183a321568d01debb519467ea46d5"}, {"line": 18899, "relation": "association", "evidence": "On a molecular level, studies suggest that acetylcholine (ACh) increases serotonin (5-HT) release through nicotinic receptors located at nerve terminals.", "citation": {"type": "PubMed", "reference": "16426583"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 96, "target": 17, "key": "73f93a03ed2d50d51cf978f66cc7bcb155b6ff07463dea7f5a406925cda67a1d43610fbd9c2db8ba22942480b881031c98cdb9ab6634bf359b6e4e3a82e24ddd"}, {"line": 44200, "relation": "regulates", "evidence": "Nicotinic acetylcholine receptors (nAChRs). Activation of the neuronal pentameric nAChRs is involved in diverse brain functions including synaptic plasticity and memory [237, 238] and enhances transmitter release in several brain regions including the hippocampus [239], the spinal cord dorsal horn [240], the olfactory bulb, and the amygdala [241]. The increase of synaptic plasticity by ABeta¸ requires activation of nAChRs [242]. Because activation of nAChRs is necessary for the ABeta¸-induced increase of synaptic plasticity and memory under normal conditions, ABeta¸ may modify glutamate release with a mechanism dependent upon activation of nAChRs [83]. However, several reports of the effect of ABeta¸42 on nAChRs are conflicting. Some studies have reported that ABeta¸42 activates nAChRs [243, 244], while others indicate that ABeta¸42 inhibits nAChRs [245, 246]. Interestingly, picomolar concentrations of ABeta¸42 were effective in activating nAChRs while higher levels of ABeta¸ produced inhibitory action. The disparity may depend on the nanomolar ABeta¸1Ã¢â‚¬â€œ42 inhibition of nicotine-induced Ca2+ responses while picomolar ABeta¸42 directly evokes sustained increases in presynaptic Ca2+ via nAChRs [244]. ABeta¸42 binds to the nAChR with picomolar affinity [247]. This binding can modulate presynaptic, glutamate-mediated synaptic transmission or glutamate release, suggesting that ABeta¸42-dependent cholinergic modulation activates signal transduction mechanisms that ultimately result in synaptic transmission and memory consolidation [248]. However, it remains to be determined whether these effects are mediated by a direct physical interaction of the ABeta¸ peptide with the nAChRs. Immunohistochemical studies on human sporadic AD brains show that ABeta¸42 and nAChR, are both present in neuritic plaques and co-localize in individual cortical neurons suggesting that ABeta¸ could be tightly associated with nAChR [247]. Alternatively, ABeta¸ might be responsible for regulation of nAChR function through strong binding with membrane lipids [249]. Picomolar or higher ABeta¸42 acting through nAChRs, can elicit ERK MAPK activation in hippocampal cultures [245, 250] possibly triggered by Ca2+ influx [243, 251]. ERK is known to regulate transcription factors such as CREB and Elk-1 by phosphorylation [140], which help initiate transcription of memory-associated genes that contain their respective regulatory elements [252]. Therefore, over-activation of nAChRs and excessive Ca2+ influx or dysregulation of Ca2+ homeostasis provide a molecular mechanism for the cholinergic dysfunction that is a hallmark of AD [253, 254].", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 96, "target": 90, "key": "f22292444655e4cf1c994a2ac29c7f4263f7557909e2a9a96aba29c970d78d42e11a8fdae4b54bbd497c7ebfcf6d2335e963cbdc43d789f646c5fdff027562a1"}, {"line": 44223, "relation": "increases", "evidence": "Nicotinic acetylcholine receptors (nAChRs). Activation of the neuronal pentameric nAChRs is involved in diverse brain functions including synaptic plasticity and memory [237, 238] and enhances transmitter release in several brain regions including the hippocampus [239], the spinal cord dorsal horn [240], the olfactory bulb, and the amygdala [241]. The increase of synaptic plasticity by ABeta¸ requires activation of nAChRs [242]. Because activation of nAChRs is necessary for the ABeta¸-induced increase of synaptic plasticity and memory under normal conditions, ABeta¸ may modify glutamate release with a mechanism dependent upon activation of nAChRs [83]. However, several reports of the effect of ABeta¸42 on nAChRs are conflicting. Some studies have reported that ABeta¸42 activates nAChRs [243, 244], while others indicate that ABeta¸42 inhibits nAChRs [245, 246]. Interestingly, picomolar concentrations of ABeta¸42 were effective in activating nAChRs while higher levels of ABeta¸ produced inhibitory action. The disparity may depend on the nanomolar ABeta¸1Ã¢â‚¬â€œ42 inhibition of nicotine-induced Ca2+ responses while picomolar ABeta¸42 directly evokes sustained increases in presynaptic Ca2+ via nAChRs [244]. ABeta¸42 binds to the nAChR with picomolar affinity [247]. This binding can modulate presynaptic, glutamate-mediated synaptic transmission or glutamate release, suggesting that ABeta¸42-dependent cholinergic modulation activates signal transduction mechanisms that ultimately result in synaptic transmission and memory consolidation [248]. However, it remains to be determined whether these effects are mediated by a direct physical interaction of the ABeta¸ peptide with the nAChRs. Immunohistochemical studies on human sporadic AD brains show that ABeta¸42 and nAChR, are both present in neuritic plaques and co-localize in individual cortical neurons suggesting that ABeta¸ could be tightly associated with nAChR [247]. Alternatively, ABeta¸ might be responsible for regulation of nAChR function through strong binding with membrane lipids [249]. Picomolar or higher ABeta¸42 acting through nAChRs, can elicit ERK MAPK activation in hippocampal cultures [245, 250] possibly triggered by Ca2+ influx [243, 251]. ERK is known to regulate transcription factors such as CREB and Elk-1 by phosphorylation [140], which help initiate transcription of memory-associated genes that contain their respective regulatory elements [252]. Therefore, over-activation of nAChRs and excessive Ca2+ influx or dysregulation of Ca2+ homeostasis provide a molecular mechanism for the cholinergic dysfunction that is a hallmark of AD [253, 254].", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 96, "target": 45, "key": "0e08de768bbbe8c9255451c99ea37840d3ca2555e955fefc4fb331d32f38a666b21742da512a474a8ef4fd222433e74f3970f7a99b7f8f41dfa5e8c927afadf4"}, {"line": 18146, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 97, "target": 10, "key": "2366657ad3b47788b51d95643a74f629af2238babb56e2d72e8de5b00e688298908513ba93309138e3d7ce849acc4e560d39461dabd4b07e01c2b3af73a03529"}, {"line": 18190, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 97, "target": 11, "key": "0efb64670a152dc78fda51c7546d758ab0f78bbe1d74901135f58d1f3add4592e118e19ab218ce1a7b61f7a91a7ece82d9098077ca84df14376681d1578c8703"}, {"line": 18903, "relation": "association", "evidence": "On a molecular level, studies suggest that acetylcholine (ACh) increases serotonin (5-HT) release through nicotinic receptors located at nerve terminals.", "citation": {"type": "PubMed", "reference": "16426583"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 97, "target": 17, "key": "300351fc3acc0495d312f4ab622b1995997e69d229e33c76d70bc69cebba23463e737464aabddf4ec8a7f40a0e9760b7576a17d900eb05ea21dd915d2db6cc5d"}, {"line": 47031, "relation": "positiveCorrelation", "evidence": "Inflammatory components related to AD neuroinflammation include brain cells such as microglia and astrocytes, the classic and alternate pathways of the complement system, the pentraxin acute-phase proteins, neuronal-type nicotinic acetylcholine receptors (AChRs), peroxisomal proliferators-activated receptors (PPARs), as well as cytokines and chemokines. Both the microglia and astrocytes have been shown to generate beta-amyloid protein (Abeta), one of the main pathologic features of AD. Abeta itself has been shown to act as a pro-inflammatory agent causing the activation of many of the inflammatory components", "citation": {"type": "PubMed", "name": "Int J Biochem Cell Biol. 2005 Feb;37(2):289-305.", "reference": "15474976"}, "annotations": {"Subgraph": {"Inflammatory response subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 97, "target": 71, "key": "a69a40b2c5003e3a230a867924867f15d61895ba6df3db2d4247c7ad55878d28e3caa2505cefc09070af62931975df710cfd4891778291e471df1a6e0db012f7"}, {"line": 18154, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 100, "target": 10, "key": "b3532aa7ee80edc3ad15ccc17728eddec9c2df8cec1f6d970dbf5660fd2f3acf11fd0084ebcaf427e45f16dd04f929fe52ed58fd364af6ea4d2134f51d5f94b2"}, {"line": 18198, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 100, "target": 11, "key": "27572b029b54a1c24a3c647a1911056b2095717b7a4e36ed7569cbda07de7d253e4b4a936ed8419a40c477dcf68df114d26d6aa1a14dcc2af6233044d74ef1d0"}, {"line": 18911, "relation": "association", "evidence": "On a molecular level, studies suggest that acetylcholine (ACh) increases serotonin (5-HT) release through nicotinic receptors located at nerve terminals.", "citation": {"type": "PubMed", "reference": "16426583"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 100, "target": 17, "key": "1d8122f790424399629a60a7c9e980914dc81df0bd8e707044a587a573e1aebd0ee2bc0ad4632a8aaf184fbc07e9e07116cdf80a3193143ba1c5502d303fe199"}, {"line": 44211, "relation": "regulates", "evidence": "Nicotinic acetylcholine receptors (nAChRs). Activation of the neuronal pentameric nAChRs is involved in diverse brain functions including synaptic plasticity and memory [237, 238] and enhances transmitter release in several brain regions including the hippocampus [239], the spinal cord dorsal horn [240], the olfactory bulb, and the amygdala [241]. The increase of synaptic plasticity by ABeta¸ requires activation of nAChRs [242]. Because activation of nAChRs is necessary for the ABeta¸-induced increase of synaptic plasticity and memory under normal conditions, ABeta¸ may modify glutamate release with a mechanism dependent upon activation of nAChRs [83]. However, several reports of the effect of ABeta¸42 on nAChRs are conflicting. Some studies have reported that ABeta¸42 activates nAChRs [243, 244], while others indicate that ABeta¸42 inhibits nAChRs [245, 246]. Interestingly, picomolar concentrations of ABeta¸42 were effective in activating nAChRs while higher levels of ABeta¸ produced inhibitory action. The disparity may depend on the nanomolar ABeta¸1Ã¢â‚¬â€œ42 inhibition of nicotine-induced Ca2+ responses while picomolar ABeta¸42 directly evokes sustained increases in presynaptic Ca2+ via nAChRs [244]. ABeta¸42 binds to the nAChR with picomolar affinity [247]. This binding can modulate presynaptic, glutamate-mediated synaptic transmission or glutamate release, suggesting that ABeta¸42-dependent cholinergic modulation activates signal transduction mechanisms that ultimately result in synaptic transmission and memory consolidation [248]. However, it remains to be determined whether these effects are mediated by a direct physical interaction of the ABeta¸ peptide with the nAChRs. Immunohistochemical studies on human sporadic AD brains show that ABeta¸42 and nAChR, are both present in neuritic plaques and co-localize in individual cortical neurons suggesting that ABeta¸ could be tightly associated with nAChR [247]. Alternatively, ABeta¸ might be responsible for regulation of nAChR function through strong binding with membrane lipids [249]. Picomolar or higher ABeta¸42 acting through nAChRs, can elicit ERK MAPK activation in hippocampal cultures [245, 250] possibly triggered by Ca2+ influx [243, 251]. ERK is known to regulate transcription factors such as CREB and Elk-1 by phosphorylation [140], which help initiate transcription of memory-associated genes that contain their respective regulatory elements [252]. Therefore, over-activation of nAChRs and excessive Ca2+ influx or dysregulation of Ca2+ homeostasis provide a molecular mechanism for the cholinergic dysfunction that is a hallmark of AD [253, 254].", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 100, "target": 90, "key": "76fbe5b13558b71afc3dd09c9f71de387c7f14b6be04bbb95516748e374b27d2f5fc73babdeebea3f34b3e71594f307eb2cee008ab276a42af7125e674166f1a"}, {"line": 44235, "relation": "increases", "evidence": "Nicotinic acetylcholine receptors (nAChRs). Activation of the neuronal pentameric nAChRs is involved in diverse brain functions including synaptic plasticity and memory [237, 238] and enhances transmitter release in several brain regions including the hippocampus [239], the spinal cord dorsal horn [240], the olfactory bulb, and the amygdala [241]. The increase of synaptic plasticity by ABeta¸ requires activation of nAChRs [242]. Because activation of nAChRs is necessary for the ABeta¸-induced increase of synaptic plasticity and memory under normal conditions, ABeta¸ may modify glutamate release with a mechanism dependent upon activation of nAChRs [83]. However, several reports of the effect of ABeta¸42 on nAChRs are conflicting. Some studies have reported that ABeta¸42 activates nAChRs [243, 244], while others indicate that ABeta¸42 inhibits nAChRs [245, 246]. Interestingly, picomolar concentrations of ABeta¸42 were effective in activating nAChRs while higher levels of ABeta¸ produced inhibitory action. The disparity may depend on the nanomolar ABeta¸1Ã¢â‚¬â€œ42 inhibition of nicotine-induced Ca2+ responses while picomolar ABeta¸42 directly evokes sustained increases in presynaptic Ca2+ via nAChRs [244]. ABeta¸42 binds to the nAChR with picomolar affinity [247]. This binding can modulate presynaptic, glutamate-mediated synaptic transmission or glutamate release, suggesting that ABeta¸42-dependent cholinergic modulation activates signal transduction mechanisms that ultimately result in synaptic transmission and memory consolidation [248]. However, it remains to be determined whether these effects are mediated by a direct physical interaction of the ABeta¸ peptide with the nAChRs. Immunohistochemical studies on human sporadic AD brains show that ABeta¸42 and nAChR, are both present in neuritic plaques and co-localize in individual cortical neurons suggesting that ABeta¸ could be tightly associated with nAChR [247]. Alternatively, ABeta¸ might be responsible for regulation of nAChR function through strong binding with membrane lipids [249]. Picomolar or higher ABeta¸42 acting through nAChRs, can elicit ERK MAPK activation in hippocampal cultures [245, 250] possibly triggered by Ca2+ influx [243, 251]. ERK is known to regulate transcription factors such as CREB and Elk-1 by phosphorylation [140], which help initiate transcription of memory-associated genes that contain their respective regulatory elements [252]. Therefore, over-activation of nAChRs and excessive Ca2+ influx or dysregulation of Ca2+ homeostasis provide a molecular mechanism for the cholinergic dysfunction that is a hallmark of AD [253, 254].", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 100, "target": 45, "key": "3ffc77b428c89da207a37f012f212040af87f7587a5429c4a5d61dd616c63c22c37f66b1e3f5a0b9fa2c3f431f58cfe6aee70f6e7385ce4e55bee6ac03fd8fcf"}, {"line": 47027, "relation": "positiveCorrelation", "evidence": "Inflammatory components related to AD neuroinflammation include brain cells such as microglia and astrocytes, the classic and alternate pathways of the complement system, the pentraxin acute-phase proteins, neuronal-type nicotinic acetylcholine receptors (AChRs), peroxisomal proliferators-activated receptors (PPARs), as well as cytokines and chemokines. Both the microglia and astrocytes have been shown to generate beta-amyloid protein (Abeta), one of the main pathologic features of AD. Abeta itself has been shown to act as a pro-inflammatory agent causing the activation of many of the inflammatory components", "citation": {"type": "PubMed", "name": "Int J Biochem Cell Biol. 2005 Feb;37(2):289-305.", "reference": "15474976"}, "annotations": {"Subgraph": {"Inflammatory response subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 100, "target": 71, "key": "cfb7d6182ac7037bf787a2249b9b97d9068229328d9a968a7ed612112945c0d181c62b3e6636b1e8add763c2350691c2495409addecb8cda1cff72935bddcc79"}, {"line": 18158, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 101, "target": 10, "key": "1f2af5ec5bec979c567a89b0e52c0babd73a6348891ec3e724a3b4c1b8c2cf30c4030ecaa81abdc8c12249b5fa242813cf64f205173d9d4161661a65f3a13e5d"}, {"line": 18202, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 101, "target": 11, "key": "0f330368b23f2561d2dc4a106d47b7dfbb7c38a2257973af48956c556c7fa81c0255a3073780284b1cb16b308dbd0e5ea93a8953e5136d17811955a6f5bb39ff"}, {"line": 18915, "relation": "association", "evidence": "On a molecular level, studies suggest that acetylcholine (ACh) increases serotonin (5-HT) release through nicotinic receptors located at nerve terminals.", "citation": {"type": "PubMed", "reference": "16426583"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 101, "target": 17, "key": "b684b6856b1b3d0d9b757dfce84aa6f17747289dcab39362a9da1dc4f0e525837530602e26e4cdaf3c46dad93e3ed6276f43b9f2b791c00fb09f8b712331ecd0"}, {"line": 44231, "relation": "increases", "evidence": "Nicotinic acetylcholine receptors (nAChRs). Activation of the neuronal pentameric nAChRs is involved in diverse brain functions including synaptic plasticity and memory [237, 238] and enhances transmitter release in several brain regions including the hippocampus [239], the spinal cord dorsal horn [240], the olfactory bulb, and the amygdala [241]. The increase of synaptic plasticity by ABeta¸ requires activation of nAChRs [242]. Because activation of nAChRs is necessary for the ABeta¸-induced increase of synaptic plasticity and memory under normal conditions, ABeta¸ may modify glutamate release with a mechanism dependent upon activation of nAChRs [83]. However, several reports of the effect of ABeta¸42 on nAChRs are conflicting. Some studies have reported that ABeta¸42 activates nAChRs [243, 244], while others indicate that ABeta¸42 inhibits nAChRs [245, 246]. Interestingly, picomolar concentrations of ABeta¸42 were effective in activating nAChRs while higher levels of ABeta¸ produced inhibitory action. The disparity may depend on the nanomolar ABeta¸1Ã¢â‚¬â€œ42 inhibition of nicotine-induced Ca2+ responses while picomolar ABeta¸42 directly evokes sustained increases in presynaptic Ca2+ via nAChRs [244]. ABeta¸42 binds to the nAChR with picomolar affinity [247]. This binding can modulate presynaptic, glutamate-mediated synaptic transmission or glutamate release, suggesting that ABeta¸42-dependent cholinergic modulation activates signal transduction mechanisms that ultimately result in synaptic transmission and memory consolidation [248]. However, it remains to be determined whether these effects are mediated by a direct physical interaction of the ABeta¸ peptide with the nAChRs. Immunohistochemical studies on human sporadic AD brains show that ABeta¸42 and nAChR, are both present in neuritic plaques and co-localize in individual cortical neurons suggesting that ABeta¸ could be tightly associated with nAChR [247]. Alternatively, ABeta¸ might be responsible for regulation of nAChR function through strong binding with membrane lipids [249]. Picomolar or higher ABeta¸42 acting through nAChRs, can elicit ERK MAPK activation in hippocampal cultures [245, 250] possibly triggered by Ca2+ influx [243, 251]. ERK is known to regulate transcription factors such as CREB and Elk-1 by phosphorylation [140], which help initiate transcription of memory-associated genes that contain their respective regulatory elements [252]. Therefore, over-activation of nAChRs and excessive Ca2+ influx or dysregulation of Ca2+ homeostasis provide a molecular mechanism for the cholinergic dysfunction that is a hallmark of AD [253, 254].", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 101, "target": 45, "key": "43e5f7e30bb50ed7cf7e2a3c59d6c8459c9be179b564f194c3b76cf446250619bc5bb8a924869aae780e3e690a1f0f8f7215baa08268d934e88dd65c5b3c32bc"}, {"line": 18162, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 102, "target": 10, "key": "99879e94cdb94cc5c1a5057b918b363bdc5b1f2fa3875f27baff44536c8e7f9f194bb64e84e9e29f8e41b03762c0ae1ede92f0d8b8ea52e7b30403cc2ef52a9b"}, {"line": 18205, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 102, "target": 11, "key": "0e04a448e8e9dad10715d70ef5d5f6173ebbebccb90f1940bc9f1b51cfa245072fb840e9d3a704d3d33a2737290d686de7f460f37a205a39e3c4f1a9fce3eb66"}, {"line": 18919, "relation": "association", "evidence": "On a molecular level, studies suggest that acetylcholine (ACh) increases serotonin (5-HT) release through nicotinic receptors located at nerve terminals.", "citation": {"type": "PubMed", "reference": "16426583"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 102, "target": 17, "key": "f0a4c34070bfeec58481875de18ea3568e8009db58e9b82ed722eb020ba9451ce3407a97b242044a0d5ac566f253eb8a49cf55fb7028be660c22bc01386b0958"}, {"line": 44219, "relation": "increases", "evidence": "Nicotinic acetylcholine receptors (nAChRs). Activation of the neuronal pentameric nAChRs is involved in diverse brain functions including synaptic plasticity and memory [237, 238] and enhances transmitter release in several brain regions including the hippocampus [239], the spinal cord dorsal horn [240], the olfactory bulb, and the amygdala [241]. The increase of synaptic plasticity by ABeta¸ requires activation of nAChRs [242]. Because activation of nAChRs is necessary for the ABeta¸-induced increase of synaptic plasticity and memory under normal conditions, ABeta¸ may modify glutamate release with a mechanism dependent upon activation of nAChRs [83]. However, several reports of the effect of ABeta¸42 on nAChRs are conflicting. Some studies have reported that ABeta¸42 activates nAChRs [243, 244], while others indicate that ABeta¸42 inhibits nAChRs [245, 246]. Interestingly, picomolar concentrations of ABeta¸42 were effective in activating nAChRs while higher levels of ABeta¸ produced inhibitory action. The disparity may depend on the nanomolar ABeta¸1Ã¢â‚¬â€œ42 inhibition of nicotine-induced Ca2+ responses while picomolar ABeta¸42 directly evokes sustained increases in presynaptic Ca2+ via nAChRs [244]. ABeta¸42 binds to the nAChR with picomolar affinity [247]. This binding can modulate presynaptic, glutamate-mediated synaptic transmission or glutamate release, suggesting that ABeta¸42-dependent cholinergic modulation activates signal transduction mechanisms that ultimately result in synaptic transmission and memory consolidation [248]. However, it remains to be determined whether these effects are mediated by a direct physical interaction of the ABeta¸ peptide with the nAChRs. Immunohistochemical studies on human sporadic AD brains show that ABeta¸42 and nAChR, are both present in neuritic plaques and co-localize in individual cortical neurons suggesting that ABeta¸ could be tightly associated with nAChR [247]. Alternatively, ABeta¸ might be responsible for regulation of nAChR function through strong binding with membrane lipids [249]. Picomolar or higher ABeta¸42 acting through nAChRs, can elicit ERK MAPK activation in hippocampal cultures [245, 250] possibly triggered by Ca2+ influx [243, 251]. ERK is known to regulate transcription factors such as CREB and Elk-1 by phosphorylation [140], which help initiate transcription of memory-associated genes that contain their respective regulatory elements [252]. Therefore, over-activation of nAChRs and excessive Ca2+ influx or dysregulation of Ca2+ homeostasis provide a molecular mechanism for the cholinergic dysfunction that is a hallmark of AD [253, 254].", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 102, "target": 45, "key": "ad8c164fc1e2d270c2ecb657824b929b4af64042ac843830367cd8b97a20d59af96b58116235cd16db037acd48a2ca53294a0cf322f236784117101edd4203cc"}, {"line": 47035, "relation": "positiveCorrelation", "evidence": "Inflammatory components related to AD neuroinflammation include brain cells such as microglia and astrocytes, the classic and alternate pathways of the complement system, the pentraxin acute-phase proteins, neuronal-type nicotinic acetylcholine receptors (AChRs), peroxisomal proliferators-activated receptors (PPARs), as well as cytokines and chemokines. Both the microglia and astrocytes have been shown to generate beta-amyloid protein (Abeta), one of the main pathologic features of AD. Abeta itself has been shown to act as a pro-inflammatory agent causing the activation of many of the inflammatory components", "citation": {"type": "PubMed", "name": "Int J Biochem Cell Biol. 2005 Feb;37(2):289-305.", "reference": "15474976"}, "annotations": {"Subgraph": {"Inflammatory response subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 102, "target": 71, "key": "a7757e3dad399a6fd958389ac1359e7bfa7c75d046e03b2e41fe6521c38768b3d895881c6c8e9a40bd2d43d45004c32ca3d5a17ca1013e7f888fbd48913237ad"}, {"line": 18166, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 103, "target": 10, "key": "1e6adc6a53b7d6bbaf171a1fa4d9efac42bda7c4ff323d8f5d9083922a3c6aa1a005a2d01f264263269eb65d4f675d249baf1e468ad13c334c636303ef7c2d6b"}, {"line": 18209, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 103, "target": 11, "key": "7ff283b165d3da2758a2418613c281ada0460d9b151681d56abe0d06ea66b5a22f252e3fae55b6f65a597e0af0b612a473b8b46f70f0d9db0680f8f841de5a3c"}, {"line": 18923, "relation": "association", "evidence": "On a molecular level, studies suggest that acetylcholine (ACh) increases serotonin (5-HT) release through nicotinic receptors located at nerve terminals.", "citation": {"type": "PubMed", "reference": "16426583"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 103, "target": 17, "key": "4bff026b73808b4c26f29287f10f60461f44c6606496b7f6f67d20f9b7acee97f208ccb71c053cc25f19a9a2b03c0c3f47ba4fe7256709ce546f49ffaa5d6fdd"}, {"line": 44204, "relation": "regulates", "evidence": "Nicotinic acetylcholine receptors (nAChRs). Activation of the neuronal pentameric nAChRs is involved in diverse brain functions including synaptic plasticity and memory [237, 238] and enhances transmitter release in several brain regions including the hippocampus [239], the spinal cord dorsal horn [240], the olfactory bulb, and the amygdala [241]. The increase of synaptic plasticity by ABeta¸ requires activation of nAChRs [242]. Because activation of nAChRs is necessary for the ABeta¸-induced increase of synaptic plasticity and memory under normal conditions, ABeta¸ may modify glutamate release with a mechanism dependent upon activation of nAChRs [83]. However, several reports of the effect of ABeta¸42 on nAChRs are conflicting. Some studies have reported that ABeta¸42 activates nAChRs [243, 244], while others indicate that ABeta¸42 inhibits nAChRs [245, 246]. Interestingly, picomolar concentrations of ABeta¸42 were effective in activating nAChRs while higher levels of ABeta¸ produced inhibitory action. The disparity may depend on the nanomolar ABeta¸1Ã¢â‚¬â€œ42 inhibition of nicotine-induced Ca2+ responses while picomolar ABeta¸42 directly evokes sustained increases in presynaptic Ca2+ via nAChRs [244]. ABeta¸42 binds to the nAChR with picomolar affinity [247]. This binding can modulate presynaptic, glutamate-mediated synaptic transmission or glutamate release, suggesting that ABeta¸42-dependent cholinergic modulation activates signal transduction mechanisms that ultimately result in synaptic transmission and memory consolidation [248]. However, it remains to be determined whether these effects are mediated by a direct physical interaction of the ABeta¸ peptide with the nAChRs. Immunohistochemical studies on human sporadic AD brains show that ABeta¸42 and nAChR, are both present in neuritic plaques and co-localize in individual cortical neurons suggesting that ABeta¸ could be tightly associated with nAChR [247]. Alternatively, ABeta¸ might be responsible for regulation of nAChR function through strong binding with membrane lipids [249]. Picomolar or higher ABeta¸42 acting through nAChRs, can elicit ERK MAPK activation in hippocampal cultures [245, 250] possibly triggered by Ca2+ influx [243, 251]. ERK is known to regulate transcription factors such as CREB and Elk-1 by phosphorylation [140], which help initiate transcription of memory-associated genes that contain their respective regulatory elements [252]. Therefore, over-activation of nAChRs and excessive Ca2+ influx or dysregulation of Ca2+ homeostasis provide a molecular mechanism for the cholinergic dysfunction that is a hallmark of AD [253, 254].", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 103, "target": 90, "key": "4b7274830103d758c07732c3766ed696d0d51d57bf2667baea02330030992f5637887cccc91595c1485f62549d3e8dc31d6048434fd70893e06b3a20c462c9cc"}, {"line": 44227, "relation": "increases", "evidence": "Nicotinic acetylcholine receptors (nAChRs). Activation of the neuronal pentameric nAChRs is involved in diverse brain functions including synaptic plasticity and memory [237, 238] and enhances transmitter release in several brain regions including the hippocampus [239], the spinal cord dorsal horn [240], the olfactory bulb, and the amygdala [241]. The increase of synaptic plasticity by ABeta¸ requires activation of nAChRs [242]. Because activation of nAChRs is necessary for the ABeta¸-induced increase of synaptic plasticity and memory under normal conditions, ABeta¸ may modify glutamate release with a mechanism dependent upon activation of nAChRs [83]. However, several reports of the effect of ABeta¸42 on nAChRs are conflicting. Some studies have reported that ABeta¸42 activates nAChRs [243, 244], while others indicate that ABeta¸42 inhibits nAChRs [245, 246]. Interestingly, picomolar concentrations of ABeta¸42 were effective in activating nAChRs while higher levels of ABeta¸ produced inhibitory action. The disparity may depend on the nanomolar ABeta¸1Ã¢â‚¬â€œ42 inhibition of nicotine-induced Ca2+ responses while picomolar ABeta¸42 directly evokes sustained increases in presynaptic Ca2+ via nAChRs [244]. ABeta¸42 binds to the nAChR with picomolar affinity [247]. This binding can modulate presynaptic, glutamate-mediated synaptic transmission or glutamate release, suggesting that ABeta¸42-dependent cholinergic modulation activates signal transduction mechanisms that ultimately result in synaptic transmission and memory consolidation [248]. However, it remains to be determined whether these effects are mediated by a direct physical interaction of the ABeta¸ peptide with the nAChRs. Immunohistochemical studies on human sporadic AD brains show that ABeta¸42 and nAChR, are both present in neuritic plaques and co-localize in individual cortical neurons suggesting that ABeta¸ could be tightly associated with nAChR [247]. Alternatively, ABeta¸ might be responsible for regulation of nAChR function through strong binding with membrane lipids [249]. Picomolar or higher ABeta¸42 acting through nAChRs, can elicit ERK MAPK activation in hippocampal cultures [245, 250] possibly triggered by Ca2+ influx [243, 251]. ERK is known to regulate transcription factors such as CREB and Elk-1 by phosphorylation [140], which help initiate transcription of memory-associated genes that contain their respective regulatory elements [252]. Therefore, over-activation of nAChRs and excessive Ca2+ influx or dysregulation of Ca2+ homeostasis provide a molecular mechanism for the cholinergic dysfunction that is a hallmark of AD [253, 254].", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 103, "target": 45, "key": "a2254961653f157098f642ee82c9242760dbbbfc6bd754e1bcdfd9f10caa3086c00db8b226c5e450b5b6fdcfd6a30c76af9dc29cafc058d6c1accee7cffee101"}, {"line": 18170, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 95, "target": 10, "key": "b67a3760e862dc184ca314e336a03d1ba8414784e525bcf31fd6c4b30e685220863b2773d7edbf822667c0473b1a5d04caa1a6ffa8d3861f2ab5ce4b6bcd46fc"}, {"line": 18213, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 95, "target": 11, "key": "ceea92885ecf7ce2dad644a6d336a1baaf3a07a45fb3272a890cc156917ec677688a73ce887dbec66fae5a36084622e4222bd38d316edcc543ced546400c2a9c"}, {"line": 18927, "relation": "association", "evidence": "On a molecular level, studies suggest that acetylcholine (ACh) increases serotonin (5-HT) release through nicotinic receptors located at nerve terminals.", "citation": {"type": "PubMed", "reference": "16426583"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 95, "target": 17, "key": "ed2bf8f439a0dfe1bac18965a81b4fe3149290c6334f268d0641cabc8e5668c33e7ca2ebf405bfda6da67b9f8a7ef0a57fcb62d1682f31666c170f2a97a3cb89"}, {"line": 18178, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 107, "target": 11, "key": "bbd66d30ac570178a41d1db8003e19ac77551921a74e2f438e57293e6355957ab51d71ef3c8b60df20846d7bd2699a308310a39d2b347bc4755ae12325efc3a6"}, {"line": 18935, "relation": "association", "evidence": "On a molecular level, studies suggest that acetylcholine (ACh) increases serotonin (5-HT) release through nicotinic receptors located at nerve terminals.", "citation": {"type": "PubMed", "reference": "16426583"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 107, "target": 17, "key": "b899e8cfa329ff64b6056c1207a0a060cf4592de07e091383f188d9df1d955bcb00abac3a519b5c634ef78359dce96edc7f139d37c50b0d6b4f3b6f3c302c470"}, {"line": 44243, "relation": "increases", "evidence": "Nicotinic acetylcholine receptors (nAChRs). Activation of the neuronal pentameric nAChRs is involved in diverse brain functions including synaptic plasticity and memory [237, 238] and enhances transmitter release in several brain regions including the hippocampus [239], the spinal cord dorsal horn [240], the olfactory bulb, and the amygdala [241]. The increase of synaptic plasticity by ABeta¸ requires activation of nAChRs [242]. Because activation of nAChRs is necessary for the ABeta¸-induced increase of synaptic plasticity and memory under normal conditions, ABeta¸ may modify glutamate release with a mechanism dependent upon activation of nAChRs [83]. However, several reports of the effect of ABeta¸42 on nAChRs are conflicting. Some studies have reported that ABeta¸42 activates nAChRs [243, 244], while others indicate that ABeta¸42 inhibits nAChRs [245, 246]. Interestingly, picomolar concentrations of ABeta¸42 were effective in activating nAChRs while higher levels of ABeta¸ produced inhibitory action. The disparity may depend on the nanomolar ABeta¸1Ã¢â‚¬â€œ42 inhibition of nicotine-induced Ca2+ responses while picomolar ABeta¸42 directly evokes sustained increases in presynaptic Ca2+ via nAChRs [244]. ABeta¸42 binds to the nAChR with picomolar affinity [247]. This binding can modulate presynaptic, glutamate-mediated synaptic transmission or glutamate release, suggesting that ABeta¸42-dependent cholinergic modulation activates signal transduction mechanisms that ultimately result in synaptic transmission and memory consolidation [248]. However, it remains to be determined whether these effects are mediated by a direct physical interaction of the ABeta¸ peptide with the nAChRs. Immunohistochemical studies on human sporadic AD brains show that ABeta¸42 and nAChR, are both present in neuritic plaques and co-localize in individual cortical neurons suggesting that ABeta¸ could be tightly associated with nAChR [247]. Alternatively, ABeta¸ might be responsible for regulation of nAChR function through strong binding with membrane lipids [249]. Picomolar or higher ABeta¸42 acting through nAChRs, can elicit ERK MAPK activation in hippocampal cultures [245, 250] possibly triggered by Ca2+ influx [243, 251]. ERK is known to regulate transcription factors such as CREB and Elk-1 by phosphorylation [140], which help initiate transcription of memory-associated genes that contain their respective regulatory elements [252]. Therefore, over-activation of nAChRs and excessive Ca2+ influx or dysregulation of Ca2+ homeostasis provide a molecular mechanism for the cholinergic dysfunction that is a hallmark of AD [253, 254].", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 107, "target": 45, "key": "440b6c535982f4febd8ba219dfd626506673d5987631c1cb73084f84056f98ceba32349e3477a1fbd3e20126cdd2e5246c68218fde7db67e2eccc1be0c814ec3"}, {"line": 18182, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "subject": {"modifier": "Activity"}, "source": 108, "target": 11, "key": "4dfa019ca801856bcf6c39abb72e86cb15f338a807b9cb444ee92bb102f4c08c994d125c52fccdf0e75066b367ec743bf2f7945c7eed305c2024af245a38251a"}, {"line": 18939, "relation": "association", "evidence": "On a molecular level, studies suggest that acetylcholine (ACh) increases serotonin (5-HT) release through nicotinic receptors located at nerve terminals.", "citation": {"type": "PubMed", "reference": "16426583"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 108, "target": 17, "key": "45893936a9b08683f1a23fa6e7e93b8c2f598eef96924cb45283c6b692597e0f73e2647887c5f36d6149a156ca03542033cb42957e45fd4efa36c966111f4ef7"}, {"line": 15553, "relation": "association", "evidence": "In the central nervous system, galanin alters the release of several neurotransmitters. In particular the ability of galanin to inhibit acetylcholine release, along with the observation of hyperinervation of galanin fibres in the human basal forebrain of Alzheimer's disease patients, suggest a possible role for galanin in the cholinergic dysfunction, characteristic of the disease. Moreover, galanin has been suggested to be involved in other neuronal functions, such as learning and memory, epileptic activity, nociception, spinal reflexes and feeding. Galanin has also been shown to increase the levels of growth hormone, prolactin and luteinizing hormone, to inhibit glucose induced insulin release and to affect gastrointestinal motility.", "citation": {"type": "PubMed", "name": "Curr Drug Targets CNS Neurol Disord. 2002 Dec;1(6):531-41.", "reference": "12769595"}, "annotations": {"Subgraph": {"Galanin subgraph": true, "Neuroprotection subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 53, "target": 111, "key": "93bc9549574acd52323cbf9096aa978b3e17496a46edb756c4f84dfdfd5c372f63f79f14bc6fc76917f41ab79febf4d38e76f801f83010f628f79f89f29568ec"}, {"line": 16397, "relation": "isA", "evidence": "Deficit in central cholinergic neurotransmission is a consistent change associated with Alzheimer's disease (AD). Donepezil hydrochloride exhibits selective inhibition of acetylcholinesterase (AChE) and is widely used for the treatment of AD.", "citation": {"type": "PubMed", "name": "Br J Clin Pharmacol. 2008 Apr;65(4):472-9", "reference": "18070217"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 22, "target": 1, "key": "10dc9099972d1d3b867655d6b333d8f6f6c7ba9798a7d2873c33bdd929a7a1118e9d2af3a3f78acc401ef268f1ce03cc891819ee5b633be82ad637804a156b02"}, {"line": 16467, "relation": "isA", "evidence": "Alzheimer disease (AD) is associated with a decreased APP forms ratio (APPr) between the three major forms. This study demonstrated that donepezil, a drug acting as an inhibitor of acetylcholinesterase, affects APP metabolism in Alzheimer disease, restoring the ratio of APP forms in platelets up to the normal range after 4 weeks of treatment.", "citation": {"type": "PubMed", "name": "Eur Neuropsychopharmacol. 2002 Jun;12(3):195-200", "reference": "12007670"}, "annotations": {"Subgraph": {"Non-amyloidogenic subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 22, "target": 1, "key": "86fce68c677a870c6524493e3bd4a51db48ece8ec86d06258f5562296eaa264959b40a0fc40d4f31bc12c6ca7dc194f66567c68f8a1497992ab7b1a6b695350c"}, {"line": 16401, "relation": "decreases", "evidence": "Deficit in central cholinergic neurotransmission is a consistent change associated with Alzheimer's disease (AD). Donepezil hydrochloride exhibits selective inhibition of acetylcholinesterase (AChE) and is widely used for the treatment of AD.", "citation": {"type": "PubMed", "name": "Br J Clin Pharmacol. 2008 Apr;65(4):472-9", "reference": "18070217"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 22, "target": 88, "key": "0dda0c6f195ba625d7fce39eac6306c8e32d5c31e5d7c1629453bffa05d61584d77011e2ac38e18deb60bd68a51af7467d5b52d22deb1b4b153e87c601acc862"}, {"line": 16471, "relation": "directlyDecreases", "evidence": "Alzheimer disease (AD) is associated with a decreased APP forms ratio (APPr) between the three major forms. This study demonstrated that donepezil, a drug acting as an inhibitor of acetylcholinesterase, affects APP metabolism in Alzheimer disease, restoring the ratio of APP forms in platelets up to the normal range after 4 weeks of treatment.", "citation": {"type": "PubMed", "name": "Eur Neuropsychopharmacol. 2002 Jun;12(3):195-200", "reference": "12007670"}, "annotations": {"Subgraph": {"Non-amyloidogenic subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "object": {"modifier": "Activity"}, "source": 22, "target": 88, "key": "c3153bb7fd90ffa046d168bcd637cf0a50d20ac7ed28d4c3539c594f5e7eefa3cbb13130b62c12c25b80b8802f53fc0884a733f030a00da855b93ec8a0b1f212"}, {"line": 16427, "relation": "increases", "evidence": "Donepezil 5 and 10 mg/day significantly improved cognition and global clinical function compared with placebo in well designed short term trials (14 to 30 weeks) in 161 to 818 patients with mild to moderate Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Br J Clin Pharmacol. 2008 Apr;65(4):472-9", "reference": "18070217"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Species": {"9606": true}, "Confidence": {"High": true}}, "source": 22, "target": 66, "key": "50009885aa2a1e9678f8129d6251b651538476490a67d12bc879c604dcf851df722c58d8e1b8de12e48719c9de5f479f6bc11549ea10346bcb2701d219fbfa5c"}, {"line": 16443, "relation": "increases", "evidence": "The donepezil group demonstrated a greater likelihood of increases in both non-declarative and declarative processes.", "citation": {"type": "PubMed", "name": "Curr Alzheimer Res. 2007 Jul;4(3):273-6", "reference": "17627484"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Species": {"9606": true}, "Confidence": {"High": true}}, "source": 22, "target": 69, "key": "9a344c13ca5a3428c0267bb9746081d3c85ec9afcf2bae6522636e1bd64aca462cba8aba04a6fe6413ceeedb533e02a69203e0ca6e2f82084f8cabb936ddd6b7"}, {"line": 16463, "relation": "regulates", "evidence": "Alzheimer disease (AD) is associated with a decreased APP forms ratio (APPr) between the three major forms. This study demonstrated that donepezil, a drug acting as an inhibitor of acetylcholinesterase, affects APP metabolism in Alzheimer disease, restoring the ratio of APP forms in platelets up to the normal range after 4 weeks of treatment.", "citation": {"type": "PubMed", "name": "Eur Neuropsychopharmacol. 2002 Jun;12(3):195-200", "reference": "12007670"}, "annotations": {"Subgraph": {"Non-amyloidogenic subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 22, "target": 43, "key": "54c96863e223f51af1a93203935ae0cb4fd2ab9d38fa38217f9f63f32e1188cd0958be42ce36d2a9da544bf90b07e5677baf41b2b939bbf109e47fd450b334de"}, {"line": 16497, "relation": "decreases", "evidence": "Taken together, our results suggest that the neuroprotective effects of donepezil against Abeta42-induced neurotoxicity are mediated through activation of PP2A, but its additional mechanisms including regulation of GSK-3beta and nAChRs activity would partially contribute to its effects. This observation led us to assume that additional mechanisms of donepezil, including its inhibitory effect on GSK-3beta activity and/or the activation role of nicotinic acetylcholine receptors (nAChRs), might be involved. Donepezil increased neuronal viability with reduced p-tau by enhancing PP2A activity.", "citation": {"type": "PubMed", "name": "J Neurochem. 2013 Nov;127(4):562-74", "reference": "23711227"}, "annotations": {"Subgraph": {"Tau protein subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 22, "target": 87, "key": "c3ee9b3bc06581a4b9431a8cf29701aeaae7fdd29f8a7a93d081cd9fa33107afd73aadcb4fbe0d350387ff0246548ecd05226d159e06ee84b195e21ced7b5ddb"}, {"line": 16504, "relation": "decreases", "evidence": "Taken together, our results suggest that the neuroprotective effects of donepezil against Abeta42-induced neurotoxicity are mediated through activation of PP2A, but its additional mechanisms including regulation of GSK-3beta and nAChRs activity would partially contribute to its effects. This observation led us to assume that additional mechanisms of donepezil, including its inhibitory effect on GSK-3beta activity and/or the activation role of nicotinic acetylcholine receptors (nAChRs), might be involved. Donepezil increased neuronal viability with reduced p-tau by enhancing PP2A activity.", "citation": {"type": "PubMed", "name": "J Neurochem. 2013 Nov;127(4):562-74", "reference": "23711227"}, "annotations": {"Subgraph": {"GSK3 subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 22, "target": 115, "key": "a2e7330219cc01bd98329ab690c9d6eaa454a43b7b669a804d322ed87c68674d67e21cb4c0d818e91edf074fbc94ab6657850229f38105b9369b4473ca1c31e4"}, {"line": 16510, "relation": "increases", "evidence": "Taken together, our results suggest that the neuroprotective effects of donepezil against Abeta42-induced neurotoxicity are mediated through activation of PP2A, but its additional mechanisms including regulation of GSK-3beta and nAChRs activity would partially contribute to its effects. This observation led us to assume that additional mechanisms of donepezil, including its inhibitory effect on GSK-3beta activity and/or the activation role of nicotinic acetylcholine receptors (nAChRs), might be involved. Donepezil increased neuronal viability with reduced p-tau by enhancing PP2A activity.", "citation": {"type": "PubMed", "name": "J Neurochem. 2013 Nov;127(4):562-74", "reference": "23711227"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 22, "target": 96, "key": "4ae659aa7b203ced5dd3fecb2ffe48c2be21f1af7276ff47cd1aa0bf7c5861f62f933ca5598cec337abc50395aed6fd1461e8fbf36b4a1e9eec2bff52b74212d"}, {"line": 16514, "relation": "increases", "evidence": "Taken together, our results suggest that the neuroprotective effects of donepezil against Abeta42-induced neurotoxicity are mediated through activation of PP2A, but its additional mechanisms including regulation of GSK-3beta and nAChRs activity would partially contribute to its effects. This observation led us to assume that additional mechanisms of donepezil, including its inhibitory effect on GSK-3beta activity and/or the activation role of nicotinic acetylcholine receptors (nAChRs), might be involved. Donepezil increased neuronal viability with reduced p-tau by enhancing PP2A activity.", "citation": {"type": "PubMed", "name": "J Neurochem. 2013 Nov;127(4):562-74", "reference": "23711227"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 22, "target": 97, "key": "2b70a8e4f5a72ca49e5cb0d2621a288e062a5e23a492f11ebf1763dfa02c9f273046222c765132178fe030ca59b955a125bf69136e2f969b7e2d503c3c98b695"}, {"line": 16518, "relation": "increases", "evidence": "Taken together, our results suggest that the neuroprotective effects of donepezil against Abeta42-induced neurotoxicity are mediated through activation of PP2A, but its additional mechanisms including regulation of GSK-3beta and nAChRs activity would partially contribute to its effects. This observation led us to assume that additional mechanisms of donepezil, including its inhibitory effect on GSK-3beta activity and/or the activation role of nicotinic acetylcholine receptors (nAChRs), might be involved. Donepezil increased neuronal viability with reduced p-tau by enhancing PP2A activity.", "citation": {"type": "PubMed", "name": "J Neurochem. 2013 Nov;127(4):562-74", "reference": "23711227"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 22, "target": 98, "key": "54962a420ccdfe9b24c06a7af989f4667e7646b96104da3478aee7f94e9907f9db14cbdf4806e2fc0acd7b756d8302cb338dadba970d6eae4eded290c355cdcb"}, {"line": 16522, "relation": "increases", "evidence": "Taken together, our results suggest that the neuroprotective effects of donepezil against Abeta42-induced neurotoxicity are mediated through activation of PP2A, but its additional mechanisms including regulation of GSK-3beta and nAChRs activity would partially contribute to its effects. This observation led us to assume that additional mechanisms of donepezil, including its inhibitory effect on GSK-3beta activity and/or the activation role of nicotinic acetylcholine receptors (nAChRs), might be involved. Donepezil increased neuronal viability with reduced p-tau by enhancing PP2A activity.", "citation": {"type": "PubMed", "name": "J Neurochem. 2013 Nov;127(4):562-74", "reference": "23711227"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 22, "target": 100, "key": "311213bffadd8eb5a4265a281b45967d25120271d1f60b11b2c48b2b7708f04bc7c8aeb19ef599662dd5343ed5cea6ca419882b85f56d122ba8400c3f308eec2"}, {"line": 16526, "relation": "increases", "evidence": "Taken together, our results suggest that the neuroprotective effects of donepezil against Abeta42-induced neurotoxicity are mediated through activation of PP2A, but its additional mechanisms including regulation of GSK-3beta and nAChRs activity would partially contribute to its effects. This observation led us to assume that additional mechanisms of donepezil, including its inhibitory effect on GSK-3beta activity and/or the activation role of nicotinic acetylcholine receptors (nAChRs), might be involved. Donepezil increased neuronal viability with reduced p-tau by enhancing PP2A activity.", "citation": {"type": "PubMed", "name": "J Neurochem. 2013 Nov;127(4):562-74", "reference": "23711227"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 22, "target": 101, "key": "8ba878725b1a5f82593295b5e6e057eb70b181c5e7c867fa3ad21c91877f826a6c794d7558f65c8e7b30b97c746af05bd4d64297ede619240b8224ef31781a4a"}, {"line": 16530, "relation": "increases", "evidence": "Taken together, our results suggest that the neuroprotective effects of donepezil against Abeta42-induced neurotoxicity are mediated through activation of PP2A, but its additional mechanisms including regulation of GSK-3beta and nAChRs activity would partially contribute to its effects. This observation led us to assume that additional mechanisms of donepezil, including its inhibitory effect on GSK-3beta activity and/or the activation role of nicotinic acetylcholine receptors (nAChRs), might be involved. Donepezil increased neuronal viability with reduced p-tau by enhancing PP2A activity.", "citation": {"type": "PubMed", "name": "J Neurochem. 2013 Nov;127(4):562-74", "reference": "23711227"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 22, "target": 102, "key": "ef018b34285f85aa47fb05f66789c049f1c8831e6e043a128655105d3ec948b98f2aab59d28b93c5532c6c7bceb9285775f356d418db38439e87be897bd086a0"}, {"line": 16534, "relation": "increases", "evidence": "Taken together, our results suggest that the neuroprotective effects of donepezil against Abeta42-induced neurotoxicity are mediated through activation of PP2A, but its additional mechanisms including regulation of GSK-3beta and nAChRs activity would partially contribute to its effects. This observation led us to assume that additional mechanisms of donepezil, including its inhibitory effect on GSK-3beta activity and/or the activation role of nicotinic acetylcholine receptors (nAChRs), might be involved. Donepezil increased neuronal viability with reduced p-tau by enhancing PP2A activity.", "citation": {"type": "PubMed", "name": "J Neurochem. 2013 Nov;127(4):562-74", "reference": "23711227"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 22, "target": 103, "key": "974f8d4d6435b66c801b79bcb3e9cfbd859436b57c8f9107c6eb029bdfb5c473202962982af56f7b10ab7633bf6e4ea967eb9660c7e857f82ec78d326e852c17"}, {"line": 16538, "relation": "increases", "evidence": "Taken together, our results suggest that the neuroprotective effects of donepezil against Abeta42-induced neurotoxicity are mediated through activation of PP2A, but its additional mechanisms including regulation of GSK-3beta and nAChRs activity would partially contribute to its effects. This observation led us to assume that additional mechanisms of donepezil, including its inhibitory effect on GSK-3beta activity and/or the activation role of nicotinic acetylcholine receptors (nAChRs), might be involved. Donepezil increased neuronal viability with reduced p-tau by enhancing PP2A activity.", "citation": {"type": "PubMed", "name": "J Neurochem. 2013 Nov;127(4):562-74", "reference": "23711227"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 22, "target": 95, "key": "0c362200e950c8ae39fc6ab96bb8d42fc6658a909d592685a132bbd53aa53faec9930136f2cba3cd5359abea5ca1444d6196a1f9e5d1d915dbfbddd1c9e6ce06"}, {"line": 16542, "relation": "increases", "evidence": "Taken together, our results suggest that the neuroprotective effects of donepezil against Abeta42-induced neurotoxicity are mediated through activation of PP2A, but its additional mechanisms including regulation of GSK-3beta and nAChRs activity would partially contribute to its effects. This observation led us to assume that additional mechanisms of donepezil, including its inhibitory effect on GSK-3beta activity and/or the activation role of nicotinic acetylcholine receptors (nAChRs), might be involved. Donepezil increased neuronal viability with reduced p-tau by enhancing PP2A activity.", "citation": {"type": "PubMed", "name": "J Neurochem. 2013 Nov;127(4):562-74", "reference": "23711227"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 22, "target": 105, "key": "72946bd6f76a9c9086e741b96b1bbbe9d4fb64b76c52ef516d5acc70451afd3bef06954e338fdfa4f2f38cd31548725ed5c6f610307cd7592c00415e04514414"}, {"line": 16546, "relation": "increases", "evidence": "Taken together, our results suggest that the neuroprotective effects of donepezil against Abeta42-induced neurotoxicity are mediated through activation of PP2A, but its additional mechanisms including regulation of GSK-3beta and nAChRs activity would partially contribute to its effects. This observation led us to assume that additional mechanisms of donepezil, including its inhibitory effect on GSK-3beta activity and/or the activation role of nicotinic acetylcholine receptors (nAChRs), might be involved. Donepezil increased neuronal viability with reduced p-tau by enhancing PP2A activity.", "citation": {"type": "PubMed", "name": "J Neurochem. 2013 Nov;127(4):562-74", "reference": "23711227"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 22, "target": 107, "key": "08b2524785d7e66d6e2b3aae5a46b535ad233a791124293d419c1f6802a5a36716f8b87673a0947a6c84f9c6ceb9f1134aceda04b5cacc881776f978f705c0f6"}, {"line": 16550, "relation": "increases", "evidence": "Taken together, our results suggest that the neuroprotective effects of donepezil against Abeta42-induced neurotoxicity are mediated through activation of PP2A, but its additional mechanisms including regulation of GSK-3beta and nAChRs activity would partially contribute to its effects. This observation led us to assume that additional mechanisms of donepezil, including its inhibitory effect on GSK-3beta activity and/or the activation role of nicotinic acetylcholine receptors (nAChRs), might be involved. Donepezil increased neuronal viability with reduced p-tau by enhancing PP2A activity.", "citation": {"type": "PubMed", "name": "J Neurochem. 2013 Nov;127(4):562-74", "reference": "23711227"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 22, "target": 108, "key": "064550245f6aa1025f3b3830493d74b6429f9225acacfed65620acfdab3c49806e3069dcad5c3bfc684a67404db595069f7b73a3d874c37792161f4f0c86865e"}, {"line": 17631, "relation": "increases", "evidence": "Currently available treatments for Alzheimer's disease (EC 3.1.1.7 (acetylcholinesterase) inhibitors and memantine) improve cognitive function, but do not slow the long-term progression of this disorder.", "citation": {"type": "PubMed", "name": "Lancet Neurol. 2010 Mar;9(3):235-7", "reference": "20170836"}, "annotations": {"FDASTATUS": {"Phase 3": true}, "DiseaseState": {"Mild AD": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 1, "target": 66, "key": "d6b6c8b99aef1959be29c65469f05f3748e384f6fcbf7dd2d91e4378fa1929d345c07b2df442f9f797318c46a1b15e0838e7113f6a1ab1730ee1cabc2fc33dbb"}, {"line": 16565, "relation": "isA", "evidence": "Rivastigmine tartrate is a reversible cholinesterase inhibitor indicated for the symptomatic treatment of mild to moderate dementia. Rivastigmine has been shown to improve or maintain patients' performance in 3 major domains: cognitive function, global function (ADLs), and behavior.", "citation": {"type": "PubMed", "reference": "12860489"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 31, "target": 1, "key": "d04d656c574e758ef97bea15cdff145a2aedeec4b6db3fb3c719e3e113ceaf706a8d1010082ef49d116129db6ea20ec3a384c9fe361e776156e095da49c67a4b"}, {"line": 16569, "relation": "increases", "evidence": "Rivastigmine tartrate is a reversible cholinesterase inhibitor indicated for the symptomatic treatment of mild to moderate dementia. Rivastigmine has been shown to improve or maintain patients' performance in 3 major domains: cognitive function, global function (ADLs), and behavior.", "citation": {"type": "PubMed", "reference": "12860489"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 31, "target": 66, "key": "1638d879cf1d33993aa494186a6a02bc553b786f53740140444f43ca855cf3c00969b25d4b79d0d9518fb075e6f6ff87f2748d23b9afbdb2ee0c2a227295bcde"}, {"line": 16573, "relation": "increases", "evidence": "Rivastigmine tartrate is a reversible cholinesterase inhibitor indicated for the symptomatic treatment of mild to moderate dementia. Rivastigmine has been shown to improve or maintain patients' performance in 3 major domains: cognitive function, global function (ADLs), and behavior.", "citation": {"type": "PubMed", "reference": "12860489"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 31, "target": 65, "key": "795d694eb347e22a5b99ba5c9a7186ba92b292d49236adc386c5ef084e1419df9ce9e65fa4bde33cf913bb94206ea5bf894f50f5537496684114e5984cc3a651"}, {"line": 29015, "relation": "decreases", "evidence": "In conclusion, inhibition of both BuChE and AChE with rivastigmine was improved the cognition without affecting on the peripheral IR in the elderly patients with LOAD by HOMA.", "citation": {"type": "PubMed", "name": "J Nutr Health Aging. 2012 Feb;16(2):139-41", "reference": "22323348"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 31, "target": 88, "key": "33ad4d2fd66723fbfaa4b084ac0b70f972b1c77719055658be5b1a0bf1a1936edc970d75a76865aeee8256c69cf4e02194697da556aea28c43d70ff2f26bb655"}, {"line": 29331, "relation": "decreases", "evidence": "Inhibition of acetylcholinesterase activity by rivastigmine decreases lipopolysaccharide-induced IL-1beta expression in the hypothalamus of ewes", "citation": {"type": "PubMed", "reference": "23291013"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 31, "target": 88, "key": "e14fc3e12182ca9cee053594f89dce35e807ec66ac081c615bfc7927d3eddc1d2e796b44fd22b945835a09ac59bd360603633f6dd1ef403352135f73c2cae1ee"}, {"line": 29019, "relation": "decreases", "evidence": "In conclusion, inhibition of both BuChE and AChE with rivastigmine was improved the cognition without affecting on the peripheral IR in the elderly patients with LOAD by HOMA.", "citation": {"type": "PubMed", "name": "J Nutr Health Aging. 2012 Feb;16(2):139-41", "reference": "22323348"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 31, "target": 91, "key": "e9fbd09e97c3818600c3b26807d4b91d8cbb3264279ac5f7ea58b0cf2f61544131407961feb9f79a90aa3a07d64168baf03b94403827c47d5b54da3bb4cce48e"}, {"line": 16623, "relation": "increases", "evidence": "This study found that galantamine effected significant benefits on the cognitive, functional, and behavioral symptoms of mild to moderate AD in this population of Korean patients.", "citation": {"type": "PubMed", "name": "Clin Ther. 2004 Oct;26(10):1608-18", "reference": "15598477"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Species": {"9606": true}, "Confidence": {"High": true}}, "source": 24, "target": 66, "key": "7fc1c3e6b483460cc33aecc2c7b9347c28f52f6b6cfa4f2be8d30f287f7aff5b0dd37932682b94cb81043e456adbf2d580f03e4bd92597f527183dd5f76f8b9e"}, {"line": 16627, "relation": "increases", "evidence": "This study found that galantamine effected significant benefits on the cognitive, functional, and behavioral symptoms of mild to moderate AD in this population of Korean patients.", "citation": {"type": "PubMed", "name": "Clin Ther. 2004 Oct;26(10):1608-18", "reference": "15598477"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Species": {"9606": true}, "Confidence": {"High": true}}, "source": 24, "target": 65, "key": "96a9c55463ccfeceb8d54bcc061dbf17a95eeb5f32114d73c8176ca49524e12339dd3cd69226b17498bb7ea60954e99fd1cb1262711fadaffa45f87f77d85d8e"}, {"line": 16641, "relation": "isA", "evidence": "Galantamine is a phenanthrene alkaloid (similar to codeine) and acts as a reversible inhibitor of AChE with a competitive action. In addition, galantamine's nicotinic agonist properties may provide an additional therapeutic mechanism to AChE inhibition.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2004 Nov 24;131(1-2):136-40", "reference": "15530663"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 24, "target": 1, "key": "bc377544f6757f9de92ef33ed547b176c2a07e876693ab108b8c8b8026595ef505141edddc40f467d7094e3a61d719b9fcb4f7a75decc79574aa063d86882a69"}, {"line": 16645, "relation": "decreases", "evidence": "Galantamine is a phenanthrene alkaloid (similar to codeine) and acts as a reversible inhibitor of AChE with a competitive action. In addition, galantamine's nicotinic agonist properties may provide an additional therapeutic mechanism to AChE inhibition.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2004 Nov 24;131(1-2):136-40", "reference": "15530663"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 24, "target": 88, "key": "8b26a3d4fe5d78aff35e9f19e311b28c96ffd5dff3faceedb7a3d3e526cb80e852555219ee8716f1922c1c808ea8ac23eaebb5fd0f1a0be875420226c6857130"}, {"line": 16649, "relation": "isA", "evidence": "Galantamine is a phenanthrene alkaloid (similar to codeine) and acts as a reversible inhibitor of AChE with a competitive action. In addition, galantamine's nicotinic agonist properties may provide an additional therapeutic mechanism to AChE inhibition.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2004 Nov 24;131(1-2):136-40", "reference": "15530663"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 24, "target": 16, "key": "d6d3cd9ae1c72ab465e08ec7fc1e500d3b903b7cc6ba2f94d579b778450a10919da904042f404122cc46430b7349ffd30387785730106aea921b80b41fc4d7f2"}, {"line": 16663, "relation": "increases", "evidence": "Galantamine increases the availability of ACh in the cholinergic synapse by competitively inhibiting AChE, the enzyme responsible for its breakdown. Galantamine also potentiates cholinergic neurotransmission by positively modulating the response of nAChRs to ACh.", "citation": {"type": "PubMed", "name": "Biol Psychiatry. 2001 Feb 1;49(3):289-99", "reference": "11230880"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 24, "target": 17, "key": "6107d322a0657f14bd1dbec63de07fc6658406c6ae8382cec1b8d98381bcc986b857d5cb16a31395137cb9bb4d6f071ee4a9b7d9e06a0d9b75248f3df40a786d"}, {"line": 16667, "relation": "increases", "evidence": "Galantamine increases the availability of ACh in the cholinergic synapse by competitively inhibiting AChE, the enzyme responsible for its breakdown. Galantamine also potentiates cholinergic neurotransmission by positively modulating the response of nAChRs to ACh.", "citation": {"type": "PubMed", "name": "Biol Psychiatry. 2001 Feb 1;49(3):289-99", "reference": "11230880"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 24, "target": 64, "key": "91888f4a8bb9d1d131cddc588c2495c9f8843a5db939bf0a7f6687b4b4bd46b882ca16f5d1960068032c25cc1ca3b60e88ae338581028b9bec2cf032e33d8343"}, {"line": 16671, "relation": "increases", "evidence": "Galantamine increases the availability of ACh in the cholinergic synapse by competitively inhibiting AChE, the enzyme responsible for its breakdown. Galantamine also potentiates cholinergic neurotransmission by positively modulating the response of nAChRs to ACh.", "citation": {"type": "PubMed", "name": "Biol Psychiatry. 2001 Feb 1;49(3):289-99", "reference": "11230880"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 24, "target": 96, "key": "5c1614bfd23a6110118d2f581f725f80ed15be5433d99228aa3f58866034e3484922f326f101b12867ad03d244b51d58b2f29cca7ae2e08ce7ff9db1aa5bdf65"}, {"line": 18098, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 24, "target": 96, "key": "08270f903e09c8e389f9b6e4df24ff4f76ae1772f016465931e2c726a09afafe9e04c9a5f68c3e45a377578ef2269a1b856173a181d761e16acca1ccbee4c944"}, {"line": 16675, "relation": "increases", "evidence": "Galantamine increases the availability of ACh in the cholinergic synapse by competitively inhibiting AChE, the enzyme responsible for its breakdown. Galantamine also potentiates cholinergic neurotransmission by positively modulating the response of nAChRs to ACh.", "citation": {"type": "PubMed", "name": "Biol Psychiatry. 2001 Feb 1;49(3):289-99", "reference": "11230880"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 24, "target": 97, "key": "16ab5290a1679eae4f94f93ae91c171eac47c18180780871c84c3b1a728fb98a94d9a7f58e913984fac7c86e8df1485a80108467981aaf92b16f0529279a803b"}, {"line": 18102, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 24, "target": 97, "key": "05e9abdde1fdc5a657fd1e4867cc17f44f558775fdc6d571e7a276352547ae2e9483aca24b2b00be46614bdc2b347175ef2bf4ee378ec5feeb1999722db66d2a"}, {"line": 16679, "relation": "increases", "evidence": "Galantamine increases the availability of ACh in the cholinergic synapse by competitively inhibiting AChE, the enzyme responsible for its breakdown. Galantamine also potentiates cholinergic neurotransmission by positively modulating the response of nAChRs to ACh.", "citation": {"type": "PubMed", "name": "Biol Psychiatry. 2001 Feb 1;49(3):289-99", "reference": "11230880"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 24, "target": 98, "key": "35ad924ab3dd3759e13a46d44fa08a7417d4565064a14f8d4faeddda1194fbb772a60e522952e32a51146b04d8658827b4e6613adeeb7d542cc001ec27721b32"}, {"line": 18106, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 24, "target": 98, "key": "b83d99ea9e8f74dd2b4f4a2112e2964b237e84943287312616b80f1778c5e5858580c97eb9e8152b2062a2a992cd9671a6b681122657183cbd6be43941694595"}, {"line": 16683, "relation": "increases", "evidence": "Galantamine increases the availability of ACh in the cholinergic synapse by competitively inhibiting AChE, the enzyme responsible for its breakdown. Galantamine also potentiates cholinergic neurotransmission by positively modulating the response of nAChRs to ACh.", "citation": {"type": "PubMed", "name": "Biol Psychiatry. 2001 Feb 1;49(3):289-99", "reference": "11230880"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 24, "target": 100, "key": "ac31864e107a0a66f25bd330cf96b4c7c8de56bc4d1ce3f4d5f625a65cd5ac364ae8b5ede833a70a9b8d5da5b8ae3675cd55f80432246e19b55e81342b212391"}, {"line": 18110, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 24, "target": 100, "key": "9791c52f68d4ec0eca2484db336b07f982b06727a621b36da2a5d21c182fc52df492cf7c94323251a1ce886c3d1213153f694e105aa46e7f6361224d0bbf199d"}, {"line": 16687, "relation": "increases", "evidence": "Galantamine increases the availability of ACh in the cholinergic synapse by competitively inhibiting AChE, the enzyme responsible for its breakdown. Galantamine also potentiates cholinergic neurotransmission by positively modulating the response of nAChRs to ACh.", "citation": {"type": "PubMed", "name": "Biol Psychiatry. 2001 Feb 1;49(3):289-99", "reference": "11230880"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 24, "target": 101, "key": "dfdb5c6c81784b541801bd826ae1b0a2bd45430eeffc9e8ac53b2ec836344ad85a8e458232338111e210cab0adb8754ef09be7ca4b4e009d6ad1cfba8aa3c664"}, {"line": 18114, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 24, "target": 101, "key": "385d44bba71fe4755f359775fc3d108941b2dd482fc550b479b3595334f2c7bdd42af936475bba0f3711c6afcd809b7fd57e8ea69e2162714f11b287c9bbf345"}, {"line": 16691, "relation": "increases", "evidence": "Galantamine increases the availability of ACh in the cholinergic synapse by competitively inhibiting AChE, the enzyme responsible for its breakdown. Galantamine also potentiates cholinergic neurotransmission by positively modulating the response of nAChRs to ACh.", "citation": {"type": "PubMed", "name": "Biol Psychiatry. 2001 Feb 1;49(3):289-99", "reference": "11230880"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 24, "target": 102, "key": "aa9b64947b53179b5c9d237f7a58612e29b30f35eb048dbf79ebaecaceb45f625b1dc1e074a6ed59dfa9519c8f428a6770802a8443fdd8dda959e5eb30409f15"}, {"line": 18118, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 24, "target": 102, "key": "b1340589f4856d1ce9351543166fdcdca56651ac12fe6677d2801446a5e5bf1625cafb6653d2bf5b04430fa57b0c6debb3aa14ece1b01e4e4088c5dd5e1cf86b"}, {"line": 16695, "relation": "increases", "evidence": "Galantamine increases the availability of ACh in the cholinergic synapse by competitively inhibiting AChE, the enzyme responsible for its breakdown. Galantamine also potentiates cholinergic neurotransmission by positively modulating the response of nAChRs to ACh.", "citation": {"type": "PubMed", "name": "Biol Psychiatry. 2001 Feb 1;49(3):289-99", "reference": "11230880"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 24, "target": 103, "key": "e9f17bb6fca50882174c2d328b2cf5af24f151d08828f5b4e84cd64352004840178482551184b306c61a0eb34cb840b3d659cd6f8e31f353e86f6e2683855365"}, {"line": 18122, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 24, "target": 103, "key": "f05a2dbec2bbf48f6d1747399ac29408810c31a21d0be02db7d4f6c90d28373d13a63a818a14f5b951c92d6c6eddadab842e01f88b636535aeb3718e0659cbe9"}, {"line": 16699, "relation": "increases", "evidence": "Galantamine increases the availability of ACh in the cholinergic synapse by competitively inhibiting AChE, the enzyme responsible for its breakdown. Galantamine also potentiates cholinergic neurotransmission by positively modulating the response of nAChRs to ACh.", "citation": {"type": "PubMed", "name": "Biol Psychiatry. 2001 Feb 1;49(3):289-99", "reference": "11230880"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 24, "target": 95, "key": "7cff7233d960385067147ac40fde0c6d87fdcd4dd059a9afe7a984b3ea5b72d2caa38699dc1d3050ae33e822b15f86f7dcf1d7f9ea50bc8d59e3b0d1929fe99d"}, {"line": 18126, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 24, "target": 95, "key": "5d33238700595285d88b8eff2d544a0cddbc5459dc9ebcc3fe76841b23f62b50e35f033abbf8025ae14a25d338d1853c7822ce358611de65bb12970dae68f6f4"}, {"line": 16703, "relation": "increases", "evidence": "Galantamine increases the availability of ACh in the cholinergic synapse by competitively inhibiting AChE, the enzyme responsible for its breakdown. Galantamine also potentiates cholinergic neurotransmission by positively modulating the response of nAChRs to ACh.", "citation": {"type": "PubMed", "name": "Biol Psychiatry. 2001 Feb 1;49(3):289-99", "reference": "11230880"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 24, "target": 105, "key": "1f2ac1d8f96a8c343158e569707ee61c5bec4998efbbc5b0d35019d2519758ad028b807b97712110f3544db5fcbbd28974f170c3fcbbaf0b42a283008d405cdd"}, {"line": 18130, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 24, "target": 105, "key": "5b0fb4b8b57ba4bfb5be53d86dd0cbfa71d4113e75dff6e2f5fe3578a447ce381996ef18e1316a23022d3aead52f90b794b0c2708bb141576e4b483f58d1e72c"}, {"line": 16707, "relation": "increases", "evidence": "Galantamine increases the availability of ACh in the cholinergic synapse by competitively inhibiting AChE, the enzyme responsible for its breakdown. Galantamine also potentiates cholinergic neurotransmission by positively modulating the response of nAChRs to ACh.", "citation": {"type": "PubMed", "name": "Biol Psychiatry. 2001 Feb 1;49(3):289-99", "reference": "11230880"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 24, "target": 107, "key": "681487940d79ce1006d0c4664fe33213101054fab6b0015b3f834ad8c7696931fbe4e6a23117d1a9828ef08a243cf379233766a2a99846c6af303616bdd73e17"}, {"line": 18134, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 24, "target": 107, "key": "4f618742934b97fbd011564622aa1dbe0fdeb24f482bcf369fb7428c7db8104b826c7ce1d70eb2d136962cd804591995773aff1d921b05113a2adf0574f884c1"}, {"line": 16711, "relation": "increases", "evidence": "Galantamine increases the availability of ACh in the cholinergic synapse by competitively inhibiting AChE, the enzyme responsible for its breakdown. Galantamine also potentiates cholinergic neurotransmission by positively modulating the response of nAChRs to ACh.", "citation": {"type": "PubMed", "name": "Biol Psychiatry. 2001 Feb 1;49(3):289-99", "reference": "11230880"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 24, "target": 108, "key": "3a28de0f69e27bfedde1e1b37c959a02e06e9de0109af1d63d00c417a5a80316c5874d51a1811d14f83a91f98ec176a92829098f6ab79d6375c2abe45468c94d"}, {"line": 18138, "relation": "increases", "evidence": "Galantamine and nefiracetam have been shown to potentiate the phasic activity of nicotinic acetylcholine receptors (nAChRss) in the brain. Stimulation of nAChRss is also known to cause release of various neurotransmitters including glutamate and gamma-aminobutyric acid (GABA).", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 24, "target": 108, "key": "3f4c726b255da4c567887b0cdd2c0faab03ff99a7108f3a812fe1000535d0b8893045943b8616b162ff33cdf979a19af4f0be58a0093bd2f08f5003c437a038a"}, {"line": 17635, "relation": "increases", "evidence": "Currently available treatments for Alzheimer's disease (EC 3.1.1.7 (acetylcholinesterase) inhibitors and memantine) improve cognitive function, but do not slow the long-term progression of this disorder.", "citation": {"type": "PubMed", "name": "Lancet Neurol. 2010 Mar;9(3):235-7", "reference": "20170836"}, "annotations": {"FDASTATUS": {"Phase 3": true}, "DiseaseState": {"Mild AD": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 26, "target": 66, "key": "7199a5e33725e792e9e880bc978e716ce767ffe8dc95a273a712379d27de19e9c4c409c64910f60f960bd63b28433bfe3056fb3fa9d907b1a52898245b75d6d6"}, {"line": 17321, "relation": "isA", "evidence": "Physostigmine, an acetyl cholinesterase inhibitor, and arecoline, a muscarinic agonist, have been shown to improve Alzheimer presenile dementia in some patients when administered parenterally. Both of these compounds are ineffective orally due to first-pass metabolism.", "citation": {"type": "PubMed", "name": "J Pharm Sci. 1991 Aug;80(8):750-1", "reference": "1791534"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 18, "target": 15, "key": "b0d1c017edad8bb7aa1f9774c6c5fd77873abc8c651821172257392db568df41329878b8f593a21de3d4930d3f6566ba213c058f48993a4ffb868e7fd1968574"}, {"line": 17329, "relation": "decreases", "evidence": "Physostigmine, an acetyl cholinesterase inhibitor, and arecoline, a muscarinic agonist, have been shown to improve Alzheimer presenile dementia in some patients when administered parenterally. Both of these compounds are ineffective orally due to first-pass metabolism.", "citation": {"type": "PubMed", "name": "J Pharm Sci. 1991 Aug;80(8):750-1", "reference": "1791534"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 18, "target": 142, "key": "8816570445b8935d8d5cd1f9f6e4d9c1c51f630d6c98453326fdee2ddc197ed26e210c206f671b92addba39b5374049a02231d6f353a1ce25a331c0a6a59045a"}, {"line": 17350, "relation": "increases", "evidence": "In an attempt to improve cognitive function in AD, arecoline (a muscarinic cholinergic receptor agonist) was given to patients with probable or possible AD in a two-phase design, and verbal memory function was examined. Results indicate that some patients demonstrate reliable improvements of verbal memory during arecoline treatment.", "citation": {"type": "PubMed", "name": "Psychopharmacol Bull. 1991;27(3):315-9", "reference": "1775605"}, "annotations": {"Species": {"9606": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 18, "target": 69, "key": "a462f160c696309c36ba7d2591da76802f2a6020d4f9b98dc0bf021777e75a5dda37629000f4ca247b478a23da5bf5422234fc78c0ce27d18396a07572d1230e"}, {"line": 17370, "relation": "increases", "evidence": "Treatment with the muscarinic agonist arecoline improves memory retention in patients with Alzheimer's disease (AD). In animal models, arecoline selectively increases local cerebral glucose utilization (LCGU).We examined (1) whether these focal increases in metabolism were coupled to local cerebral blood flow (LCBF) and (2) whether the effect of arecoline on LCGU and LCBF was dependent upon duration of drug administration. In general, LCBF correlated closely with LCGU following arecoline 2 mg/kg administration, but heterogeneous regions were present.", "citation": {"type": "PubMed", "name": "Brain Res. 1994 Mar 28;641(1):65-75", "reference": "8019853"}, "annotations": {"Species": {"10116": true}, "MeSHAnatomy": {"Cerebrum": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 18, "target": 69, "key": "7e9529142ee2a152f5e15d6f48531417566cb19e0a384e3ef30b29f09bd0dca9dbbd6e57277664e57b32d3ea67f0dd8c2f300c07da6678cd67d81b00ed9d6f1a"}, {"line": 17374, "relation": "increases", "evidence": "Treatment with the muscarinic agonist arecoline improves memory retention in patients with Alzheimer's disease (AD). In animal models, arecoline selectively increases local cerebral glucose utilization (LCGU).We examined (1) whether these focal increases in metabolism were coupled to local cerebral blood flow (LCBF) and (2) whether the effect of arecoline on LCGU and LCBF was dependent upon duration of drug administration. In general, LCBF correlated closely with LCGU following arecoline 2 mg/kg administration, but heterogeneous regions were present.", "citation": {"type": "PubMed", "name": "Brain Res. 1994 Mar 28;641(1):65-75", "reference": "8019853"}, "annotations": {"Species": {"10116": true}, "MeSHAnatomy": {"Cerebrum": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 18, "target": 47, "key": "59ff2b34a2cbc6915cf34acb7f71353c5e467f3a2d34ff975bddbe5aad62f8e6e80d64ad2032c153072e73ae0297a0723c763645ae46c48e865e6e0a229bfae3"}, {"line": 17378, "relation": "increases", "evidence": "Treatment with the muscarinic agonist arecoline improves memory retention in patients with Alzheimer's disease (AD). In animal models, arecoline selectively increases local cerebral glucose utilization (LCGU).We examined (1) whether these focal increases in metabolism were coupled to local cerebral blood flow (LCBF) and (2) whether the effect of arecoline on LCGU and LCBF was dependent upon duration of drug administration. In general, LCBF correlated closely with LCGU following arecoline 2 mg/kg administration, but heterogeneous regions were present.", "citation": {"type": "PubMed", "name": "Brain Res. 1994 Mar 28;641(1):65-75", "reference": "8019853"}, "annotations": {"Species": {"10116": true}, "MeSHAnatomy": {"Cerebrum": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 18, "target": 44, "key": "740913b4f9b416ee3a49551b5ac976348790287eec2f6180c5402be2d46b8fa6e6f64c058ad8c0f1600aca9e3d1c3639b151c8f78d3de60b4f259a32736099e4"}, {"line": 17389, "relation": "increases", "evidence": "The mechanisms by which arecoline improves cognitive function are not known. We have demonstrated that arecoline can differentially influence cerebral blood flow and metabolism with both acute and chronic administration. Studies of cerebral glucose metabolism in patients with early or late onset of AD demonstrate glucose metabolic deficits in the temporal and parietal cortex. In advanced cases of AD, cerebral blood flow also can be reduced throughout the cortex.", "citation": {"type": "PubMed", "name": "Brain Res. 1994 Mar 28;641(1):65-75", "reference": "8019853"}, "annotations": {"MeSHAnatomy": {"Cerebrum": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 18, "target": 66, "key": "271799214c61b1a71c1e70d61fc3473d63bebd6b8feaebcaa1c742af8c52abbd4e38e55d4cd6525aa9cf79ca61c6cf21adfa661a1ff8530abf8695c6095198e5"}, {"line": 17410, "relation": "increases", "evidence": "Acute arecoline administered to 14 subjects produced unpleasant side-effects (e.g. nausea, vomiting), mean adrenocorticotrophic hormone (p = .0006), cortisol (p = .0001) and beta-endorphin (p = .0001) levels were elevated. Thus, high-dose arecoline activates the hypothalamic-pituitary-adrenal (HPA) axis and may increase other anterior pituitary hormone levels, likely representing a 'stress response', but cognition-enhancing, low doses of arecoline do not produce a glucocorticoid response. Hence, arecoline-induced memory improvement is not due to the induction of 'stress' nor to the elevation of peripheral corticosteroid levels.", "citation": {"type": "PubMed", "reference": "8584603"}, "annotations": {"MeSHAnatomy": {"Brain": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 18, "target": 20, "key": "96e126713b9c704858461ca1d689794e9cdefc3d5ea04ad8975c2f26732896a7f15059f7109f4f21bbc3f87ba1eb3913daf93478dfaca2f1288543d782e11410"}, {"line": 17539, "relation": "increases", "evidence": "Cumulative evidence from human and animal studies suggests that central activation of the HPA axis by cholinergic drugs can result in the elevation of plasma levels of several neuropeptides including adrenocorticotrophic hormone (ACTH), cortisol, b-endorphin, vasopressin, and epinephrine. Neuropeptides can modulate neurotransmission and can effect cognition. It has, therefore, been speculated that cognitive enhancement by cholinergic drugs could be mediated by the central activation of the HPA axis.", "citation": {"type": "PubMed", "reference": "8584603"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 20, "target": 57, "key": "0d7a7660feea4b75df8bc4cd4dcdef5a3966cc761fbb218e60f416d46745cc104b8f81f21eb978ffe418f8b61a0fa52789b8d9a4ce606a8833ac086470329473"}, {"line": 17559, "relation": "increases", "evidence": "Cumulative evidence from human and animal studies suggests that central activation of the HPA axis by cholinergic drugs can result in the elevation of plasma levels of several neuropeptides including adrenocorticotrophic hormone (ACTH), cortisol, b-endorphin, vasopressin, and epinephrine. Neuropeptides can modulate neurotransmission and can effect cognition. It has, therefore, been speculated that cognitive enhancement by cholinergic drugs could be mediated by the central activation of the HPA axis.", "citation": {"type": "PubMed", "reference": "8584603"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 20, "target": 66, "key": "7baad142c205fc70160010b15f920bbe2752b1a242317d1579af1b842f5c38fc82403b9e34d583493b12c371204948a6fefc5b1b227d24f069c29c6587715778"}, {"line": 17325, "relation": "isA", "evidence": "Physostigmine, an acetyl cholinesterase inhibitor, and arecoline, a muscarinic agonist, have been shown to improve Alzheimer presenile dementia in some patients when administered parenterally. Both of these compounds are ineffective orally due to first-pass metabolism.", "citation": {"type": "PubMed", "name": "J Pharm Sci. 1991 Aug;80(8):750-1", "reference": "1791534"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 29, "target": 2, "key": "e12725b2103310671f237ab8347a580b400c2559abb1f6cb9a946c5d1e507c255f333758f35ba5b66e429936c7916de89613f41144fa2b887c3759ac4dd91798"}, {"line": 17333, "relation": "decreases", "evidence": "Physostigmine, an acetyl cholinesterase inhibitor, and arecoline, a muscarinic agonist, have been shown to improve Alzheimer presenile dementia in some patients when administered parenterally. Both of these compounds are ineffective orally due to first-pass metabolism.", "citation": {"type": "PubMed", "name": "J Pharm Sci. 1991 Aug;80(8):750-1", "reference": "1791534"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 29, "target": 142, "key": "a277effcb82271294d350e9a524d9a0851a2855c31d554a7f48c498aca39ed157a4a1ac557ae91f42c2a22b4bb57f081dec12849a99de691ff22fb0b818776f5"}, {"line": 17575, "relation": "increases", "evidence": "Cumulative evidence from human and animal studies suggests that central activation of the HPA axis by cholinergic drugs can result in the elevation of plasma levels of several neuropeptides including adrenocorticotrophic hormone (ACTH), cortisol, b-endorphin, vasopressin, and epinephrine. Neuropeptides can modulate neurotransmission and can effect cognition. It has, therefore, been speculated that cognitive enhancement by cholinergic drugs could be mediated by the central activation of the HPA axis.", "citation": {"type": "PubMed", "reference": "8584603"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "object": {"modifier": "Activity"}, "source": 6, "target": 79, "key": "930e73397bbc03382db43ce55ee1ae067d329ff85b71b834eaa06486ac40a1d6611e71e87718b6982a6e1eb4ebf1eb608eef974c669cfb786e3685d52e1e1c3a"}, {"line": 17521, "relation": "increases", "evidence": "Cumulative evidence from human and animal studies suggests that central activation of the HPA axis by cholinergic drugs can result in the elevation of plasma levels of several neuropeptides including adrenocorticotrophic hormone (ACTH), cortisol, b-endorphin, vasopressin, and epinephrine. Neuropeptides can modulate neurotransmission and can effect cognition. It has, therefore, been speculated that cognitive enhancement by cholinergic drugs could be mediated by the central activation of the HPA axis.", "citation": {"type": "PubMed", "reference": "8584603"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "MeSHAnatomy": {"Plasma": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 79, "target": 20, "key": "8fa57bf4817d10f9f13deeb0a5016d75be15e2f2fb022bbb823f4a7d763b05f5c5c47fa11c5add55ffe056a47946bd2f9d31e8c29360142c2f9c099f45346d3d"}, {"line": 17525, "relation": "increases", "evidence": "Cumulative evidence from human and animal studies suggests that central activation of the HPA axis by cholinergic drugs can result in the elevation of plasma levels of several neuropeptides including adrenocorticotrophic hormone (ACTH), cortisol, b-endorphin, vasopressin, and epinephrine. Neuropeptides can modulate neurotransmission and can effect cognition. It has, therefore, been speculated that cognitive enhancement by cholinergic drugs could be mediated by the central activation of the HPA axis.", "citation": {"type": "PubMed", "reference": "8584603"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "MeSHAnatomy": {"Plasma": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 79, "target": 21, "key": "30c8f1bad599411e9f650e3f7416ab170e5d994737acb8b796cac5755a0cf9cb3b906955a7b68c7f5d98e3837c5cb8fdd4fa3ff0cb49a5a5d474617b1fdec0bb"}, {"line": 17529, "relation": "increases", "evidence": "Cumulative evidence from human and animal studies suggests that central activation of the HPA axis by cholinergic drugs can result in the elevation of plasma levels of several neuropeptides including adrenocorticotrophic hormone (ACTH), cortisol, b-endorphin, vasopressin, and epinephrine. Neuropeptides can modulate neurotransmission and can effect cognition. It has, therefore, been speculated that cognitive enhancement by cholinergic drugs could be mediated by the central activation of the HPA axis.", "citation": {"type": "PubMed", "reference": "8584603"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "MeSHAnatomy": {"Plasma": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 79, "target": 34, "key": "fb4432744c013b9be2f95d6749ba728c9ce50dfc528d26cb1aea82e5a0427141a943d1631a87966a78ddf8ff6390d3af20bda343d7b28ed791151b62ba6cc1a5"}, {"line": 17533, "relation": "increases", "evidence": "Cumulative evidence from human and animal studies suggests that central activation of the HPA axis by cholinergic drugs can result in the elevation of plasma levels of several neuropeptides including adrenocorticotrophic hormone (ACTH), cortisol, b-endorphin, vasopressin, and epinephrine. Neuropeptides can modulate neurotransmission and can effect cognition. It has, therefore, been speculated that cognitive enhancement by cholinergic drugs could be mediated by the central activation of the HPA axis.", "citation": {"type": "PubMed", "reference": "8584603"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "MeSHAnatomy": {"Plasma": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 79, "target": 0, "key": "35bf95a562ed2f2c9be54cd1bc17d226cafd25f7ee5826bbe1274c13567397dbe25b1f7e2aa4f63fd5980cf6b1d0a62966f0ffb8a4878abb4c1d3db8dcb736ba"}, {"line": 17579, "relation": "increases", "evidence": "Cumulative evidence from human and animal studies suggests that central activation of the HPA axis by cholinergic drugs can result in the elevation of plasma levels of several neuropeptides including adrenocorticotrophic hormone (ACTH), cortisol, b-endorphin, vasopressin, and epinephrine. Neuropeptides can modulate neurotransmission and can effect cognition. It has, therefore, been speculated that cognitive enhancement by cholinergic drugs could be mediated by the central activation of the HPA axis.", "citation": {"type": "PubMed", "reference": "8584603"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "subject": {"modifier": "Activity"}, "source": 79, "target": 66, "key": "b5df025a02d3719de59b94ed5021520e2b2733161b736826b79726d37d2ff50fdcc971f7260d3f07fb588b59835f12eff1198208b6501592ef110968813f3cad"}, {"line": 17551, "relation": "increases", "evidence": "Cumulative evidence from human and animal studies suggests that central activation of the HPA axis by cholinergic drugs can result in the elevation of plasma levels of several neuropeptides including adrenocorticotrophic hormone (ACTH), cortisol, b-endorphin, vasopressin, and epinephrine. Neuropeptides can modulate neurotransmission and can effect cognition. It has, therefore, been speculated that cognitive enhancement by cholinergic drugs could be mediated by the central activation of the HPA axis.", "citation": {"type": "PubMed", "reference": "8584603"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 0, "target": 57, "key": "2c7a69d384d1681c354aa12444b381d531913323a91bbeac03593142a0f4976b6804169bf925a182b6df4e5359482edd3cd5e05e55cd655130bb807a6c49729e"}, {"line": 17571, "relation": "increases", "evidence": "Cumulative evidence from human and animal studies suggests that central activation of the HPA axis by cholinergic drugs can result in the elevation of plasma levels of several neuropeptides including adrenocorticotrophic hormone (ACTH), cortisol, b-endorphin, vasopressin, and epinephrine. Neuropeptides can modulate neurotransmission and can effect cognition. It has, therefore, been speculated that cognitive enhancement by cholinergic drugs could be mediated by the central activation of the HPA axis.", "citation": {"type": "PubMed", "reference": "8584603"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 0, "target": 66, "key": "f099c02a58fe79896ec8a69f1d262fe87b010b8281a3259ffc95f9dfa52b27ec1e6bcebe19f1f36e898d41919251c351940949f2d0690f4021c63625ab05a776"}, {"line": 17993, "relation": "increases", "evidence": "Nefiracetam is undergoing preclinical and clinical tests as a cognition-enhancing drug in Alzheimer's disease (AD).", "citation": {"type": "PubMed", "name": "Psychopharmacology (Berl). 1997 May;131(2):130-9", "reference": "9201800"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 28, "target": 66, "key": "c5d75c33fa400c4fe3d320d209a118c1524d4bdc5b98bbec4afbd55a758e8bdeef1753ec8340f34372ccde45e6796b01240ec11ae4e617c1d0b0d39d1ba4a28e"}, {"line": 18400, "relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "annotations": {"Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 28, "target": 66, "key": "f3c1ad464041d2bb4641d16aa12d10cd1d5f432116f9e02b6582ec55c283dd599cb2fab3699f8dbd1af92aa2166e7bcfb8295245f8ad95abbb6008a7ed639216"}, {"line": 18024, "relation": "increases", "evidence": "We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 28, "target": 114, "key": "5132abfdd5597641e6c052ea85ac22fac7d6f719e52a1e1f50cc2a4ea003760ff84b56c24585175f053dfbe11e776ac95869b83ed5a12dd50f85946f12fed185"}, {"line": 18313, "relation": "increases", "evidence": "In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.", "citation": {"type": "PubMed", "reference": "21821968"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 28, "target": 114, "key": "21ca4ed6246f7cf9865f78bfb15b5431c491e68f518ef6a58586b42f9d220b2440f51241129067ca300319ff54cc847122ab7208470ec766ad27b937c27e5052"}, {"line": 18028, "relation": "increases", "evidence": "We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 28, "target": 96, "key": "7ea090d2e86466135a92631f2206f4da9368e19ec70fadb6eccadbcc10a17a7e63b0ed6d938f1e150ce1f21abc283192edf8ca2fee6a5ff1cfe3d253405d9ab4"}, {"line": 18032, "relation": "increases", "evidence": "We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 28, "target": 97, "key": "142442c05bcc95c4900eb4c4a5328f2eaca1d367d110513660ec0cca4ff8de5ff9b50dbc75ca8a49ac1bcf720da29006c9049e6461c274a4273260822b0379d8"}, {"line": 18036, "relation": "increases", "evidence": "We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 28, "target": 98, "key": "4ef37a9824955c6bb1c22f7e7a93d382dbde9cfabbbcb423d8641449e6a82cdfe85d22467ed342415d2620cac6ff7d116742b67728d7a903847cf5559323e07c"}, {"line": 18040, "relation": "increases", "evidence": "We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 28, "target": 100, "key": "0deb641164367e97795ad293d15d1698535e0ecd3210b62f45886d5f463e13d5ef616f66506c3b12dc2156eb19423e1b9d275fdbe0b5ca63bb17dcda3d0fb481"}, {"line": 18044, "relation": "increases", "evidence": "We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 28, "target": 101, "key": "1440605f2d5a58efe7a1d9ff77de0f30a0a26715a3a32b398858d1d229f56cda60433f17601332dbe6e7c5e80a7d24c88c06efad86d8a2b68185d6990c88f9db"}, {"line": 18048, "relation": "increases", "evidence": "We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 28, "target": 102, "key": "b3f3f5614d1a1667a7812cc225ba14c8720b9b419805d6f0efb9b4d55d280b84ea5d3fcc723d4ec78c13a4fdf1b050cf037518c2dec5123c50b7401d37792e1d"}, {"line": 18052, "relation": "increases", "evidence": "We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 28, "target": 103, "key": "cc70739d14f8740ad06e34ac2199c335cdf421b01d2b4a9fb5f54ab4c5c2ffe46cbbb9b2939933c681169981dd3e1c8dd4d5a872edac008f09a253d641fd4aef"}, {"line": 18056, "relation": "increases", "evidence": "We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 28, "target": 95, "key": "af720cc589fcd6f945e4517ebd1e6b9819a4312c1347d3d6c6d2ecda0e5c0e8e230606e33c2ce7724b1c17fa4230824805aaec793b556fb2c964fca1d89159c8"}, {"line": 18060, "relation": "increases", "evidence": "We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 28, "target": 105, "key": "293f4e7ea15defbae3d442c4d92098b6db577a3af113a0465bbaece199c73a4a3f7f35ff2ceb534abb588a610801768740ac683ff0e338112f0b84cedfa0ce8c"}, {"line": 18064, "relation": "increases", "evidence": "We have previously demonstrated that the nootropic drug nefiracetam potentiates the activity of both nicotinic acetylcholine and NMDA receptors and that nefiracetam modulates the glycine binding site of the NMDA receptor.", "citation": {"type": "PubMed", "name": "Mol Pharmacol. 2007 Feb;71(2):580-7", "reference": "17095583"}, "annotations": {"Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 28, "target": 107, "key": "9f77159c0976e49581e6f97abe9dd71cbc9734196cf4ada602f359f215ccae86a42207f08547654dce33912c39919dce36365a3b84d646269e962e1699b5eb13"}, {"line": 18240, "relation": "isA", "evidence": "The nefiracetam-induced increase in the frequency of mEPSCs and mIPSCs over and above the level achieved by ACh alone would contribute to the therapeutic effect of nefiracetam as the cholinergic system is known to be downregulated in the brain of Alzheimer's disease patients.The therapeutic effects of galantamine are ascribed to the modest potentiation of nACh receptor and NMDA receptor activities in addition to the modest inhibition of acetylcholinesterase.", "citation": {"type": "PubMed", "name": "Neuroscience. 2009 May 5;160(2):484-91", "reference": "19272425"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"GABA subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 28, "target": 1, "key": "1c6824d9e4fbe2100aea1cfc5f4d1a5f5b629c0f13b2bb735e7a14a4c0eb15f2e4fa5326f505ee11d942b94a26cae255ee00682964a47198d32ea133dda68303"}, {"line": 18317, "relation": "increases", "evidence": "In conclusion, nefiracetam enhances NMDA-receptor function through stimulation of its glycine binding site and nefiracetam-induced CaMKII activation likely contributes to improvement of cognition, learning, and memory.", "citation": {"type": "PubMed", "reference": "21821968"}, "annotations": {"Species": {"10116": true}, "Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 28, "target": 75, "key": "04777800bea8e9ba574a16c5002232424a1bc493fadea7ce2418ae6dd868c1a08cac3dda9904f74727e2be156cfe304d688f327da2eb1a712e18a24e28e5f2ae"}, {"line": 18352, "relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "annotations": {"Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 28, "target": 78, "key": "9536c7493472d31c1b74377372aea293cbe40240b4b69b1650f96ac394c07fcfca544b0ba80a81029b539bea6a0e6a4aac31363fa56ee63a7ba751e1edd66b9d"}, {"line": 18356, "relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "annotations": {"Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 78, "target": 96, "key": "c15cbfbea578248782c7ee0d0d0ea07fca1b3db05f4e6cadf86f67f0b5a0d6177aa60b7182bc48e9e771358312114e6e09d314238bcfd1c1e1ee51d3e29baa81"}, {"line": 18360, "relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "annotations": {"Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 78, "target": 97, "key": "7d78af86433871d2ed6aceef370363ad510d0eb3b3f58446b6f9a5d4541a9778a14bd3648c249bb23bf401459f7ee680ff3be2a013411418059931832847385d"}, {"line": 18364, "relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "annotations": {"Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 78, "target": 98, "key": "14dcbf6022ca960fdacf0d0be56391cb691599442196d26fd96bbc91283ac2302a2439d156d1ceed7e7a65d8d5f21ef2af9ab139e6e7c2851c1ed687f64b09f4"}, {"line": 18368, "relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "annotations": {"Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 78, "target": 100, "key": "aacf431c7e25d1071f5016adeb95789aebc02dea89e65b2d9b95799759ab7c9aef46f2a5d27e378145bcd42483e7753f44503c147c994252508a5e2446a4a064"}, {"line": 18372, "relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "annotations": {"Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 78, "target": 101, "key": "9edf0fea99305ddbb5616c2921d19e5789cd61ca2e8d105837a64e71fac2c77058083f38cbd48c8ca834faa242f3a42dba0ec02eabf670d4c2c5a4ea1aae6787"}, {"line": 18376, "relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "annotations": {"Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 78, "target": 102, "key": "635b09bd62bf65352db23db15161ead3026e96151a329cfd23933d4e8e57ddb9faa62ddafd449e93955d48dabbbd5b3c1d1af6c8916d7fa714cf2cdfc0098e02"}, {"line": 18380, "relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "annotations": {"Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 78, "target": 103, "key": "065ae4e7de309a15ceaacdda36889af67508c565b585944a8d1f88c68deb94c8371fb9c86d76fce80aa273e40778847bc3b8c0bb2192bf121bbdefcd109c24eb"}, {"line": 18384, "relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "annotations": {"Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 78, "target": 95, "key": "b69a202335dd28814178b8f6c4b4cfda2e2588e60c125b0e92375c15c1f5e585bf51cd062ce7b08ad0343e5734e5852a4ba7ad680bb56cf7a6d709e6d2e48753"}, {"line": 18388, "relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "annotations": {"Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 78, "target": 105, "key": "277452498133afc65f5b0a570479aab3aefce23e4e26677e591be293669d22ec5d93a1b0f95de45c406775567c3dafdcfcf97948a2b684718710c5d28b45c14e"}, {"line": 18392, "relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "annotations": {"Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 78, "target": 107, "key": "3e333f56c528243e5322fd75b70557fe62ab1dfdc45ad31c06d3c1739e513abda670ffdddaf586c18982e45ea46ff5fbf858b991110449a0e690076f711efb56"}, {"line": 18396, "relation": "increases", "evidence": "The results of the present study, thus, suggest that nefiracetam enhances activity of nicotinic ACh receptors by interacting with a PKC pathway, thereby increasing glutamate release from presynaptic terminals, and then leading to a sustained facilitation of hippocampal neurotransmission. This may represent a cellular mechanism underlying the cognition-enhancing action of nefiracetam. The results also provide the possibility that nefiracetam could be developed as a promising therapeutic drug for senile dementia or Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Brain Res Mol Brain Res. 2000 Aug 14;80(1):53-62", "reference": "11039729"}, "annotations": {"Subgraph": {"GABA subgraph": true, "NMDA receptor": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 78, "target": 108, "key": "342d96634f1a6a2baa83458152c4d0b98860afe047f8576aa7919508cd28bd27ec77e2af37ce4ae4a9c9a8ed18c1a73392886d4db606f59a601023039e02860e"}, {"line": 20764, "relation": "decreases", "evidence": "Tacrine, a cholinesterase inhibitor, was approved for the treatment of Alzheimer's disease.", "citation": {"type": "PubMed", "name": "Drug Metab Dispos. 2004 Aug;32(8):805-12", "reference": "15258105"}, "annotations": {"Disease": {"Alzheimer's disease": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 33, "target": 142, "key": "625394de8a1c4c17f51853726999d04b12152fafa91cf289e993668b24cd422528adbf74262f2e3a5a2d5ba7ecb8c293ee17bf7fa153ad5d15a61e1bc061c638"}, {"line": 68543, "relation": "increases", "evidence": "Not only do these two molecules stimulate (miR-132 & EGR1) synaptic activity and plasticity, they are also involved in Alzheimer's disease pathology and might, in addition, affect cholinergic function. In addition, miR-132 and EGR1 showed a significant positive correlation with choline acetyltransferase expression.", "citation": {"type": "PubMed", "name": "Brain. 2016 Mar;139(Pt 3):908-21. doi: 10.1093/brain/awv383. Epub 2016 Jan 20.", "reference": "26792551"}, "annotations": {"Subgraph": {"Gamma secretase subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 110, "target": 64, "key": "f657b7de85d478434f2215a7934e2553dc4fb7745b147932f77c0d2c29e1bf5af0276c20687343a942e4fcd1012aa321d3258faec133d3b48e265e963402bba6"}, {"line": 68547, "relation": "positiveCorrelation", "evidence": "Not only do these two molecules stimulate (miR-132 & EGR1) synaptic activity and plasticity, they are also involved in Alzheimer's disease pathology and might, in addition, affect cholinergic function. In addition, miR-132 and EGR1 showed a significant positive correlation with choline acetyltransferase expression.", "citation": {"type": "PubMed", "name": "Brain. 2016 Mar;139(Pt 3):908-21. doi: 10.1093/brain/awv383. Epub 2016 Jan 20.", "reference": "26792551"}, "annotations": {"Subgraph": {"Gamma secretase subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 110, "target": 92, "key": "d3119e4fa24804183014e119257c98c4b0bec088034a08038a87c690d451a7e59d99d9f917c6dd5224b9d8757aef2872f6c6054fecb373a0ad363368c091868c"}, {"line": 25492, "relation": "increases", "evidence": "In the rats injected with insulin, it was found that their learning and memory abilities were improved significantly (P < 0.01) and that the expression of the nicotinic acetylcholine receptors were increased and GFAP positive astrocytes were decreased obviously (P < 0.05), as compared with the model rats. Insulin is able to enhance the learning and memory abilities of the Alzheimer's disease-like rats, possibly by improving the function of the acetylcholine system and decreasing the astrocytes proliferation in the brain.", "citation": {"type": "PubMed", "name": "Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2008 Nov;24(4):494-8", "reference": "21158163"}, "annotations": {"Species": {"10116": true}, "Disease": {"Alzheimer's disease": true}, "MeSHAnatomy": {"Brain": true, "Astrocytes": true}, "Subgraph": {"Insulin signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 139, "target": 68, "key": "9be1421666ad1fddb84162d681ee7c72cc539e935b0ad86d8bcc638299145d6971d7355bc559be3660718340560bbeee3d2d25688cdff6dc1865ae51e68ebe56"}, {"line": 25496, "relation": "increases", "evidence": "In the rats injected with insulin, it was found that their learning and memory abilities were improved significantly (P < 0.01) and that the expression of the nicotinic acetylcholine receptors were increased and GFAP positive astrocytes were decreased obviously (P < 0.05), as compared with the model rats. Insulin is able to enhance the learning and memory abilities of the Alzheimer's disease-like rats, possibly by improving the function of the acetylcholine system and decreasing the astrocytes proliferation in the brain.", "citation": {"type": "PubMed", "name": "Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2008 Nov;24(4):494-8", "reference": "21158163"}, "annotations": {"Species": {"10116": true}, "Disease": {"Alzheimer's disease": true}, "MeSHAnatomy": {"Brain": true, "Astrocytes": true}, "Subgraph": {"Insulin signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 139, "target": 69, "key": "5a3e705716bdfe13a88c9fce600a40186875f4bbed9682774271b923f71155a1843c984f3c73cf6e8b466d006014440c872bb8afd30279d1b524e274ae9af0fc"}, {"line": 25500, "relation": "increases", "evidence": "In the rats injected with insulin, it was found that their learning and memory abilities were improved significantly (P < 0.01) and that the expression of the nicotinic acetylcholine receptors were increased and GFAP positive astrocytes were decreased obviously (P < 0.05), as compared with the model rats. Insulin is able to enhance the learning and memory abilities of the Alzheimer's disease-like rats, possibly by improving the function of the acetylcholine system and decreasing the astrocytes proliferation in the brain.", "citation": {"type": "PubMed", "name": "Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2008 Nov;24(4):494-8", "reference": "21158163"}, "annotations": {"Species": {"10116": true}, "Disease": {"Alzheimer's disease": true}, "MeSHAnatomy": {"Brain": true, "Astrocytes": true}, "Subgraph": {"Insulin signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 139, "target": 129, "key": "ef87e96e4336b5fa88126f3e82c8a09ff7e0b6807517178a9215fa7a88cb0016319d3dcf20c6a6aff8b83d333e1ab4cfe3db595b6c87524d848f23d7266a84b9"}, {"line": 25504, "relation": "increases", "evidence": "In the rats injected with insulin, it was found that their learning and memory abilities were improved significantly (P < 0.01) and that the expression of the nicotinic acetylcholine receptors were increased and GFAP positive astrocytes were decreased obviously (P < 0.05), as compared with the model rats. Insulin is able to enhance the learning and memory abilities of the Alzheimer's disease-like rats, possibly by improving the function of the acetylcholine system and decreasing the astrocytes proliferation in the brain.", "citation": {"type": "PubMed", "name": "Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2008 Nov;24(4):494-8", "reference": "21158163"}, "annotations": {"Species": {"10116": true}, "Disease": {"Alzheimer's disease": true}, "MeSHAnatomy": {"Brain": true, "Astrocytes": true}, "Subgraph": {"Insulin signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 139, "target": 130, "key": "ba70edbc89a74bae005f1d953902770da877e548a7794c3336fddbda68f34e4d75311a81b7aea5d013f9f42cd830f9e08ea95c28c927e0e7b2670f2871abf24e"}, {"line": 25508, "relation": "increases", "evidence": "In the rats injected with insulin, it was found that their learning and memory abilities were improved significantly (P < 0.01) and that the expression of the nicotinic acetylcholine receptors were increased and GFAP positive astrocytes were decreased obviously (P < 0.05), as compared with the model rats. Insulin is able to enhance the learning and memory abilities of the Alzheimer's disease-like rats, possibly by improving the function of the acetylcholine system and decreasing the astrocytes proliferation in the brain.", "citation": {"type": "PubMed", "name": "Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2008 Nov;24(4):494-8", "reference": "21158163"}, "annotations": {"Species": {"10116": true}, "Disease": {"Alzheimer's disease": true}, "MeSHAnatomy": {"Brain": true, "Astrocytes": true}, "Subgraph": {"Insulin signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 139, "target": 131, "key": "c089eb3e9f95938afae3440b6b349927cde00e83af21c84a0caa3283d1029ebca649ed6ddfad9fde936e81d0bf5d1f6c3c4f831dad58c451248b77dccf7aa03f"}, {"line": 25512, "relation": "increases", "evidence": "In the rats injected with insulin, it was found that their learning and memory abilities were improved significantly (P < 0.01) and that the expression of the nicotinic acetylcholine receptors were increased and GFAP positive astrocytes were decreased obviously (P < 0.05), as compared with the model rats. Insulin is able to enhance the learning and memory abilities of the Alzheimer's disease-like rats, possibly by improving the function of the acetylcholine system and decreasing the astrocytes proliferation in the brain.", "citation": {"type": "PubMed", "name": "Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2008 Nov;24(4):494-8", "reference": "21158163"}, "annotations": {"Species": {"10116": true}, "Disease": {"Alzheimer's disease": true}, "MeSHAnatomy": {"Brain": true, "Astrocytes": true}, "Subgraph": {"Insulin signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 139, "target": 132, "key": "01d0215cfd81083fc3c3202ae45ff9f96cfebcbd5363ef0bfb08db8c55e50481eb0245effa8dc662c448214f112688bfca850bb340a506a251f987ffa615954c"}, {"line": 25516, "relation": "increases", "evidence": "In the rats injected with insulin, it was found that their learning and memory abilities were improved significantly (P < 0.01) and that the expression of the nicotinic acetylcholine receptors were increased and GFAP positive astrocytes were decreased obviously (P < 0.05), as compared with the model rats. Insulin is able to enhance the learning and memory abilities of the Alzheimer's disease-like rats, possibly by improving the function of the acetylcholine system and decreasing the astrocytes proliferation in the brain.", "citation": {"type": "PubMed", "name": "Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2008 Nov;24(4):494-8", "reference": "21158163"}, "annotations": {"Species": {"10116": true}, "Disease": {"Alzheimer's disease": true}, "MeSHAnatomy": {"Brain": true, "Astrocytes": true}, "Subgraph": {"Insulin signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 139, "target": 133, "key": "a77956074c32b5b1c8f9be92d29a40d45e26d39541253485c5c24978d3948d8d2fcd2a77dca4e1c5b3b5b019dee60932bad02c5c058761086488a24ecd98e572"}, {"line": 25520, "relation": "increases", "evidence": "In the rats injected with insulin, it was found that their learning and memory abilities were improved significantly (P < 0.01) and that the expression of the nicotinic acetylcholine receptors were increased and GFAP positive astrocytes were decreased obviously (P < 0.05), as compared with the model rats. Insulin is able to enhance the learning and memory abilities of the Alzheimer's disease-like rats, possibly by improving the function of the acetylcholine system and decreasing the astrocytes proliferation in the brain.", "citation": {"type": "PubMed", "name": "Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2008 Nov;24(4):494-8", "reference": "21158163"}, "annotations": {"Species": {"10116": true}, "Disease": {"Alzheimer's disease": true}, "MeSHAnatomy": {"Brain": true, "Astrocytes": true}, "Subgraph": {"Insulin signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 139, "target": 134, "key": "9e0fda5b60b05b50bdf4f63774646119bbdf5883edb5c692e62b37c1fa84036586a8becef2c10c8d5449b428bbf76f2f18ebe9e88634cc6fd32299d64f2be9d8"}, {"line": 25524, "relation": "increases", "evidence": "In the rats injected with insulin, it was found that their learning and memory abilities were improved significantly (P < 0.01) and that the expression of the nicotinic acetylcholine receptors were increased and GFAP positive astrocytes were decreased obviously (P < 0.05), as compared with the model rats. Insulin is able to enhance the learning and memory abilities of the Alzheimer's disease-like rats, possibly by improving the function of the acetylcholine system and decreasing the astrocytes proliferation in the brain.", "citation": {"type": "PubMed", "name": "Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2008 Nov;24(4):494-8", "reference": "21158163"}, "annotations": {"Species": {"10116": true}, "Disease": {"Alzheimer's disease": true}, "MeSHAnatomy": {"Brain": true, "Astrocytes": true}, "Subgraph": {"Insulin signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 139, "target": 135, "key": "2e84410162f52eaf9673f34889a995b824801727f13aa3c4b03ac33c34ff42b222ca3603b0169a32b8d507247ea0dd27cda8a8717edf4c0f11974c02cb6c6f19"}, {"line": 25528, "relation": "increases", "evidence": "In the rats injected with insulin, it was found that their learning and memory abilities were improved significantly (P < 0.01) and that the expression of the nicotinic acetylcholine receptors were increased and GFAP positive astrocytes were decreased obviously (P < 0.05), as compared with the model rats. Insulin is able to enhance the learning and memory abilities of the Alzheimer's disease-like rats, possibly by improving the function of the acetylcholine system and decreasing the astrocytes proliferation in the brain.", "citation": {"type": "PubMed", "name": "Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2008 Nov;24(4):494-8", "reference": "21158163"}, "annotations": {"Species": {"10116": true}, "Disease": {"Alzheimer's disease": true}, "MeSHAnatomy": {"Brain": true, "Astrocytes": true}, "Subgraph": {"Insulin signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 139, "target": 128, "key": "0ec4f7fbdc8bcc316f338d8d550391cb8ebfbf992ead3ca029067532ca9b8649c52bd024772429664b35e889bc0a528bad4a6f44df0ed8d9245220dc6ebee40d"}, {"line": 25532, "relation": "increases", "evidence": "In the rats injected with insulin, it was found that their learning and memory abilities were improved significantly (P < 0.01) and that the expression of the nicotinic acetylcholine receptors were increased and GFAP positive astrocytes were decreased obviously (P < 0.05), as compared with the model rats. Insulin is able to enhance the learning and memory abilities of the Alzheimer's disease-like rats, possibly by improving the function of the acetylcholine system and decreasing the astrocytes proliferation in the brain.", "citation": {"type": "PubMed", "name": "Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2008 Nov;24(4):494-8", "reference": "21158163"}, "annotations": {"Species": {"10116": true}, "Disease": {"Alzheimer's disease": true}, "MeSHAnatomy": {"Brain": true, "Astrocytes": true}, "Subgraph": {"Insulin signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 139, "target": 136, "key": "a0e3fef7b38301bae676581a1013bd7c5d5237a565012a47dbc7a41ac197097f93fa48df38d95b1b9d74ed131988a1263a2ec59e24f127981c9ea5816713326d"}, {"line": 25536, "relation": "increases", "evidence": "In the rats injected with insulin, it was found that their learning and memory abilities were improved significantly (P < 0.01) and that the expression of the nicotinic acetylcholine receptors were increased and GFAP positive astrocytes were decreased obviously (P < 0.05), as compared with the model rats. Insulin is able to enhance the learning and memory abilities of the Alzheimer's disease-like rats, possibly by improving the function of the acetylcholine system and decreasing the astrocytes proliferation in the brain.", "citation": {"type": "PubMed", "name": "Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2008 Nov;24(4):494-8", "reference": "21158163"}, "annotations": {"Species": {"10116": true}, "Disease": {"Alzheimer's disease": true}, "MeSHAnatomy": {"Brain": true, "Astrocytes": true}, "Subgraph": {"Insulin signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 139, "target": 137, "key": "4cd035acac70d9bac33a1c3b6ae55f585e7f352049adfcc6486304199da9c4030044f89d31f2702b533175a6312376090f2481e5528dfc1dc6c1e814c8dfe0a5"}, {"line": 25540, "relation": "increases", "evidence": "In the rats injected with insulin, it was found that their learning and memory abilities were improved significantly (P < 0.01) and that the expression of the nicotinic acetylcholine receptors were increased and GFAP positive astrocytes were decreased obviously (P < 0.05), as compared with the model rats. Insulin is able to enhance the learning and memory abilities of the Alzheimer's disease-like rats, possibly by improving the function of the acetylcholine system and decreasing the astrocytes proliferation in the brain.", "citation": {"type": "PubMed", "name": "Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2008 Nov;24(4):494-8", "reference": "21158163"}, "annotations": {"Species": {"10116": true}, "Disease": {"Alzheimer's disease": true}, "MeSHAnatomy": {"Brain": true, "Astrocytes": true}, "Subgraph": {"Insulin signal transduction": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 139, "target": 138, "key": "df45ced50c46e9f6b74015c2a399bf2fa9a57f0c9ce56e5e26c0d2a869cc617217f9a6213241ba6e99e87a1fa18c086d202b9dd16adc0915fde5609e9d2b9c2b"}, {"line": 30311, "relation": "increases", "evidence": "Our results suggest that such amyloid-AChE complexes are formed when AChE interacts with the growing amyloid fibrils and accelerates the assembly of Abeta peptides", "citation": {"type": "PubMed", "reference": "9325095"}, "annotations": {"Subgraph": {"Amyloidogenic subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 42, "target": 80, "key": "ed2686a70c40337940b0b2f486997f74f384cc29281eb8bd16e4113c9580ce1c7c68b1d6e89658ffe2a608924dcf6e8703fbd5bbc8b7f3a751a4f8356e481e04"}, {"line": 29622, "relation": "decreases", "evidence": "Cyclosporine A inhibits acetylcholinesterase activity in selected parts of the rat brain.", "citation": {"type": "PubMed", "name": "Neurosci Lett. 2003 Mar 27;339(3):251-3", "reference": "12633900"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "object": {"modifier": "Activity"}, "source": 8, "target": 88, "key": "72b04cdd725705605d57357eb0525c713e286ea699805b078f445e60309d640cfa54587d0b6b38429c41068ad64319904e4ee35de60a1a060a7e055c984e4314"}, {"line": 29753, "relation": "decreases", "evidence": "Cyclosporine results in decreased expression of BCHE mRNA", "citation": {"type": "PubMed", "name": "Toxicol Sci. 2010 May;115(1):66-79", "reference": "20106945"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 8, "target": 145, "key": "e0e2c48284aa2614e82e1d94f5b9f57531abca10c13ad2a22568c138d29d81315690a7fca7f349ce79aaad30ff31c509da6683f9ca458790e46ea430353b25e9"}, {"line": 30119, "relation": "increases", "evidence": "The neurotoxicity induced by AChE-Abeta complexes indicated that they trigger more neurodegeneration than those of the Abeta peptide alone", "citation": {"type": "PubMed", "name": "Subcell Biochem2005", "reference": "15709485"}, "annotations": {"Subgraph": {"Amyloidogenic subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 76, "target": 56, "key": "d7bef2abcc8588ae06b65882044e9a601fa46eff8dc53946a56cddfc04681d55cb6c8d2b4a2353a111f25bf3bd55bdf63c2bf7e06048da0eb64d6be6f91fd5d4"}, {"line": 30148, "relation": "increases", "evidence": "These results, together with binding assays, have suggested that AChE may contribute to the generation of amyloid deposits and/or physically affects fibril assembly. Moreover, it has also been shown that the neurotoxicity of Abeta peptide aggregates depends on the amount of AChE bound to the complexes, suggesting that AChE may play a key role in the neurodegeneration observed in an AD patients brain.", "citation": {"type": "PubMed", "name": "Bioorg Med Chem2007", "reference": "17681794"}, "annotations": {"Subgraph": {"Amyloidogenic subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 76, "target": 56, "key": "66fce897195b8317965abb5146b0a3dae232efb3c03c860cabbc73bd151f104a998d2141115868aa9bcf5128d3553ea19ed5c6078b757f884fb374f2c707b72d"}, {"line": 33219, "relation": "increases", "evidence": " It has also been shown in animal pmodels that under conditions of reduced M1/M3 muscarinic acetylcholine receptor stimulation the secretory pathway of APP processing is inhibited and that constitutive upregulation of M1/M3-associated PKC increases APP secretion.", "citation": {"type": "PubMed", "name": "Prog Neurobiol1998", "reference": "9775403"}, "annotations": {"Subgraph": {"Amyloidogenic subgraph": true, "Regulation of actin cytoskeleton subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 93, "target": 74, "key": "a6683788c7be9c091e7ee083289beca358f420aaad024efc77f5f5bb705a897260e6ee087f70a379a59294100a54deb7ffbe092987951910eb01c7f83a3334df"}, {"line": 38592, "relation": "regulates", "evidence": "Presenilin 1 interacts with acetylcholinesterase and alters its enzymatic activity and glycosylation.", "citation": {"type": "PubMed", "name": "Mol Cell Biol2008", "reference": "18299393"}, "annotations": {"Subgraph": {"Gamma secretase subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 81, "target": 67, "key": "ae7f16bbb1a135571d0df67776007f53934046c9a092f30fb9ae0dfc6c5bad21637a3b3f8d14fa4fba50f92699221de275947f3ce0181ba79960bc111879293d"}, {"line": 43323, "relation": "increases", "evidence": "Picomolar extracellular ABeta¸ also binds nAChR, glutamate receptors (NMDAR) and Ca2+ ion channels (e.g. VDCCs, TRPC) and causes Ca2+ influx at controlled rates into the cytoplasm and mitochondria.", "citation": {"type": "PubMed", "reference": "20847424"}, "annotations": {"Subgraph": {"Amyloidogenic subgraph": true, "Glutamatergic subgraph": true, "Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 77, "target": 58, "key": "838cd55c77ca9c7d6c453869d671d89e8afc462c74ce4bb73eca786afa905b50ab6d95caa09dbe5dfce86f7296fcbf36941ca0c93ddf5b8158f1431c479263b4"}, {"line": 56929, "relation": "decreases", "evidence": "Estradiol inhibits the reaction [Acetylcholine affects the activity of [CHRNA3 protein binds to CHRNB4 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11711029"}, "annotations": {"Species": {"9606": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "object": {"modifier": "Activity"}, "source": 23, "target": 37, "key": "5ecc53383d2ddd6890abfe6284dc6d4e59e028f3b2d53bfb70926e7d0b314489a3ade2d8a618665cb49cdf6fb9979ca6de336a5ac1942e723473a76910868f6d"}, {"line": 56933, "relation": "regulates", "evidence": "Estradiol inhibits the reaction [Acetylcholine affects the activity of [CHRNA3 protein binds to CHRNB4 protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "11711029"}, "annotations": {"Species": {"9606": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "object": {"modifier": "Activity"}, "source": 37, "target": 84, "key": "09ba04c04a28a4e349af9974af708a6d079a956753c32a6d3a936b40d0f4c73f365ad043d62b5fd9925bd422839cfa846765d52bdfb9a8415bf18a893be59492"}, {"line": 56803, "relation": "decreases", "evidence": "resveratrol results in decreased expression of CHRNB1 protein", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "18089832"}, "annotations": {"Species": {"9606": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 30, "target": 104, "key": "da2cfca9a3b267f8ce0ae094a2bcf55839646d7475dc63159850f9c8c557de5aa240b63a64f5fee8a6e5b9ac3408fe8bfb45b5e68518b5c7fdb334c5256878ba"}, {"line": 56790, "relation": "negativeCorrelation", "evidence": "[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of CHRNB1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20938992"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 9, "target": 127, "key": "466526b755f4b429729ee040be2a38aa8c859d316f62d11f2be65b74527d86c75640d86e976309ca30498aa9fb4c91188007d6f01cfe0aac52a13e700a4466cc"}, {"line": 56782, "relation": "negativeCorrelation", "evidence": "[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of CHRNB1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20938992"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 127, "target": 27, "key": "4624136b6539b5c2d9eeffc21a64b257834330f0a172a4aea2a8ed57e3efdf8f56402f5aa3b43db26fe3a2a2ae564c52dac97986b64be1b7194d43073dfdc3de"}, {"line": 56786, "relation": "negativeCorrelation", "evidence": "[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of CHRNB1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20938992"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 127, "target": 19, "key": "1ba51e1d61f19abaab050cabb1e732a579b82ca366b19bb970ac6c0a2841555bc0245a2f42db7f7d759e535fdb38f352d4ef1371d88d3a869b68c0b2c5206155"}, {"line": 56790, "relation": "negativeCorrelation", "evidence": "[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of CHRNB1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20938992"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 127, "target": 9, "key": "4c81b7ecb2a1f02d58a752c2434b73e5e4a3a2d4c4ba14a743d636eb93610b4061d7f48c40c5a55f1f79d144ff83c77f9cf42c4efd2593186e0ec74fe8517308"}, {"line": 56819, "relation": "decreases", "evidence": "Copper Sulfate results in decreased expression of CHRNB1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "19549813"}, "annotations": {"Species": {"9606": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"High": true}}, "source": 7, "target": 147, "key": "78894df44065676a86c71165e4a3160b8c1c58fee284b5e1abf4257f5d5f0012b1c93884392284ed1fda1dbdd3a4f870fa6179ed05f4fb39cb9a04575056c22e"}, {"line": 56782, "relation": "negativeCorrelation", "evidence": "[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of CHRNB1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20938992"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 27, "target": 127, "key": "539e1f9507fcfbe4c1f87bdfbf87e93f16a61210f2ffe4694a5eb698095a2c6a30a2041de6e1b2fedd8fd782444dd04aeb3c0f1dda23dd259c120e777b771929"}, {"line": 56786, "relation": "negativeCorrelation", "evidence": "[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of CHRNB1 mRNA", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "20938992"}, "annotations": {"Species": {"10090": true}, "Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "source": 19, "target": 127, "key": "a06e2d77ef633af850942ffef2a00d0e283973bd918e7a2f54e73348707826a2aa713b9c8318a6848577c90fedf1863e85fd98266dc0c3618d62b79908934262"}, {"line": 56832, "relation": "decreases", "evidence": "pozanicline inhibits the reaction [Bungarotoxins binds to [CHRNA1 protein binds to CHRNB1 protein binds to CHRND protein binds to CHRNG protein]]", "citation": {"type": "PubMed", "name": "Reference from AD_HBP Data", "reference": "9336329"}, "annotations": {"Subgraph": {"Acetylcholine signaling subgraph": true}, "Confidence": {"Medium": true}}, "object": {"modifier": "Activity"}, "source": 38, "target": 83, "key": "ab0b7d4a7d2c0bd612eb16416dc8b250613f519c3285e64eaca2e081d2319f99dac5475ddcc20f8965d401ac7eb0eb324ff6eace727819de34f01595cb5f4437"}]}